Free Online Dating Sites For Disables In Us
SPECTRAL MEDICAL $EDT.TO $EDTFX
2021.12.21 19:49 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX
Apps or websites like education and kid-safe experiences are available by default while filtering out sites designed for older age groups, like social media. Teen - Crafted for teens 13-17 years old. Most apps or websites and categories are available while limiting access to many popular apps or sites that are 18+. Nowadays, dating sites and applications are incredibly numerous. All of us have our own favorite services. Some single men and women are looking for free dating sites, while others do not mind spending money to get access to advanced features and total users’ profiles. Free local dating sites. With over 95 million members, happn is the dating app that lets you find everyone you have crossed paths with; the people destiny has decided you should meet. Best 4 hookup dating sites to Get Laid For Free. Absolutely for local singles flock to find free photo personals, or not. Free Online Dating for Mature Men and Women. At CFdating your russian apps is treated like classified information, because you know what - link it is. Across our entire website you'll notice in your browser's URL bar that each of our pages is encrypted with top-level SSL encryption - while many dating sites only include encryption on their payment pages, we've implemented it site-free because. By combing through various websites on online dating apps, you might find some promo codes or hacks, but approach them with caution since they may not work. Other than that, there is a three-day free trial of Tinder Gold in your Tinder app. Do I Qualify for the Free Tinder Gold Trial? Not everyone can enjoy Tinder Gold for free.
$EDT.TO $EDTXFMarket cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
- IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
- SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
- GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
- LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
- TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
- COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
- ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
- SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
- IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
- NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
- ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
Spectral Medical is a small cap (~$50M CAD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Free Online Dating Sites For Disabled In Us 2019
Product 2: DIMIDIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236toWallstreetbetsnew [link][comments]
2021.12.21 19:46 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX
$EDT.TO $EDTXFMarket cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
- IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
- SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
- GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
- LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
- TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
- COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
- ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
- SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
- IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
- NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
- ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
Spectral Medical is a small cap (~$50M CAD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Product 2: DIMI
DIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
Free Online Dating Sites For Disabled In Us Locations
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236tobiotech_stocks [link][comments]
2021.12.21 19:44 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX
$EDT.TO $EDTXFMarket cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
- IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
- SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
- GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
- LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
- TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
- COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
- ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
- SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
- IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
- NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
- ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
Spectral Medical is a small cap (~$50M CAD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Product 2: DIMI
DIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236toBiotechplays [link][comments]
2021.12.21 19:43 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX
$EDT.TO $EDTXFMarket cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
- IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
- SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
- GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
- LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
- TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
- COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
- ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
- SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
- IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
- NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
- ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
Spectral Medical is a small cap (~$50M CAD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Product 2: DIMI
DIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236tobiotech_stocks [link][comments]
2021.12.21 19:34 GoldBug236SPECTRAL MEDICAL $EDT.TO $EDTFX
$EDT.TO $EDTXFMarket cap ~$50M CAD
Share price ~.27 CAD @ DEC 20, 2021
Shares out 228M
Ideal time horizon for our investment: 1 Year
Spectral Medical (EDT.TO or EDTXF USA) is a small cap (~$50M CAD) medical device company listed on the TSX in Canada that is on the cusp of commercializing multiple products that they either already have FDA approval or are just at the cusp of requesting approvals for. Its flagship project is a treatment for severe sepsis that is in an FDA stage 3b confirmatory trial. As far as the writers know this is the only company with a Phase 3 trial for sepsis in North America.
Corporate Presentation
PowerPoint Presentation (spectraldx.com)
UPDATE AT THE BOTTOM OF WRITEUP
BACKGROUND & WRITE UP
Here is an investment thesis for Spectral Medical ($EDT.TO) written by a couple of retail investors; one with a degree in commerce and the other with a PhD in science. Disclaimer: A warning to the reader that we are by no means experts on biotech stocks or very knowledgeable about FDA trials. This is not an endorsement to buy or sell shares of the company. A more detailed disclaimer can be found at the bottom. We had spent a significant amount of time doing research and reading to get to where we are with this investment. How well we did is up for debate. In this paper we attempt to address as much as we could. There is an abundance of information rendering it impossible for us to comprehensively discuss all of the strengths and weaknesses that we saw, however, after many iterations we have boiled it down to the following points that we wanted to highlight. The first 6 points establish the basis and essence of our high conviction trade and things we, and probably any investor, would like to see in any company.
WHY WE LIKE IT?
- IF APPROVED, NO COMPETITORS IN THE SEPSIS SPACE FOR AT LEAST 5 YEARS (HUGE MOAT)
- SOLVING HOLY GRAIL OF MEDICAL PROBLEMS, SEPSIS (LARGE MARKET)
- GROUP OF HIGHLY PUBLISHED AND ACCOMPLISHED PROFESSIONALS (TEAM IS TOP SHELF)
- LAST YEAR THE COMPANY SIGNED A DISTRIBUTION AGREEMENT AND RECEIVED UPFRONT PAYMENT WITH ONE OF LARGEST MEDICAL HEALTHCARE COMPANIES LISTED ON NYSE (BUY IN FROM MAJOR - SALES STRATEGY)
- TRIAL IS REASONABLY CLOSE TO COMPLETION (1 YEAR TIME HORIZON)
- COMPANY IS WELL FUNDED FOR PMX TRIAL (NO DILUTION EXPECTED)
- ALREADY APPROVED IN EUROPE AND JAPAN WHERE IT HAS TREATED 300 000+ PATIENTS
- SPECULATION AS TRIAL(S) NEAR(S) COMPLETION COULD CAUSE UPWARDS PRICE PRESSURE AS IT HAS DONE IN THE PAST
- IF THE COMPANY LIVES UP TO ITS US LISTING PROMISE IN THE SHORT TERM WE SEE A MUCH LARGER INVESTING AUDIENCE
- NEW CMO HIRE OPENS WORLD OF POTENTIAL OPPORTUNITIES
- ADDITIONAL PRODUCT PIPELINE IN HOME DIALYSIS PARTIALLY FDA APPROVED AND PROVIDES BACKSTOP
Spectral Medical is a small cap (~$80M USD) medical device company that is on the cusp of commercializing multiple products that they either already have or are nearing the corner for FDA approvals. Its flagship project is a treatment for severe sepsis that is currently in an FDA Stage 3b confirmatory trial with an expectation for completion in late 2021. This product is known as “PMX” and has NO COMPETITORS as there are NO FDA approved solutions for sepsis in the market and none coming any time soon. PMX has been licensed to Spectral ($EDT) with exclusivity to the North American market. The product has already been in use in real clinical settings as it has already been approved for use in Japan and Europe by the licensor (Toray Industries) and has thus far treated 300 000+ patients to date and counting. Spectrals nearest competitor, Cytosorbent has a market cap that is multiples of where Spectral currently sits even though they are only in phase 2 and as such years behind in North America. Cytosorbents does have approval for its product in Germany with about 8.2M in revenue per quarter and growing. Having said that, North America is where we think the real opportunity lies. Noteworthy is that Spectrals ability to get the product to market is highly de-risked through an exclusive distribution agreement with Baxter, one of the largest multinational health care companies listed on NYSE. The company also has a stacked board and C suite of top notch professionals. We paid particular attention to a recent CMO hire that happens to be “the world authority in Blood Purification and Renal Replacement Therapy”. A simple google search of his name will detail numerous industry connections that we think could spell a roadmap to success at a later time. A major reason that the writers can see for the market cap to be sitting where it is, is that it has not been cross listed in the US, yet. Biotech stocks do not get a lot of love in Canada.
For Spectral, the focus on a Canadian-only listing could change in the near term. This is where we think the opportunity lies in the short term. For the long term, aside from hitting FDA milestones, we believe that there is some information asymmetry that sits with their newest CMO hire. In the latest investor deck the company states an intention to possibly list on a senior US exchange. In fact, they have already taken steps in this direction having received shareholder approval for a share consolidation in 2021 to meet listing requirements. Why would they if that’s not something they were actively pursuing? As such, we propose that they could see a significant re-rating of share price for this reason alone. There are others that we will outline below. This paper will not get into the specifics of the science and will give a general overview of the company as we see it. There is no amount of due diligence that the writers here can do regarding the science that Baxter hasn’t already done. Armed with the knowledge that Baxter has given Spectral a $6.5M CAD upfront payment for which they presumably did the most thorough due diligence, one can reasonably conclude that the science has merit. For those who want to read more about it or the company and its milestones in general, we encourage you to check out FDA filings, the company’s own presentation, or contact them directly to answer technical questions. This paper will also not get into modelling or sales predictions and will assume there is a market, the market is large, there is a credible partner in place to make sure said product is sold and revenues come in if approvals are granted. Rather, we will focus on a general overview of the company, where the information asymmetry could potentially sit, namely the lack of awareness by both retail and institutional investors in the US, as well as, their newest CMO hire.
PRODUCT PIPELINE SNAPSHOT
They have two separate product pipelines that could be/are being commercialized in the near future. PMX and DIMI. The combined addressable market size for both of the company products is $6.5B USD. There are other FDA/Health Canada fully approved products that the company currently has but they will not be discussed in any detail here as they are compliments to the grand finale.
Screenshot taken from company presentation
Product 1: PMX
PMX is intended for the treatment of patients in septic shock and has been licensed for distribution and commercialization in North America from Toray Industries in Japan where it has already been approved since 2002 and has treated over 300 000+ patients and counting. It has also been approved in Europe since 1994.
PMX has already been through 3 phases with the FDA and failed to gain approval in 2016 at the conclusion of the trial. However, they did find a subset of patients with significant relative risk reduction in mortality. A phase 3b open label trial dubbed “Tigris” has been approved since September 2019 and is currently well underway with an estimated completion at the end of 2021. Commercialization could begin as early as 2022. As the trial nears completion we see it as highly likely that the price will continue to rise in anticipation of the results as speculators arrive. It is far enough out right now to get in at what we find to be attractive prices. Interim results are expected Q2 2021. The FDA has allowed them to use the favorable data of the benefit receiving subset of patients from their failed phase 3 for this phase 3b confirmatory trial. De-risking the Phase 3b study in the sense that they are already starting with statistically significant results. The likelihood of Spectral actually having decent market penetration for PMX, if it were to be approved, is high given the fact that they have an Exclusive Distribution Agreement with Baxter, one of the largest multinational health care companies in the world. Baxter is buying exclusivity rights to distribute PMX in North America via an already completed upfront rights payment and various non dilutive milestone payments moving forward. Should the company hit these targets moving forward there is a high possibility that the company will not need to dilute any further.
Screenshot taken from company presentation
A press release for the partnership can be found on both Baxter and Spectrals websites:
https://www.baxter.com/baxter-newsroom/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-blood-filter
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
Product 2: DIMI
DIMI is a device intended for easy portable hemodialysis. DIMI, a portable dialysis machine has already been recently approved by the FDA in 2020 for in hospital use and the company is currently in the process of trying to obtain approval for home dialysis. Home dialysis is a growing market trend as it cuts down cost and risk of transporting patients. It also increases patient autonomy and comfort. From what we understand there is also a government push towards home dialysis in the US. Read more in the corporate presentation.
Screenshot taken from company presentation
US LISTING. It is our belief that the company is relatively unknown to its neighbors south of the border. If it is introduced to a much larger US investing audience it is quite possible that shareholders may see immediate benefit. Moreover, it is our unprofessional opinion that even the narrower Canadian space is not aware that the company is in pursuit of a US listing.
CMO HIRE. We have found it to be of interest that the new CMO is an established collaborator with multiple successful companies in both the dialysis and sepsis space. {Screenshot at 19 Seconds https://youtu.be/jeGXkKBHo28 } Notable mentions include its much higher market cap direct comparables NxStage and Cytosorbents. Why would this accomplished researcher at the peak of his career, fully understanding the science and risks begin working with a company that he believes could fail? After all, this isn’t a major industry player that has a massive cash cushion in the event of a failure. We would hope that he sees something of value here. A similar company, producing similar products to Spectral, that he was on the scientific advisory board for, NxStage, was sold to Fresenius for $2 Billion for what we see as an arguably inferior, albeit fully FDA approved for home use, product. Note that Spectral is well on its way. Cytosorbents has a current market cap of $400M USD and is in behind Spectral in FDA trials. He has also published numerous research articles sponsored by Baxter. On the face of it, it would appear that this small community of leading scientists and the respective companies in the field of sepsis and blood purification have all done very well market cap wise, except Spectral. In addition to the thesis that the price could go up based on a US listing we find it possible that the new CMO hire is likely to provide new opportunity to the company through his network. If the charts of any of these other companies that the CMO has advised for foreshadow what’s to come for Spectral we see this as a compelling investment.
https://spectraldx.com/spectral-medical-appoints-dr-john-kellum-as-chief-medical-office
https://www.fresenius.com/7461
https://www.modernhealthcare.com/article/20190226/NEWS/190229935/fresenius-medical-care-closes-2-billion-nxstage-acquisition
UPDATE:
We waited with this update until we were fairly confident that the company was very near term in its US listing ambitions, had a number of catalysts met and within close reach, and most importantly would not suprise us with further dilutive events.
Promises made, promises kept. The positive developments regarding the TIGRIS trial and corporate progress overall:
A US listing on a senior exchange announcement should be coming any day now as the company had stated they were aiming for early 2022 according to a December company presentation. The company stated that it was important for major milestones to line up in order for the listing to make sense and are of the belief that timing is now right. A link to the update regarding US listing can be found here: https://viavid.webcasts.com/starthere.jsp?ei=1517076&tp_key=36dec0df72
It turns out their new CEO and CMO have been delivering results as there are rumors circling various chat forums about a potential partnership with DaVita, one of two largeset nursing home operators in the US ($10.69B Market Cap). The company, after the rumors began circulating, mentioned DaVita multiple times during an investor conference call (a recording of the conference call can be found here: https://www.webcaster4.com/Webcast/Page/2813/43726 ). Additionally DaVita put out a press release regarding a new hire for a division that will specificially focus on Kidney care and more importantly home dialysis, for which Spectral is trying to provide a solution. The press release potentially had a large impact on the volume of Spectral shares traded that afternoon. (DaVita Press Release: https://finance.yahoo.com/news/davita-integrated-kidney-care-expands-110200664.html )
Spectral has gotten an additional 5 sites up and running potentially increasing enrolement by 50% over last years 10 sites. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The FDA has allowed the company to include SOFA scores for patient selection which should increase enrolement by roughly 25-50%. https://ca.finance.yahoo.com/news/spectral-medical-announces-u-fda-130000488.html
The math behind the price fall
The company had failed to materialize an attempted direct investment and spin out of its medical device division Dialco. It has been in the dog house since and was forced to exercise $3M in 40 cent warrants and take a $10M financing completed in June 2021 for business continuity. The authors did not see this coming but saw and used the opportunity to average down (have not sold a single share). The current price is at a 50% discount to what accredited and institutional investors paid just months ago. Since the hiccup, the company has been executing milestones according to plan and seems to be finally rounding the corner. https://ca.finance.yahoo.com/news/spectral-medical-inc-closes-10-130500091.html
Seasonal Tax Loss selling seems to have finally ended and double bottom appears to have passed the smell test. Hence the update at this time once we were fairly sure the financing and weak hands had blown their paper out. Volume over the last two days has increased 10 fold and we suspect that we are in the midsts of a reversal.
Trades made
Various buys with .35 cent average
Research
https://www.globenewswire.com/news-release/2019/09/24/1919871/0/en/Spectral-Medical-Launches-the-Tigris-Trial.html
“The Tigris trial, designed with input from the FDA, will provide additional data to the EUPHRATES sub population who responded positively to treatment with the PMX cartridge and had a clinically meaningful 10% reduction in 28-day mortality. This group also showed improvement in organ function and reduction in the need for vasopressors. Spectral continues to be at the forefront of innovative clinical trials as the Tigris study analysis plan includes the use of Bayesian statistics which will leverage data already obtained in the EUPHRATES trial,” said Dr. Paul Walker, President and CEO of Spectral Medical.
https://spectraldx.com/spectral-medical-provides-corporate-update-3/
“Early Tigris trial observations in-line with Euphrates post-hoc results”
https://spectraldx.com/u-s-fda-grants-510k-clearance-for-spectrals-dimi/
· Immediately enables DIMI to be used within U.S. hospitals, clinics and skilled nursing facilities
· U.S. skilled nursing facilities market represents an estimated US$2 billion market annually
https://spectraldx.com/baxter-and-spectral-medical-announce-exclusive-distribution-agreement-for-blood-filter-in-u-s-and-canada/
· Agreement will enable Baxter to expand its Acute Therapies portfolio to address unmet needs
· Agreement provides Spectral with a strategic commercialization partner and their access to a large number of hospitals
· Spectral to receive upfront exclusive rights payment
https://spectraldx.com/spectral-medical-provides-corporate-update-2/
Exploration of a senior U.S. listing: The Company has been studying the potential benefits of a secondary listing on a senior U.S. exchange. Based on the stage of development of the Company, management’s observations regarding the market for peers of the Corporation whose securities are listed on a stock exchange in the U.S., the Company believes that there are potential benefits of a U.S. listing, including a potential increase in long-term shareholder value creation through broader exposure of sell-side and buy-side investment industry players.
ANALYST COVERAGE
https://www.cantechletter.com/2019/11/paradigm-capital-launches-coverage-of-spectral-medical-with-a-buy/
Disclaimer contd.: We own Spectral Medical shares and as such, in that regard, are biased. We are not affiliated in any way with the company or their contractors nor do we even know anyone that knows someone that works or contracts for at the company. Also, we are not financial advisors nor are we qualified to give financial advice. This is not an endorsement to buy or sell shares of the company. If you plan on investing in this stock or any other you should first speak to a qualified investment advisor. Our risk tolerances may also drastically differ from yours. This may be a given, but we also wanted to highlight that there is a risk that the company does not obtain the approvals they seek or that they run out of cash. The intent of this write-up is to shed light on a company that we perceive to be severely under undervalued and puzzlingly unknown. A fair warning that at any time and without warning we may buy or sell shares.
We did our absolute best to try and not be misleading in any way and will include references to most of what was written here using hyperlinks to credible sources and the company’s own documents. Having said that, we too, are human and it is possible that in this write-up we have made mistakes. It is not out of malice, we encourage everyone that reads this thread to do their own due diligence.
We welcome all opposing views and hope that if we have made mistakes, shortcomings, flaws, gaps in our research you will point them out. It will only help us save money if we have overlooked something of importance. This is an ongoing conversation.
submitted byGoldBug236topennystocks [link][comments]
2021.12.16 02:29 kirantCovid-19 Update for December 15: 456 new cases (4.51% tests positive), 387 recoveries, 3 deaths + Public Rapid Test Kit Availability + Booster Dose Expansion + Restriction Easing
Data is taken from the Covid-19 portal and today's media availability with Premier Jason Kenney, Minister of Health Jason Copping, and Dr Deena Hinshaw. Dr Hinshaw's next availability will likely be next week.RESTRICTIONS
- Multiple restrictions are currently in effect. A summary is given on this page
- You can get proof of your vaccination here. Alberta's general vaccination proof has shifted to only QR code documentation (Military and First Nations records still qualify as acceptable)
Date Eligibility Criteria Active 2 doses at least 2 weeks before . Documentation of exemption . Paid negative PCR or Rapid Test from last 72 hours
Dose | Recommendation Booking Time |
---|---|
1st | All 5+ are eligible |
2nd | 8 weeks after first shot |
3rd | - |
- 50+ (First Nation/Inuit/Metis 18+) | 6 months after 2nd |
- Immunocompromised | 8 weeks after 2nd |
- Supportive living | 5+ months after 2nd (AHS will schedule) |
- Travel necessary dose | 4+ weeks after 2nd |
- Healthcare workers | 6 months after 2nd |
- Albertans with 2 AstraZeneca doses | 6 months after 2nd dose |
- Albertans with Janssen vaccine | 6 months after dose |
Date | Testing Availability |
---|---|
Current | Recommended for symptomatic cases |
Dec 17 | Free Rapid Test Kit (while supplies last) |
- For values where 'Current' and 'Total' are the same, I have left results under Total
Value | Current | Change | Total |
---|---|---|---|
Total cases | — | +4561 | 339,997 |
- Variant cases2 | — | +1643 | 114,403 |
Active cases | 4,082 | +66 | — |
- Active variant cases | 3,103 (76.0% of active) | -176 (-5.6%) | — |
- Cases with 'Unknown source' | 2,387 (58.5% of active) | +63 (+0.6%) | — |
Tests | — | +10,120 (~4.51% positive) | 6,248,951 |
People tested | — | +2,066 | 2,611,784 (~584,208/million) |
Hospitalizations | 362 | -4 -6 based on yesterday's post/portal data | 15,339 (+31) |
ICU (Capacity: 228 (+0), Baseline: 173) | 71 | +1 | 2,970 (+2) |
Deaths | — | +3 | 3,286 |
Recoveries | — | +387 | 332,629 |
Albertans with 1+ vaccinations | — | +5,102 | 3,455,615 (~83.2% of eligible) |
Albertans fully vaccinated | — | +3,638 | 3,195,968 (~77.0% of eligible) |
Albertans with additional vaccinations | — | +15,629 | 547,909 |
Eligible Albertans not vaccinated | — | -5,102 | 696,633 (~16.8% of eligible) |
Albertans ineligible for vaccination | — | +0 | 267,791 |
- 0 cases were removed today (normal range is 5-20)
3 Includes cases from previous days
2. CASES BY VACCINATION STATUS
- Division of hospitalizations by age and vaccination status for the past 120 days can be found at this link
Metric | Total | Fully Vaccinated | Partially Vaccinated | Not Vaccinated |
---|---|---|---|---|
% of Population | 100% | 72.3% | 5.9% | 21.8% |
New Cases1 | +456 | +282 | +10 | +1642 |
% of Cases | 100% | 61.8% | 2.2% | 36.0% |
Per 100k in Group | +10.3 | +8.8 | +3.9 | +17.0 |
Active Cases | 4,082 (+66) | 1,921 (+103) | 106 (-2) | 2,055 (-35) |
% of Cases | 100% | 47.1% (+1.8%) | 2.6% (-0.1%) | 50.3% (-1.7%) |
Per 100k in Group | 92.4 (+1.5) | 60.1 (+3.2) | 40.8 (-1.0) | 213.1 (-2.5) |
Currently Hospitalized | 362 (-4) | 126 (-1) | 14 (+0) | 222 (-3) |
% of Hospitalized | 100% | 34.8% (+0.1%) | 3.9% (+0.0%) | 61.3% (-0.1%) |
Per 100k in Group | 8.2 (-0.1) | 3.9 (-0.0) | 5.4 (-0.0) | 23.0 (-0.2) |
In ICU | 71 (+1) | 18 (+1) | 2 (+0) | 51 (+0) |
% of ICU cases | 100% | 25.4% (+1.1%) | 2.8% (-0.0%) | 71.8% (-1.0%) |
Per 100k in Group | 1.61 (+0.02) | 0.56 (+0.03) | 0.77 (-0.00) | 5.29 (+0.03) |
Free Dating Sites Chat
2 - 15 cases were in Albertans <5 (not eligible for vaccination)3. AGE DISTRIBUTION
Active and Total Cases
Age Bracket | Active Cases | New Cases | Total |
---|---|---|---|
<1 | 25 (+0) | +2 | 2,078 |
1-4 | 198 (-6) | +13 | 13,353 |
5-9 | 559 (-26) | +38 | 22,078 |
10-19 | 613 (-2) | +53 | 47,139 |
20-29 | 382 (+31) | +67 | 59,243 |
30-39 | 711 (+12) | +81 | 64,993 |
40-49 | 676 (+38) | +97 | 52,279 |
50-59 | 407 (+22) | +57 | 37,101 |
60-69 | 298 (+6) | +34 | 22,532 |
70-79 | 132 (-7) | +6 | 10,117 |
80+ | 80 (-1) | +5 | 8,794 |
Unknown | 1 (-1) | +3 | 290 |
Age Bracket | New Recoveries | Total Recoveries | New Deaths | Total Deaths |
---|---|---|---|---|
<1 | +2 | 2,053 | +0 | 0 |
1-4 | +19 | 13,154 | +0 | 1 |
5-9 | +64 | 21,519 | +0 | 0 |
10-19 | +55 | 46,525 | +0 | 1 |
20-29 | +36 | 58,845 | +0 | 16 |
30-39 | +69 | 64,248 | +0 | 34 |
40-49 | +59 | 51,522 | +0 | 81 |
50-59 | +35 | 36,485 | +0 | 209 |
60-69 | +28 | 21,784 | +0 | 450 |
70-79 | +12 | 9,227 | +1 | 758 |
80+ | +4 | 6,981 | +2 | 1,733 |
Unknown | +4 | 286 | +0 | 3 |
Age Bracket | New Hospitalizations | Ever Hospitalized | New ICU | Ever in ICU |
---|---|---|---|---|
<1 | +0 | 101 | +0 | 22 |
1-4 | +2 | 88 | +0 | 14 |
5-9 | +0 | 47 | +0 | 14 |
10-19 | +1 | 244 | +0 | 34 |
20-29 | +2 | 861 | +1 | 119 |
30-39 | +1 | 1,573 | +0 | 251 |
40-49 | +3 | 1,862 | +0 | 410 |
50-59 | +7 | 2,578 | +1 | 683 |
60-69 | +6 | 2,764 | +0 | 780 |
70-79 | +5 | 2,512 | +0 | 514 |
80+ | +4 | 2,704 | +0 | 127 |
Unknown | +0 | 5 | +0 | 2 |
Summary of Vaccinations
Value | Change | Total |
---|---|---|
Doses delivered | +24,300 | 7,194,947 (~1,627,802/million) |
Albertans with 1+ doses | +5,102 | 3,455,615 (~781,806/million) |
Albertans fully vaccinated | +3,638 | 3,195,968 (~723,063/million) |
Albertans with additional doses | +15,629 | 547,909 (~123,960/million) |
Albertans not vaccinated (eligible) | -5,102 | 696,633 (~157,608/million) |
Albertans not eligible for vaccine | +0 | 267,791 (~60,586/million) |
- Vaccinations by age can found at this link
- A version of this chart with the age column repeated can be found here if needed.
- Geospatial data on vaccinations can be found at this link
Reported Variants of Concern/Interest
- Not all positive tests from May 1 - June 1 and Sept 9 - Nov 23 were screened
- Based on a lack of current cases, Alpha (B.1.1.7), Beta (B.1.351), and Gamma (P.1) are not being shown on this table
Zone | Delta (B.1.617) Cases | Total | Kappa (B.1.617.1) Cases | Total | Omicron (B.1.1.529) Cases | Total |
---|---|---|---|---|---|---|
Total | +154 | 65,429 | +0 | 19 | +10 | 60 |
Calgary | +72 | 15,188 | +0 | 6 | +7 | 34 |
Edmonton | +57 | 22,185 | +0 | 0 | +0 | 2 |
Central | +7 | 8,199 | +0 | 13 | +2 | 15 |
South | +9 | 6,018 | +0 | 0 | +0 | 8 |
North | +8 | 13,836 | +0 | 0 | +1 | 1 |
Unknown | +1 | 3 | +0 | 0 | +0 | 0 |
- The value is updated by Alberta Health on Mondays
- Last update: December 13
- Next potential update: December 27
Zone | R Value (Confidence interval) | Change since November 29 |
---|---|---|
Province-wide | 0.96 (0.92-1.01) | +0.08 |
Edmonton | 0.99 (0.92-1.07) | +0.04 |
Calgary | 0.96 (0.90-1.03) | +0.06 |
Rest of Province | 0.93 (0.86-1.01) | +0.13 |
Zone | Active Cases | People Tested | Total | New Cases | Total | New Deaths | Total |
---|---|---|---|---|---|---|---|
Calgary | 1,766 (+75) | +814 | 1,034,718 | +220 | 125,683 | +0 | 855 |
Central | 504 (-7) | +189 | 237,167 | +48 | 38,681 | +0 | 410 |
Edmonton | 1,221 (+23) | +681 | 822,110 | +125 | 105,366 | +2 | 1,326 |
North | 373 (-9) | +166 | 252,455 | +46 | 46,787 | +0 | 405 |
South | 213 (-16) | +134 | 165,817 | +17 | 23,442 | +1 | 290 |
Unknown | 5 (+0) | +82 | 99,517 | +0 | 38 | +0 | 0 |
City/Municipality | Total | Active | Recovered | Deaths |
---|---|---|---|---|
Calgary | 100,290 (+159) | 1,274 (+51) | 98,288 (+108) | 728 (+0) |
Edmonton | 78,460 (+68) | 667 (+17) | 76,745 (+50) | 1,048 (+1) |
Red Deer | 9,499 (+5) | 89 (-1) | 9,326 (+6) | 84 (+0) |
Fort McMurray | 8,240 (+11) | 43 (+6) | 8,179 (+5) | 18 (+0) |
Lethbridge | 7,274 (+7) | 80 (-8) | 7,132 (+15) | 62 (+0) |
Grande Prairie | 7,005 (+1) | 46 (-2) | 6,904 (+3) | 55 (+0) |
Medicine Hat | 4,614 (+2) | 39 (-4) | 4,497 (+6) | 78 (+0) |
Mackenzie County | 3,332 (+2) | 18 (-2) | 3,261 (+4) | 53 (+0) |
Brooks | 2,105 (+1) | 4 (+1) | 2,077 (+0) | 24 (+0) |
Cardston County | 1,873 (+0) | 11 (-1) | 1,822 (+1) | 40 (+0) |
High River | 1,409 (+6) | 30 (+5) | 1,369 (+1) | 10 (+0) |
I.D. No 9 (Banff) | 1,135 (+0) | 0 (+0) | 1,134 (+0) | 1 (+0) |
Warner County | 799 (+1) | 9 (+0) | 786 (+1) | 4 (+0) |
Wood Buffalo | 485 (+0) | 1 (+0) | 482 (+0) | 2 (+0) |
Wheatland County | 405 (-1) | 4 (+0) | 400 (-1) | 1 (+0) |
Rest of Alberta | 113,072 (+194) | 1,767 (+4) | 110,227 (+188) | 1,078 (+2) |
7. CASES IN HOSPITALS
Spatial distribution of hospital usage:
- Hospitalization zone are where the patient is receiving care, not zone of residence
Zone | Hospitalized | ICU |
---|---|---|
Calgary | 110 (-1) | 19 (+1) |
Edmonton | 112 (-4) | 33 (+0) |
Central | 69 (+1) | 9 (+0) |
South | 25 (-1) | 6 (+0) |
North | 46 (+1) | 4 (+0) |
- Note: The baseline capacity of ICU beds in Alberta is 173
- Last date reported: December 13
ICU Use | Number of Beds |
---|---|
Unoccupied | 37 (-13) |
Occupied (Non-Covid) | 121 (+11) |
Occupied (Covid) | 70 (+2) |
Total | 228 (+0) |
Statements by Premier Kenney
- Update was scheduled for yesterday, but shifted due to meeting and Prime Minister and other Premiers
- Still learning about Omicron, including risk of serious outcomes and vaccine effectiveness
- What is already known is spread, which is significantly more transmissible than Delta variant
- Early evidence is that it doesn't have the same rate of severe outcome (lower)
- While not a cause for panic, it could still pose a significant risk to healthcare system. Widespread transmission and small % having severe outcomes can overwhelm
- Therefore, prudent and cautious action is required until more is known
- Masking, Restrictions Exemption Program, and expansion of vaccination are continuing as they are proven successful. However, a combination of measures have to be employed
- 500,000 rapid testing kits will be made freely available from select AHS sites (~740) starting December 17
- Each kit will include 5 tests and instructions for use
- First come, first served
- You can acquire 1 kit for yourself and one for another individual if you have their Alberta Healthcare number
- Intended for use for those without symptoms. If you are symptomatic, get a PCR test
- Rapid Testing will also be made available to K-6 schools on 'Alert' status (2+ cases in last 14 days), down from 'Outbreak' status (10+ cases)
- Is currently asking federal government for more kits or more approved rapid tests
- Vaccines appear effective against severe illness, though reduced from Delta
- More breakthrough infections are occurring (from both vaccination and prior infection)
- Starting today, booster shots are open for healthcare workers and Albertans 50+ once 6 months have passed their 2nd dose
- Would like to announce faster, but limited vaccine availability (~475,000 doses in inventory, would expect ~1,000,000 needed to satisfy all who would want booster doses). Raised concerns of vaccine shortage with federal government
- Hopes further expansions will occur in near future
- Stresses that 2 doses still provide good protection regardless and is one of the most important steps
- Must continue to be cautious and to not jeopardize all progress made, even sacrifices made last Christmas
- Considering precautions taken against Omicrons, restriction easing will be made, effective immediately
- 2 household cohort is lifted (Now only limits of 10 individuals)
- Vaccination requirement is lifted (Previously required vaccination to gather indoors)
- Notes that Alberta was the only province with a vaccination requirement in gathering limits and it was leading to widespread non-compliance. With high rates of vaccination in adults
- Believes Alberta has some of the strictest indoor gathering requirements indoors. Wishes more can be done, but things can change rapidly with Covid
- In case the worst does come, AHS is preparing surge capacity
- Will take further actions if necessary
- Supports federal government's stance on travel restrictions as a method for slowing spread
- Number of breakthrough cases and waning immunity are a factor for expanding doses to healthcare workers to limit spread to patients
- 80% of the 5,000 doses received have been used
- 5,000 will be delivered next week
- Not as effective as mRNA, but will be pleased to deliver them if that's the desired vaccine
- Emphasizes that rapid test results are preliminary and not conclusive. If you get a positive, isolate and get a PCR test. A negative should not be a sign you are Covid-free and cannot be used for travel or restriction exemption program
Omicron Variant
- We have dealt with 2 variants in the past and have seen a similar story for both: we reached a point of successfully dealing with a variant of Covid, but the variant meant approach must change
- We must learn from the past
- For example, 4th wave was built off of opening too early and there was 'a devastating impact' on the healthcare system. We must be more cautious this time
- Here's what we know:
- It is more infectious
- It causes more breakthrough infections
- Early evidence suggests it may have less severe outcomes. However, with a large number of cases that could occur at once, it is causing rises in ICU in other countries
- Has heard negative impact of restrictions and knows they are real. But the risk of a 5th wave, larger than previous ones, is very real due to volume of cases
- Even with less transmissible strains, indoor gatherings are a leading cause of spread due to prolonged contact
- Limit the number of gatherings, keep them small, and outside if possible
- If indoors, consider asking guests to wear masks, maximize distance between households while eating, asking for greater masking for those at risk of seer outcome, and asking those who are not feeling well to stay home
- If the host is feeling unwell, please cancel the event
- Knows this is not what people wanted to hear today, but Covid doesn't play by the rules we want
- Strongly encourages people to take the first vaccine available. Moderna shows a small increase in effectiveness
- AHS is still reporting individuals are showing up before 6 months have elapsed. It is important to have that gap period as it gives the strongest response
Questions for Premier Kenney
Restrictions
- The federal government and some provincial governments are against easing any restrictions. Response?: Doesn't accept premise of question as he feels Alberta has the most stringent limits on gatherings. Also feels that limits that nobody follows are not going to help limit spread. This is a more realistic approach and modest change
- Why are you confident people will follow these restrictions?: They understand Covid's impact on their family and the province's healthcare system. They took action for the 4th wave. Feels that after 21 months, there is a lot of fatigue and a 2nd straight holidays at home would be devastating for mental health
- Why lift restrictions on the unvaccinated if they are still at high risk?: Alberta was the only province with restrictions on unvaccinated and they were already the most likely to ignore restrictions. Wants to also take away family divisions (specifically notes fights about having 'the unvaccinated aunt' over for Christmas) by offering alternatives such as rapid testing
- How confident are you that this won't start a 5th wave?: Small modifications are being made. Thinks it won't represent a significant risk. If it buys public confidence, then it will be more effective than stricter restrictions that nobody follows
- Would you implement tougher restrictions if you believe people would follow them?: No - restrictions are a last tool of last resort in his mind as they have negative incomes in emotional and mental well being. Thinks increases in opioid overdoses and domestic abuse may be linked to Covid restrictions. Doesn't want to 'cancel Christmas' again and wouldn't be something the province could tolerate. Asks Albertans to make responsible choices
- If the situation get worse, how will your decision making change given a perceived restriction fatigue?: If it gets worse, he'll take action. This is a challenging moment as we don't know a lot about Omicron variants. It will likely become the dominant variant but we don't know what that means yet. Suggests no Premier wants to add more restrictions right now and instead want to monitor
- Stance on federal option of implementing global travel advisories?: Waiting to see federal government's position. Premiers have raised question on efficacy. Doesn't think Canadians will handle long term impairment of travel and highlights effectiveness of the Alberta pilot travel program
- Are you comfortable with full attendance NHL games right now?: Hasn't had that conversation yet. Hasn't seen widespread cases from it
- Any thoughts about World Juniors yet?: It's more in the federal government's hands. Similar thoughts about World Juniors game attendance as NHL games
- None
- None
- One final question was in French. I wasn't able to translate fully, but what from what I could, it was primarily repeating questions/answers from the English side
- There was one question on AIMCO I am not fully qualified to translate the question or answer (as I'm not even sure I understood the question). A quick summary of Premier Kenney's response is given here.
2021.12.16 00:08 Maximum-Ad-862Brascan Gold(BRAS.CSE) Announces Ongoing Due Diligence on the 100% Earn-In Option on the Alegre Gold Project, Brazil
- Brascan Gold Inc. (CSE: BRAS) ('Brascan' or the 'Company') is pleased to announce that due diligence investigations on the Alegre Gold Project (the 'Project') in Brazil are currently underway. The due diligence includes an ongoing site visit by a consultant for Brascan, which has confirmed the existence of active or recently active artisanal mines (garimpos) apparently recovering gold from structurally controlled shear zones.
The Project comprises a single exploration licence of 9,465 hectares, accessed by a five hour drive from Belem city located in Pará State, northeastern Brazil. The due diligence is evaluating the potential of the Alegre Gold Project and the previous announced LOI between Brascan and 100% claim owner Chapada Brasil Mineração Ltda. ('CBM' or the 'Optionor').
Brascan will earn a 100% interest in the Project upon the completion of the following over two and a half years (2.5) from the signing date (all figures expressed in Canadian Dollars): (A) Paying to CBM the amount of $400,000; (B) Issuing 750,000 common shares to CBM or its nominee; and (C) Completing an exploration program with a total cumulative expenditure of $1,000,000 within two and a half (2.5) years of the signing date of the definitive agreement. The share issuances, cash payments and exploration commitments all accelerate over the two and a half year (2.5) term of the earn-in option. CBM will retain a two percent (2%) net smelter royalty (NSR), fifty percent (50%) of which can be purchased by Brascan for $1,000,000, on or before a production decision. The Company may pay finders' fees or commissions to eligible arm's-length third-parties in connection with the Project, as permitted by the Canadian Stock Exchange.
CBM reports that the Project is located on the same gold mineralization trend as Goldmining Inc.'s advanced Cachoeira gold project 15 km to the north and Oz Minerals' Centrogold Project 30 km to the south (considered one of Brazil's largest undeveloped gold projects). The Alegre Gold Project is accessible by highway from the city of Belem, which in turn is accessible by scheduled air services.
https://www.goldmining.com/projects/brazil/cachoeira/
Qualified person
Harrison Cookenboo Ph.D., P.Geo. and a QP by the standards of Canadian National Instrument 43-101, has reviewed the scientific and technical information that forms the basis for this news release and has approved the disclosure herein.
For more information, investors should review the Company's filings that are available at www.sedar.com.
Contact Information Balbir Johal Director Telephone: 604 812 1747 Email: [bjohal75@gmail.com](mailto:bjohal75@gmail.com)
2021.12.15 20:39 MorpheusIndustryThe Great Reset Timeline
I will post the first portion here as well, but it's only about one third of the full timeline.
But first, here's an honorable mention (I couldn't find a date): https://www.blackrock.com/uk/individual/products/charities/why-social-housing-deserves-a-place-in-your-portfolio
Some timelines that helped with my research: https://sociable.co/government-and-policy/timeline-great-reset-agenda-event-201-pandemic-2020/
https://www.zodlikeproductions.net/t218-id2020-accenture-deloitte-mastercard-microsoft-rockefeller-foundation-gavi-open-society-foundation-world-economic-forum-covi-pass-commonpass
https://goingdirect.solari.com/timeline-of-key-economic-events-of-the-pandemic/
...
The following is primarily a timeline of information relevant to what is discussed by Klaus Schwab, the Executive Chairman of the World Economic Forum, which describes itself as 'the International Organization for Public-Private Cooperation'. This timeline will present information based on the themes of what Shwab calls the 'Fourth Industrial Revolution', as well as potential crises that could allow for the acceleration of its implementation.
June 22-23, 2001: 'The Dark Winter exercise, held at Andrews AFB, Washington, DC, June 22-23, 2001, portrayed a fictional scenario depicting a covert smallpox attack on US citizens.'
January 14, 2005: 'Atlantic Storm was a ministerial table-top exercise convened on January 14, 2005 by the Center for Biosecurity of the University of Pittsburgh Medical Center, the Center for Transatlantic Relations of the Johns Hopkins University, and the Transatlantic Biosecurity Network. The exercise used a fictitious scenario designed to mimic a summit of transatlantic leaders forced to respond to a bioterrorist attack.'
'During the six hour meeting, the transatlantic leaders wrestled with the enormity and rapid pace of the emerging epidemics of smallpox, the tension between domestic politics and international relations, the challenge of controlling the movement of people across borders, and an international shortage of critical medical resources such as smallpox vaccine.'
September 7-8, 2006: Black ICE (Bioterrorism International Coordination Exercise)
'In the Black ICE scenario six terrorists from South Asia self-infect with smallpox and, while they are at their most contagious, travel by air to Central Asia. During their travel and upon arrival, the terrorists infect as many people as possible with the disease. National response capabilities are quickly overwhelmed and governments call upon international organizations for assistance in areas such as disease diagnosis and interventions, public health and law enforcement investigations, coordinating transportation policies, and managing displaced populations.'
August 26, 2009: Wikileaks Cable: Russia Declines USG Request to Extend Joint Smallpox Research Through ISTC
May 2010: The Rockefeller Foundation publishes: Scenarios for the Future of Technology and International Development. The section titled 'Lock Step' presents a fictitious scenario of a pandemic and its aftermath.
'The Chinese government’s quick imposition and enforcement of mandatory quarantine for all citizens, as well as its instant and near-hermetic sealing off of all borders, saved millions of lives, stopping the spread of the virus far earlier than in other countries and enabling a swifter postpandemic recovery.' (Page 18)
'During the pandemic, national leaders around the world flexed their authority and imposed airtight rules and restrictions, from the mandatory wearing of face masks to body-temperature checks at the entries to communal spaces like train stations and supermarkets. Even after the pandemic faded, this more authoritarian control and oversight of citizens and their activities stuck and even intensified.' (Page 19)
'In developed countries, this heightened oversight took many forms: biometric IDs for all citizens, for example, and tighter regulation of key industries whose stability was deemed vital to national interests.' (Page 19)
March 14, 2013: The U.S. Is Stocking Drugs for a Hypothetical Smallpox Bio-Attack
January 15, 2014: Ahead of the WEF meeting in Davos, Switzerland, Schwab announced that he hoped the WEF would push the reset button on the global economy
January 22, 2014: The WEF publishes its meeting agenda: The Reshaping of the World: Consequences for Society, Politics and Business (PDF)
'Consequently, the United Nations Secretary-General and the Executive Secretary of the United Nations Framework Convention on Climate Change (UNFCCC) agreed with the World Economic Forum jointly to advance public-private cooperation, action and ambition on climate change and broader sustainability issues.' (Page 33)
'Companies that deal with sensitive and critical information such as those in financial services should put cyberattacks at the top of their list of risks. While CEOs and corporate boards are increasingly becoming aware of the threat, not everyone knows how to respond to it effectively. In today’s hyperconnected world, companies need to have dedicated IT teams to constantly monitor technology systems and devise ways to repel cyber attacks. Encryption is another line of defence as is two-factor verification – requiring a username and password; use of biometric information, such as fingerprints and DNA, are also useful techniques.' (Page 42)
2015: Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships
Peter Daszak, President of EcoHealth Alliance: 'Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pancoronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process, Daszak stated.' (Page 73)
March 14, 2015: Statement by Prime Minister Shinzo Abe at the High Level Segment of the Third UN World Conference on Disaster Risk Reduction
'Japan is working on the reconstruction from the Great East Japan Earthquake based on the idea of 'Build Back Better,' which aims not simply to recover the same situation that existed prior to the disaster, but rather build a society that is more resilient to disasters than before.'
April 3, 2015: The next outbreak? We’re not ready Bill Gates
Bill Gates on how to respond to the next pandemic: 'And then we need to pair those medical people with the military. Taking advantage of the military's ability to move fast, do logistics, and secure areas.' (Timestamp: 6:37)
September 25, 2015: UN adopts new Global Goals, charting sustainable development for people and planet by 2030
'The 2030 Agenda compels us to look beyond national boundaries and short-term interests and act in solidarity for the long-term. We can no longer afford to think and work in silos.
Institutions will have to become fit for a grand new purpose.'
PDF: Transforming our world: the 2030 Agenda for Sustainable Development
November 9, 2015: Journal article co-authored by Ralph Baric: A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence
December 12, 2015: Klaus Schwab: The Fourth Industrial Revolution: what it means, how to respond
'Engineers, designers, and architects are combining computational design, additive manufacturing, materials engineering, and synthetic biology to pioneer a symbiosis between microorganisms, our bodies, the products we consume, and even the buildings we inhabit.'
'...governments will gain new technological powers to increase their control over populations, based on pervasive surveillance systems and the ability to control digital infrastructure.'
'Modern conflicts involving states are increasingly 'hybrid' in nature, combining traditional battlefield techniques with elements previously associated with nonstate actors. The distinction between war and peace, combatant and noncombatant, and even violence and nonviolence (think cyberwarfare) is becoming uncomfortably blurry.'
'...the tracking and sharing of information about us is a crucial part of the new connectivity. Debates about fundamental issues such as the impact on our inner lives of the loss of control over our data will only intensify in the years ahead. Similarly, the revolutions occurring in biotechnology and AI, which are redefining what it means to be human by pushing back the current thresholds of life span, health, cognition, and capabilities, will compel us to redefine our moral and ethical boundaries.'
January 10, 2016: L'interview de Klaus Schwab
Klaus Schwab when asked about implants and when they will be implemented: 'Certainly in the next ten years. At first we will implant them in our clothes, and then we could imagine that we will implant them in our brains or in our skin. And in the end, maybe, there will be a direct communication between our brain and the digital world. What we see is a kind of fusion of the physical, digital and biological world.'
May 20, 2016: ID2020 holds Inaugural Summit at the United Nations
'...the inaugural ID2020 Summit brought together over 400 people to discuss how to provide a unique digital identity to everyone on the planet, including the 1.5 billion people living without any form of recognized identification.'
'...a public-private partnership is needed to bring together the broad group of stakeholders, provide coordination, and ensure that the best technological innovations are implemented in ways that are appropriate, secure, and sustainable.'
November 11, 2016: WEF: Welcome to 2030. I own nothing, have no privacy, and life has never been better
'Welcome to the year 2030. Welcome to my city - or should I say, 'our city'. I don't own anything. I don't own a car. I don't own a house. I don't own any appliances or any clothes.'
'Everything you considered a product, has now become a service.'
'In our city we don't pay any rent, because someone else is using our free space whenever we do not need it. My living room is used for business meetings when I am not there.'
'My biggest concern is all the people who do not live in our city. Those we lost on the way. Those who decided that it became too much, all this technology. Those who felt obsolete and useless when robots and AI took over big parts of our jobs. Those who got upset with the political system and turned against it. They live different kind of lives outside of the city. Some have formed little self-supplying communities. Others just stayed in the empty and abandoned houses in small 19th century villages.'
'Once in awhile I get annoyed about the fact that I have no real privacy. No where I can go and not be registered. I know that, somewhere, everything I do, think and dream of is recorded. I just hope that nobody will use it against me.'
January 10, 2017: Dr. Fauci: 'There is no question that there will be a challenge the coming administration in the arena of infectious diseases ... there will be a surprise outbreak.'
February 6, 2017: The WEF publishes a video on social media: 8 predictions for the world in 2030: facebookDOTcom/worldeconomicforum/videos/8-predictions-for-the-world-in-2030/10154159674886479/
'You'll own nothing. And you'll be happy.'
'The US won't be the world's leading superpower.'
'You'll eat much less meat.'
'Polluters will have to pay to emit carbon dioxide.'
'Western values will have been tested to the breaking point.'
April 1, 2017: The Rockefeller Foundation awards a grant to Identity2020 Systems Inc.
'Toward the costs of establishing an alliance of governments, non-governmental organizations and private sector companies committed to providing digital identity to populations currently lacking any type of formal identification.'
June 19, 2017: Accenture, Microsoft team up on blockchain-based digital ID network
'...build a digital ID network using blockchain technology, as part of a United Nations-supported project to provide legal identification to 1.1 billion people worldwide with no official documents.'
'The companies unveiled a prototype of the network on Monday at the UN headquarters in New York during the second summit of ID2020, a public-private consortium promoting the UN 2030 Sustainable Development Goal of providing legal identity for everyone on the planet.'
June 28, 2017: World Bank Launches First-Ever Pandemic Bonds to Support $500 Million Pandemic Emergency Financing Facility
July 6, 2017: How Canadian researchers reconstituted an extinct poxvirus for $100,000 using mail-order DNA
'Eradicating smallpox, one of the deadliest diseases in history, took humanity decades and cost billions of dollars. Bringing the scourge back would probably take a small scientific team with little specialized knowledge half a year and cost about $100,000.'
October 2017: Johns Hopkins Center for Health Security publishes: The SPARS Pandemic: A Futuristic Scenario for Public Health Communicators
'From a government standpoint, the current administration is led by President Randall Archer, who took office in January 2025. Archer served as Vice President under PresidentJaclyn Bennett (2020-2024), who did not seek a second term due to health concerns.' (Page 2)
'Responding to Misinformation or Doubt about an MCM Generated by a Prominent Public Figure: Given the ability of powerful, popular figures to reinforce or to undermine public health messages, what steps might health authorities—at either national or local levels—take to reverse the negative effects of BZee’s unintended linkage of Tuskegee and Corovax...' (Page 28)
'On July 9, 2026, a week before Corovax was released for distribution in the United States, the power grid at the Grand Coulee Dam in eastern Washington State experienced a catastrophic failure. While the event did not destroy any infrastructure or result in any deaths, it did cause widespread power outages in Washington, Oregon, Idaho, Montana, and British Columbia. Though power was restored within a day of the initial outage, blackouts continued plaguing these areas over the next three weeks.' (Page 40)
'The group vigorously debated whether it was appropriate for the President to acknowledge the sacrifice that vaccine recipients had made on behalf of their communities or to console them in their grief over that sacrifice.' (Page 64)
'Reports of Corovax side effects began to gain traction. Several parents of children who experienced neurological symptoms after receiving the vaccination sued the federal government and CynBio. The lawsuit was dropped when they learned of compensation funds available through the PREP Act and the National Vaccine Injury Compensation Trust Fund.' (Page 75)
January 2018: World Economic Forum publishes: The Known Traveller: Unlocking the potential of digital identity for secure and seamless travel (In collaboration with Accenture) (PDF)
'Emerging technologies – from biometrics to distributed ledger to machine learning – offer tremendous potential to transform and enhance the global travel security system.' (Page 3)
'Security is increasingly the focus for international travellers and border agencies as a result of growing turmoil and uncertainty due to geopolitical tensions, complex international security policies, the threat of terrorism and the rise of global pandemics.' (Page 8)
February 2018 (Webster definition date): Merriam-Webster Defines 79 Percent of Americans as ‘Anti-Vaxxers’
'Peter Sokolowski, editor at large of Merriam-Webster.com, said that the entry for 'anti-vaxxer' was first added to the online dictionary in February 2018 and hasn’t been revised or changed since. It has always defined it as 'a person who opposes vaccination or laws that mandate vaccination'.'
March 28, 2018: ID2020: Immunization: an entry point for digital identity
'And because immunization is conducted in infancy, providing children with a digital child health card would give them a unique, portable digital identity early in life. And as children grow, their digital child health card can be used to access secondary services, such as primary school, or ease the process of obtaining alternative credentials. Effectively the child health card becomes the first step in establishing a legal, broadly recognized identity.'
May 15, 2018: 'Clade X is a day-long pandemic tabletop exercise that simulated a series of National Security Council–convened meetings of 10 US government leaders, played by individuals prominent in the fields of national security or epidemic response.'
Clade-X-exercise-presentation PDF: 'Clade X Virus Synthesis: Genes for neurologic virulence of Nipah have been inserted into the parainfluenza genome. Virologists with special training and a reasonably outfitted laboratory could make the virus.' (Page 27)
July 16, 2018: How Russia Is Disrupting the World Order NYT News
'Cybermeddling. Method: Undermine elections, trigger power outages, leak emails.'
September 2018: WEF Insight Report: Identity in a Digital World: A new chapter in the social contract (PDF)
'Our identity is, literally, who we are, and as the digital technologies of the Fourth Industrial Revolution advance, our identity is increasingly digital. This digital identity determines what products, services and information we can access – or, conversely, what is closed off to us.' (Page 5)
'Governments are increasingly advancing digital identity systems to support multiple goals: efficient public service delivery, sustained rule of law and robust democratic processes. At the same time, they also have a growing responsibility to ensure that systems and processes do not lead to unconstitutional intrusions into a citizen’s or resident’s privacy, or become a tool for unwarranted surveillance, discrimination and abuse.' (Page 10)
'New technologies such as Internet of Things (IoT) that establish and verify identity of produce can enable an end-to-end supply-chain traceability model.' (Page 11)
'Digital identity systems need technological innovation, robust regulatory frameworks, widespread public trust and acceptance, a design that appeals to consumers and long-term financial sustainability. This makes them ideal candidates for public-private partnerships, with clearly defined roles and incentives for all involved.' (Page 19)
January to August 2019: Crimson Contagion was a joint exercise conducted from January to August 2019, in which numerous national, state and local, private and public organizations in the US participated, in order to test the capacity of the federal government and twelve states to respond to a severe pandemic of influenza originating in China.
March 26, 2019: WHO launches new global influenza strategy
March 26, 2019: UN accuses Blackstone Group of contributing to global housing crisis
'The UN’s housing advisor has accused private equity firms and one of the world’s largest corporate residential landlords, Blackstone Group, of exploiting tenants, 'wreaking havoc' in communities and helping to fuel a global housing crisis.'
June 13, 2019: World Economic Forum and UN Sign Strategic Partnership Framework
'The World Economic Forum and the United Nations signed today a Strategic Partnership Framework outlining areas of cooperation to deepen institutional engagement and jointly accelerate the implementation of the 2030 Agenda for Sustainable Development. The framework was drafted based on a mapping of existing collaboration between the two institutions and will enable a more strategic and coordinated approach towards delivering impact.'
June 27, 2019: Former FDA Commissioner Scott Gottlieb joins Pfizer's board of directors
July 24, 2019 (funding date): 'But just last year, the National Institute for Allergy and Infectious Diseases, the organization led by Dr. Fauci, funded scientists at the Wuhan Institute of Virology and other institutions for work on gain-of-function research on bat coronaviruses.
'A second phase of the project, beginning that year, included additional surveillance work but also gain-of-function research for the purpose of understanding how bat coronaviruses could mutate to attack humans. The project was run by EcoHealth Alliance, a non-profit research group, under the direction of President Peter Daszak, an expert on disease ecology.'
August 5, 2019: Deadly Germ Research Is Shut Down at Army Lab Over Safety Concerns
'The statement said the Centers for Disease Control and Prevention decided to issue a 'cease and desist order' last month to halt the research at Fort Detrick because the center did not have 'sufficient systems in place to decontaminate wastewater' from its highest-security labs.
But there has been no threat to public health, no injuries to employees and no leaks of dangerous material outside the laboratory, Ms. Vander Linden said.
In the statement, the C.D.C. cited 'national security reasons' as the rationale for not releasing information about its decision.'
'The army institute also employed Bruce E. Ivins, a microbiologist who was a leading suspect — but who was never charged — in the anthrax mailings in 2001 that killed five people. Dr. Ivins died in 2008, apparently by suicide.'
August 19, 2019: Blackrock publishes: Dealing with the next downturn: From unconventional monetary policy to unprecedented policy coordination (PDF)
'Going direct means the central bank finding ways to get central bank money directly in the hands of public and private sector spenders. Going direct, which can be organised in a variety of different ways, works by: 1) bypassing the interest rate channel when this traditional central bank toolkit is exhausted, and; 2) enforcing policy coordination so that the fiscal expansion does not lead to an offsetting increase in interest rates.
An extreme form of 'going direct' would be an explicit and permanent monetary financing of a fiscal expansion, or so-called helicopter money.' (Page 2)
'...in a downturn the only solution is for a more formal – and historically unusual – coordination of monetary and fiscal policy to provide effective stimulus.' (Page 8)
'Any additional measures to stimulate economic growth will have to go beyond the interest rate channel and 'go direct' – when a central bank crediting private or public sector accounts directly with money. One way or another, this will mean subsidising spending – and such a measure would be fiscal rather than monetary by design. This can be done directly through fiscal policy or by expanding the monetary policy toolkit with an instrument that will be fiscal in nature, such as credit easing by way of buying equities. This implies that an effective stimulus would require coordination between monetary and fiscal policy – be it implicitly or explicitly.' (Page 8)
August 22, 2019: Symposium sponsored by the Federal Reserve Bank of Kansas City, Jackson Hole, Wyoming: Challenges for Monetary Policy
Fed Chair Jerome Powell: 'Banks and other key institutions have significantly more capital and more stable funding than before the (2007–08 financial) crisis.'
'To address this new normal, we are conducting a public review of our monetary policy strategy, tools, and communications—the first of its kind for the Federal Reserve. We are evaluating the pros and cons of strategies that aim to reverse past misses of our inflation objective. We are examining the monetary policy tools we have used both in calm times and in crisis, and we are asking whether we should expand our toolkit.'
August 26, 2019: U.S. officials fear ransomware attack against 2020 election
September 3, 2019: HHS Purchases Smallpox Vaccine to Enhance Biodefense Preparedness
'As part of ongoing preparedness efforts against biodefense threats, the U.S. Department of Health and Human Services (HHS) will purchase smallpox vaccine, called ACAM2000, to build and replenish vaccine stored in the Strategic National Stockpile (SNS) over the next decade.
Under the agreement announced today, the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR), which oversees the SNS, will award approximately $170 million to Emergent BioSolutions...'
September 4, 2019: The Bill and Melinda Gates Foundation spent $55MM on a pre-ipo equity investment into BioNtech, which later partnered with Pfizer to make its mRNA vaccine.
September 5, 2019: CommonHealth Will Enable Android™ Phone Users to Access and Share their Electronic Health Record Data with Trusted Apps and Partners
'Cornell Tech, UC San Francisco (UCSF), Sage Bionetworks, Open mHealth and The Commons Project are collaborating to develop CommonHealth, an open-source, non-profit public service designed to make it easy and secure for people to collect their electronic health record data and share it with health apps and partners that have demonstrated their trustworthiness.'
September 12, 2019 (date of database suspension): Gravitas Exclusive: Why did Wuhan lab take database of '22,000 virus samples' offline?
'The 'Bat Woman' Shi claimed that the database was taken down because of hacking attempts during the pandemic.'
'...the database was actually taken down in September 2019.'
September 17, 2019: Fed runs repo Tuesday amid worries about keeping its benchmark rate in check
'The Federal Reserve conducted a repurchase operation Tuesday involving $53 billion worth of various debt instruments as it seeks to control the level of its benchmark interest rate. It was the first such move in a decade.'
September 17, 2019: Blast sparks fire at Russian laboratory housing smallpox virus
'The smallpox virus survives in two places on Earth: at Vector and at another high-security laboratory at the US Centers for Disease Control and Prevention in Atlanta.'
September 18, 2019: The Johns Hopkins Center for Health Security publishes: Preparedness for a High-Impact Respiratory Pathogen Pandemic
'Nucleic acid (RNA and DNA)–based vaccines are widely seen as highly promising and potentially rapid vaccine development pathways, though they have not yet broken through with licensed products.' (Page 11)
'During an emergency, it should be expected that implementation of some NPIs (nonpharmaceutical interventions), such as travel restrictions and quarantine, might be pursued for social or political purposes by political leaders, rather than pursued because of public health evidence.' (Page 13)
'National governments need to prepare for the deliberate use of a respiratory pathogen.' (Page 14)
'Continued research into the science of attribution, as well as the strengthening of surveillance systems, international collaboration, and implementation of treaty agreements, particularly the Biological Weapons Convention (BWC), are all needed for an effective response to the deliberate use of a biological weapon with a high-impact respiratory pathogen.' (Page 14)
September 18, 2019: Global Preparedness Monitoring Board: A World At Risk: Annual report on global preparedness for health emergencies
'Countries, donors and multilateral institutions must be prepared for the worst. A rapidly spreading pandemic due to a lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any new pathogen for public health purposes along with the means to share limited medical countermeasures across countries.
Progress indicator(s) by September 2020 • Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.' (Page 8)
September 18, 2019: Wuhan Customs Holds 30 Days Countdown to Military Games and Emergency Response Drill at Ports (English translation)
Original source: https://web.archive.org/web/20200129163943/http://k.sina.com.cn/article_2000016880_7735d5f002000krlq.html
September 19, 2019: Executive Order 13887: Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health
September 19, 2019: ID2020 Alliance launches digital ID program with Government of Bangladesh and Gavi, announces new partners at annual summit
'Recognizing the opportunity for immunization to serve as a platform for digital identity, this program leverages existing vaccination and birth registration operations to offer newborns a persistent and portable biometrically-linked digital identity.'
September 20, 2019: The World Knows an Apocalyptic Pandemic Is Coming
September 24, 2019: FDA approves first live, non-replicating vaccine (Jynneos) to prevent smallpox and monkeypox
October 8, 2019: AB 1482 'The California Tenant Protection Act of 2019'
'Statewide law that goes into effect on January 1, 2020 and expires on January 1, 2030.'
October 18, 2019: Military World Games opens in Wuhan, ushering in new era
'This edition marks the first time that the Games have been staged outside the military barracks and the first time all the events are held in one city.'
October 18, 2019: Event 201 simulated the effects of a fictional coronavirus originating in bats but passing to humans via pigs.
'The Johns Hopkins Center for Health Security in partnership with the World Economic Forum and the Bill and Melinda Gates Foundation hosted Event 201, a high-level pandemic exercise ... The exercise illustrated areas where public/private partnerships will be necessary during the response to a severe pandemic in order to diminish large-scale economic and societal consequences.'
'Governments and the private sector should assign a greater priority to developing methods to combat mis- and disinformation prior to the next pandemic response.'
October 25, 2019: Joe Biden: We are not prepared for a pandemic. Trump has rolled back progress President Obama and I made to strengthen global health security. We need leadership that builds public trust, focuses on real threats, and mobilizes the world to stop outbreaks before they reach our shores.
November 17, 2019 (case date): Coronavirus: China’s first confirmed Covid-19 case traced back to November 17
December 12, 2019: Alleged leaked document: Confidential Disclosure Agreement between NIAID, Moderna Therapeutics, Inc. and its affiliates
'mRNA coronavirus vaccine candidates developed and jointly owned by NIAID and Moderna' (Page 105) (Signed by Ralph Baric on Page 107)
December 19, 2019: Bill Gates: 'What's next for our foundation? I'm particularly excited about what the next year could mean for one of the best buys in global health: vaccines.'
December 27, 2019 (case date): Coronavirus: France's first known case 'was in December'
December 29, 2019: Central Bank Gold Hoarding Hits 50-Year High
'...at least 37 developed central banks have participated in significant monetary easing practices like large scale overnight repos and slashing interest rates.'
January 7, 2020: Prediction For 2030: A Government Take Over Of Rental Housing
January 8, 2020: 2019 had the most CEO departures on record with more than 1,600
'A 'staggering' 1,640 CEOs left their posts in 2019, the highest year on record since Challenger, Gray, & Christmas began tracking in 2002.'
January 11, 2020: Chinese researchers reveal draft genome of virus implicated in Wuhan pneumonia outbreak
'Ralph Baric, a coronavirus researcher at the University of North Carolina, Chapel Hill, notes that of the four known SARS-related bat viruses capable of infecting humans, this one is the most distant from SARS itself. After downloading the sequence last night, his lab immediately began to try to reverse-engineer a live virus from the sequence, which can be helpful to develop antibody tests and to start experiments in animal models. 'If you want to have a strong public health response, you have to do this quickly,' says Baric, who leads one of the few labs in the world that can re-create coronaviruses just from their sequences. (Bureaucratic hurdles would make it difficult for China to ship the actual virus quickly to other countries, he says.)'
2021.12.14 16:35 Timeless777HEXO Reports First Quarter 2022 Results and Launches New Strategic Plan, 'The Path Forward' to Solidify its Position as Canada's Leading Cannabis Company
All amounts are expressed in Canadian dollars unless otherwise noted.-- HEXO reports $50.2 million in total net revenue for Q1'22, an increase of 29% compared to the fiscal quarter ended July 31, 2021 (Q4'21) -- Maintains #1 Market Share position in Canada -- Announces new strategic plan, 'The Path Forward' to strengthen its balance sheet and accelerate its transformation to become a cash flow positive company within the next four quarters.
(1) Based on Headset data for the quarter of August to October 2021
GATINEAU, Quebec, Dec. 14, 2021 (GLOBE NEWSWIRE) -- HEXO Corp (TSX: HEXO; NASDAQ: HEXO) ('HEXO' or the 'Company'), a leading producer of high-quality cannabis products, today reported its financial results for the fiscal quarter ended October 31, 2021 (Q1'22), and announced 'The Path Forward', a new strategic plan to solidify itself as Canada's leading cannabis company and position it to capitalize on international opportunities. The plan utilizes HEXO's current assets, including its recent acquisitions and unique capabilities to drive accelerated growth and become cash flow positive within the next four quarters. This plan is underpinned by actions to strengthen its balance sheet, its executive team and its corporate governance.
Q1 2022 Highlights
-- Total net revenue increased 29% to $50.2 million from $38.7 million in Q4'21, and up 70% from the comparative quarter of fiscal 2021. -- The Company closed its acquisitions of Redecan and 48North which contributed net revenues of $13.5 Million and $1.1 Million respectively during the two months ended October 31, 2022. -- The Company's total non-beverage gross margin before adjustments increased to 28% from 25% in the previous quarter. -- Revising expected synergies from acquisitions to over $50M from previously reported $35M. -- Forecasting positive cash flow within the next four quarters based on incremental cash flow of $37.5 million in fiscal 2022 and an additional $135 million in 2023 for a total of $175 million over the two years.
'We are taking immediate steps through our new strategic plan, The Path Forward, to strengthen our capital position, improve operations, accelerate organic growth and complete our transformation to be cash flow positive from operations within the next four quarters,' said Scott Cooper, President & CEO, HEXO. 'Having visited all our core sites, and in meeting with our employees and customers, I am more confident than ever in HEXO's future and our ability to accelerate the creation of short and long-term value for shareholders.'
The Path to Growth: A Strengthened Balance Sheet
As part of its plan to ensure the Company has adequate capital to meet its requirements, it is taking immediate action to reduce the dilutive effect of its senior secured convertible note ('Convertible Note'). The Company is working with investment banks, as well as its current debt holder towards a holistic solution to reduce its debt overhang.
The Company is actively evaluating alternatives in a manner which maximizes shareholder value. HEXO continues to be actively engaged in positive, ongoing conversations with its senior secured note holder on potential restructuring options of the note. As of December 14, 2021, USD$118 million and USD$375 thousand of principal on the Convertible Note has been redeemed and converted, leaving USD$241.625 million of principal outstanding.
The Path to Renewal: Enhanced Leadership Team
Totally Free Disabled Dating Site
The Company is making a series of executive changes to strengthen its focus on products, operations, and profitability. These decisions reflect HEXO's vision for building a best-in-class consumer packaged goods company that is on the path toward stable, long-term growth.HEXO is bolstering its focus on products by appointing Jackie Fletcher as Vice-President, Science & Technology. This strategic appointment will allow HEXO to leverage the deep expertise and bench strength from the Redecan acquisition as well as the practical application they applied to R&D. Jackie will report directly to Scott Cooper.
Trent MacDonald will step down from his role as Chief Financial Officer, effective March 11, 2022. Trent will continue in his role until March 11, 2022, to ensure a smooth transition while the Company completes its search for a new CFO.
'On behalf of my HEXO colleagues and our Board of Directors, I want to thank Trent for his significant contributions to the evolution of the Company,' stated Scott Cooper, President and CEO, HEXO.
To further strengthen its corporate governance, the Company has appointed John Bell as the new Chair of the Board, effective immediately. John is currently Chairman of Stack Capital, Pure Jamaican Limited and a board member of Cure Pharmaceutical. He was also a member and Chair of the Board at Canopy Growth between 2014 and 2020. His tremendous experience will further position HEXO as the market-leader in Canada.
HEXO would like to thank Dr. Michael Munzar for his dedication to HEXO as Chair and for helping to guide HEXO as it grew from a start-up to market leader, as he steps down from the Board of Directors effective immediately.
The Path Forward
The Company also announced today its new transformative plan, The Path Forward, to solidify its position as the number one cannabis company in Canada, with the goal of becoming the first amongst its peers to be cash flow positive from operations.
The Path Forward is made up of five priorities:
- Reduce manufacturing and production costs; 2. Streamline and simplify the organizational structure; 3. Realize cost synergies from acquisitions and recent plant closures; 4. Focus on revenue management, including more disciplined pricing; and 5. Accelerate growth through organic market share gains and capture missed revenue opportunities, including improving our ability to align cultivation planning with market demand, reintroduce a focus on medical and strengthen our commercial capabilities and innovation pipeline.
HEXO is also focused on delivering revenue growth and margin opportunities as it integrates its recent acquisitions of Redecan, Zenabis and 48North. The Company now expects to achieve over $50 million in synergies, significantly exceeding its initial target of $35 million. To date, the Company has achieved $25 million of run-rate synergies.
Transitory Expenses
To align with HEXO's strategy to align operations and be more disciplined stewards of capital, the Company decided to review and assess capital intensive projects. As part of that assessment, management decided to halt the Keystone Isolation Technologies project indefinitely as of October 31, 2021, resulting in a one-time charge of $11.3 million. This decision, and the Company's decision to review and assess capital intensive projects more generally, align with HEXO's strategy to optimize operations. The Company also incurred impairment losses during the period:
-- Impairment on property, plant and equipment -- The Company has completed an assessment of a certain zone within its B9 facility which has been deemed redundant by management based on its new cultivation capacity. -- Impairment on investment in associate - On October 31, 2021, there existed indicators of impairment on the Company's investment in Truss LP and as such management performed discounted cash flow valuation at October 31, 2021 which resulted in impairment to its recoverable amount. The historical carrying amount of the Truss LP investment included $42.3 million related to the fair value of warrants issued to Molson Canada as part of the initial investment in 2018. These warrants expired unexercised in October 2021. -- Acquisition and transactions costs - related to the recent acquisitions of Redecan, Zenabis and 48North amounted to $24.4 million;
Readers are referred to the 'Operation Expenses' table below in this press release.
This quarter also include one-time charges related to inventory and the ending of operations at the Langley facility.
Financial Highlights
KEY FINANCIAL PERFORMANCE INDICATORS
Condensed summary of results for the three months ended October 31, 2021, July 31, 2021 and October 31, 2020.
For the three months ended October 31, July 31, October 31, In 000's 2021 2021 2020
$ $ $ Revenue from sale of goods 69,497 53,022 41,300 Excise taxes (19,535) (14,365) (11,887)
Net revenue from sale of goods 49,962 38,657 29,413 Ancillary revenue 226 103 55
Total revenue 50,188 38,760 29,468 Cost of goods sold (82,985) (37,261) (17,544)
Gross loss before fair value adjustments (32,797) 1,499 11,924
submitted byTimeless777toHexoBets [link][comments]
2021.12.03 21:56 JaeydePandaTravelling from Canada to Scandinavia (Copenhagen + Sweden) during COVID-19 pandemic
This post is for any Canadians curious/thinking about travelling to Scandinavia or in general during the pandemic.Firstly some tips you may find helpful in advance of booking your trip:
- Sherpa Travel has been the BEST website for monitoring and reporting on COVID-19 rules by country - including layovers. I have this site bookmarked and watched it like a hawk until my departure date. It is here: Travel Restrictions (joinsherpa.com) - check it often.
- Manulife has a very good insurance plan which grants peace of mind should you test positive on your pre-departure PCR while in your destination country. They will cover a good portion of lodging and medical expenses while you recover. You can find it here. My cost for a 12 day trip was approximately $50 CAD.
- I booked my pre-departure PCR test with FlyClear (Lifelabs) and had the actual PCR done at Shoppers Drug Mart. You can book one here: FlyClear – LifeLabs . The test results came in within 12 hours which was a huge relief of course. The total cost for this was approximately $170 CAD.
- Print. Your. Documents. If you lose your phone/tablet, you're in trouble. I printed 2 x Vaccination Certificates and 2 x PCR Results.
- Download the ArriveCAN app and register in ADVANCE. Some passengers had issues with this app, it's best to ensure you have an account and it is fully functional BEFORE you embark on your trip.
- From what I could find, there is no such thing as a direct flight from Canada to Scandinavia. There are many airlines out there that fly out of Canada (in my case Toronto) with connections in the UK, Germany, France etc. Because I was alone, this also being my first time travelling to Europe - I wanted to layover in the smallest airport possible for a number of reasons/benefits:a) Not a far walk/run if a flight is delayed getting in so I can reach my next plane reasonably fastb) Smaller airport = fewer gates, less confusionc) Smaller crowds = less air sharing with other people
- I chose Icelandair Flights to Europe & Iceland Icelandair for their reasonable prices, options and the Reykjavík (KEF) small airport layover. I strongly suggest this airline based on my experiences with the Icelandair app, the ease of submitting your documents (via the app), the patience of their staff and their fluency in English. Yes they have some bad reviews, but we're in a pandemic and their jobs are equally stressful to ensure each passenger is in compliance - so if you are diligent in your own documentation - you make less work for them and of course the experience is a lot more pleasant. I strongly suggest NOT taking Economy Light - it does not allow you to change the dates of your flights whereas Economy Standard WILL allow you to move your flight date at least once. In a pandemic, this is absolutely necessary for peace of mind.
- Iceland requires that you check in to their government website before arrival. I suggest if you're taking this route that you do it well in advance (up to 72 hours) so you've got your registration in order for customs. visit.covid.is Registration You'll be given a barcode which will I'll mention later.
I checked in using the Icelandair app and submitted my passport, vaccination certificate and PCR test which gets sent to them in advance for review. The review was successful and I was granted my boarding passes.
Departure Day
I arrived at the Toronto Airport 5 hours early. This was before Omicron, and I have to say I was WAY too overcautious - but now that Omicron is a hot topic, 5 hours may not be such a bad idea. I got through security I tuckered myself out by walking and wandering around the airport hatching Pokémon Go eggs. No shame in it, it gets you moving, right?
Pre-Boarding & Flight toReykjavík (KEF)****:
The plane is boarded from the back to the front. If your seat is in the late numbers, expect to be called up first (after Priority boarding of course).
They wanted our Passports ready and asked us to pull down our masks for identification before they'd let us get on the plane. Everything else was as normal, go down the gate, take our seats and off we went.
The plane that carried us to Reykjavík (KEF) was a Boeing 737 Max 8. Don't worry - these planes have been through the ringer for inspection and safety and are very state of the art technologically. Honestly I didn't pull out my iPad or iPhone, because there was LOTS of onboard complimentary entertainment (movies/tv shows etc. - all in English). Seats have a USB port to charge your phone and a 3.5mm jack for headphones. Wi-Fi is available for 20 Euros (about $30 CAD).
Pillows and blankets were also on the seats which was a very inviting and comforting gesture if I may say.
There's tons of opportunity to grab food before the flight, but if you do want a snack or a meal, they have onboard paid meal service. Drinks are complimentary and they visit more than once between departure and arrival (with on-call service as well).
Layover in Reykjavík (KEF)
Arriving in Reykjavík (KEF) was a very unique experience. They offloaded the plane on the tarmac and a trolley was ready to take us to the airport entrance, where it was 5am and staff were very few.
They did announce on the plane before getting off however that customs was up on the 2nd floor and to have our barcode ready if we were transiting to another plane. Thank goodness they did this, because signage is sparse and so was staff.
Customs was a bit of a lineup but it went relatively quickly and my layover was 1.5 hours so time was plentiful to go through the process. They greeted us smiling and relaxed and asked us to pull down our masks, matched our faces to our Passports, show the Negative PCR test and I THOUGHT I'd need my barcode, but I suppose not as she didn't ask for it. Through customs were the gates to outbound flights and the boards were updated about 30 minutes before departure what Gate the plane was at.
Flight to Copenhagen (CPH)
In Reykjavík (KEF) there are 2 lines for boarding the next plane - the right being Priority boarding and the left being essentially everyone else. They simply asked us to scan our boarding passes on the machine, green light, the doors open and down the gate you go to take your seats. No back to front boarding, just scan and go. This was a bit more hectic, but being this plane was a Boeing 767 and had 2 aisles (vs. only 1 on the Max 8), there was more mobility on the plane. FYI - larger luggage must go on the two OUTER cabin shelves - the inner cabin shelves accommodate only smaller carry-on bags.
This plane was evidently older, but no less comfortable. Wi-Fi available onboard and all the same entertainment perks as the Max 8 with exceptions to the screens being a bit smaller I think.
Arrival in Copenhagen (CPH)
Landing in Copenhagen (CPH), they offloaded us passengers at the gate and you are almost immediately in the baggage area. There is an exit path on the floor, just follow it out. Here's where I became very confused. There's a fork in the road before you exit the baggage area that is Customs. One door has 'declarations' and the other has 'nothing to declare.' Knowing I literally packed nothing but my clothes and hygiene products, I went through the 'nothing to declare' door and POOF, I was out of the exit and in front of my eagerly waiting boyfriend.
I was in a new country. Sure it's Scandinavia but it's Denmark soil no less. No one wanted to question me? See my passport? See my negative PCR? This was WEIRD! Knowing I was going through the Denmark/Sweden border I shrugged it off, hugged and kissed Mike and we got in the car to make our way to Sweden.
Approaching the Denmark/Sweden border, I pulled out my passport and PCR test and before I could look up, a light turned green - the traffic arm went up and we had driven through an unmanned booth. What? 'Mikael - did I just go through 2 borders with no Customs checks?'
I learned this is normal I guess? Perhaps Iceland being a part of Scandinavia shares the same database as its neighbouring countries? I panicked for a long while over this, but time would tell if customs comes to get me and throws me in some kind of holding cell for illegal entry into their countries LOL.
Pre-departure PCR Test, Iceland Check-in, Flight Check-in and ArriveCAN
I booked my PCR Test well in advance of my trip with a medical company in Sweden called Kvicktest Covid-19 Quick test - kvicktest.se. The booking process was very simple, no money required up front, I did not pay until I showed up for my appointment. I had results in about 14-16 hours which was fantastic and I was issued an actual EU Covid Certificate which is widely recognized in Europe.
Once I had this result, I completed my Iceland registration (mentioned previously) and ArriveCAN registration as well.
Checking into the flight this time however something went awry. I submitted the documents the same way I did previously, but my information was not validated and my boarding passes were denied until I went to the airport. This obviously had my anxiety levels peaking.
Travel to and Arrival at Copenhagen (CPH)
Driving back to Copenhagen via the Denmark/Sweden bridge was a similar experience - no human interaction, just a green light, traffic arm lift and we were through.
When I got to the airport, they explained to me at the counter that Canada's among the most stringent when it comes to documentation and rules for entry so this was NORMAL that I was not granted boarding passes via the app. She asked me if I had the ArriveCAN app completed, I said yes, she needed the barcode ready - I provided it - and THEN I was granted my boarding passes.
Departure from Copenhagen (CPH)
After finding my Gate and sitting around waiting for boarding, the Icelandair staff asked Canadians once again to see their ArriveCAN app. If we were able to show that, we were allowed to board. The plane left considerably late from Copenhagen's tarmac. We were sitting on that plane for a good while before we taxi'd to the runway. This created a bit of stress thinking about going through Iceland customs and having to rush to the next plane with less than 40 minutes between flights.
Layover in Reykjavík (KEF)
The good news, is that Icelandair recognizes connecting flights and did reassure us that the Icelandair planes departing to the U.S. and Canada (connectors of this flight) would be waiting for us and there was no risk of us missing those planes due to this delay.
When the plane arrived, we were connected to a proper gate (contrary to the first time I visited this airport and being let off on the tarmac), and we (Canadians and Americans) were ushered to Customs where we were able to get through reasonably quickly.
Before we were allowed to board, we were asked once again to see our ArriveCAN app. Once we provided this and our passports, we were given a sticker on the passport which I can only imagine is indicative that we have fulfilled the requirements per Icelandair to board a flight landing in Canada.
Arrival in Toronto (YYZ)
Because we were delayed due to the first flight arriving late, we got to Toronto a bit late, and this perhaps was to our disadvantage, because there were several other arriving flights that required to go through customs at the same time. Once we were off the plane, we had 2 customs officers validate our passports and cleared us to go through the NEXT step of customs. This is where chaos ensued. There were hundreds - I mean HUNDREDS of people who were ushered to self-service machines where you scan your passport, make any declarations, have your photo taken and a printed page spit out the machine to give to your assigned customs officer.
It took over 1.25 hours based on the line up to get to a customs officer. Employees constantly yelling directing human traffic - just an absolute shit show.
When I approached the customs officer, he'd asked me for my print out, passport and ArriveCAN app. He likely saw my Iceland check-ins, so he asked me if I was anywhere other than Iceland - I replied yes, I'd been staying in Sweden and he asked for how long - I disclosed I was there for 12 days.
He put a green sticker on my passport 'PHAC' which I'm assuming means Public Health Agency of Canada and gave me a pamphlet which outlines the rules for COVID in Canada and their right to random testing etc. and what to do IF you're selected, etc. etc. etc.
When leaving customs, there was a fork in the road. If you have a Green sticker you were to go left and if you had no sticker you had to go right. I was given no indication to take a test or self test, so I assume I was not selected for random entry testing. I was then through customs and on my way home, exhausted, frustrated and kind of confused and curious if I didn't get a green sticker what it meant. Oh well, whatever.
2 Days Later:
I've received an email indicating that I've received it because I had been out of the country and was reminded that IF I was selected for random testing that I needed to comply with the rules etc. etc. but again I had no directions from Customs to test at the airport and I did not receive a self test like the pamphlet implied I would if I WERE selected. I will update you if anything else changes, but for now, things seem relatively normal.
Once again I hope this helps - and if it does help anyone, it was worth the write. <3 Take care and stay safe out there.
submitted byJaeydePandatotravel [link][comments]
2021.11.29 20:20 Brice9783 Battery Metal Small-caps to Watch $GEL $EDDY $LIS
The YTD chart for the VanEck Rare Earth Strategic Metals ETF (PSE: REMX) is to your left. submitted byBrice978toCanadapennystocks [link][comments] https://preview.redd.it/0diuyvpcik281.png?width=437&format=png&auto=webp&s=634c72e7b89880a8f090cc911163e0ee142550bf While midrange in returns for the sector, it illustrates the solid growth that illuminates the potential of the three Battery Metal stocks examined below. The 52-week trade range is USD54.83 to USD120.04. · Performance over 1-Year: 191.0% · Expense Ratio: 0.59% · Annual Dividend Yield: 0.47% · Assets Under Management: $1.0 billion · Inception Date: Oct. 27, 2010 “The types of mineral resources used vary by technology. Lithium, nickel, cobalt, manganese, and graphite are crucial to battery performance, longevity, and energy density. Rare earth elements are essential for permanent magnets that are vital for wind turbines and EV motors. Electricity networks need a huge amount of copper and aluminum, with copper being a cornerstone for all electricity-related technologies.' (Int'l Energy Agency) Three Juniors to Watchlist The global graphite market was valued at USD 14.3 Billion in 2019 and is expected to reach USD 21.6 Billion by 2027, registering a CAGR of 5.3% from 2020 to 2027. Likely a low estimate. Graphano Energy Ltd. (TSXV: GEL) (FSE: 97G0) (the “Company” or “Graphano Energy“) is a mining company that is focused on evaluating, acquiring, and developing graphite resources with potential—from exploration to production. https://preview.redd.it/t59vks5gik281.png?width=131&format=png&auto=webp&s=3f7f2ea3e1fbf02080b123ffd953c37dc4a15f02 https://preview.redd.it/c2ud5bllik281.png?width=358&format=png&auto=webp&s=efae624fae70f4ff83daaa3b954ab423489b7ac7 The LAB Graphite Property crosses through TIMCAL’s Lac des Iles graphite mine in southern Quebec. That property produces 25,000 tonnes of graphite annually. Recent results from Graphano’s LAB property show assay results of about 50 (of 190) samples have been received. They are in the range of 0.34% to 23.5% graphitic carbon (Cg) with 19 samples over 10% Cg, 12 samples between 5% and 10% Cg, and the remaining samples with values below 5% Cg. Once all the samples are assessed, the exploration program will be revealed. The other aspect that should excite investors is that the crossover of the LAB and Timcal deposits bring the ‘Closeology’ benefit to GEL. To review, Closeology benefits a junior mining company by: · De-risks (or mitigates) smaller plays · A lot of the exploration already done by large neighbors or predecessors · Depending on the neighbors, the junior company gets ongoing attention. · And, of course, the real possibility that the junior will be acquired by a major. Large flake graphite showings on the property were confirmed with flake size in the range of 0.5 to 5 millimeters, typically present in shear zones at the contact of gneisses and marbles where the graphite content usually ranges from 2% to 20%, based on historical information. Edison Lithium Metals (TSXV: EDDY) (OTCQB: EDDYF) (FSE: VV0) ('Edison' or the 'Company') is a Canadian-based junior mining exploration company focused on procurement, exploration, and development of cobalt, lithium, and other energy metal properties. https://preview.redd.it/66knr42uik281.png?width=283&format=png&auto=webp&s=33cae1f5cf9bc0b1dba6398b1070d06319f02c93 https://preview.redd.it/k71btn8zik281.png?width=458&format=png&auto=webp&s=335036fffb47b17d36329150fa5a44988fec2e84 The Company’s Lithium properties in Argentina are well placed. The Antofalla Salar is 130 km and five by 20km across. Also 20km from Argentina’s largest producing mine, Livent. It has been publicly stated that Antofalla has the third largest lithium brine reservoir in the world. (Albemarle Corporation). https://preview.redd.it/qa30u3p1jk281.png?width=1110&format=png&auto=webp&s=12e1877a355a49d9a1138a9b514d04b63bec970d Eddy acquired Resource Ventures S.A. (ReVe). This Argentinian corporation owns or controls the rights to over 148,000 hectares (365,708 acres) of prospective lithium brine claims in two highly prospective areas in the province of Catamarca, Argentina. Nathan Rotstein, CEO of Edison, stated;“ReVe’s assets in and around the Antofalla Salar are made up of approximately 107,000 hectares (264,397 acres) of semi-contiguous claims in the northern and southern parts of this salar, offsetting either side of Albermarle's holdings in the center of this salar. This vast block of lithium claims creates what management believes are to be an imposing entry point for EDDY as we enter the burgeoning lithium sector.” The second area is in the Salar de Pipanaco, a place of early-stage mining. Rotstein further states, 'Our claims in the Pipanaco Salar, while only early-stage exploration, may prove to be strategic for a potential regional lithium processing facility located less than 50 km from Catamarca city.” The mixture of properties with established potential and expected potential feeds into the growth seen to date and into the future. EDDY has robust lithium property acquisition plans. Lithium South Development Corporation (the 'Company') (TSX-V: LIS) (OTCQB: LISMF) (Frankfurt: OGPQ) The Hombre Muerto North Lithium Project is surrounded by two leading lithium producers, Korean giant POSCO and Livent at the northern end of the renowned Hombre Muerto Salar. The NRG-43-101 PEA is available on the site for those who like to go deep. https://preview.redd.it/o48o0x63jk281.png?width=264&format=png&auto=webp&s=798baf83d9d686e8a2249e097b45ed7e3715a551 https://preview.redd.it/3ad363e4jk281.png?width=449&format=png&auto=webp&s=ba566ae0e058d16cf6135270fff4e5f5a9cb7b48 LIS is testing methods for its Direct Lithium Extraction (DLE) method. Once determined, it will form the basis of production. Benefits include: · Reduce production time from months to hours · Increase the recovery from 42% using traditional extraction to over 80% · Eliminate the need for large evaporation ponds · Reduce the environmental footprint of any future production facility The successful deployment of this technology would be necessary to the industry and particularly LIS shareholders. https://preview.redd.it/3y4t8w97jk281.png?width=977&format=png&auto=webp&s=0324b0789e93155bf0227653f6a109fc8c3ffda2 Two production wells drilled and cased: https://preview.redd.it/i802pl6ajk281.png?width=2790&format=png&auto=webp&s=93013c77eedee1c6ed5573c88174c12f795ef74c HMN Li Project outlined · Measured and Indicated Mineral Resources of .57M tonnes Lithium · Carbonate Equivalent (LCE) and a projected mine life of 30 years. · A recent Preliminary Economic Assessment returns a Present Net Value of US$ 217 million, CAPEX of US$ 93 million, and an Internal Rate of Return of 30%. · A Feasibility Study on the project is in progress, including upgrading the current resource to reserve status. CEO Adrian Hobkirk states, 'I personally feel very optimistic that DLE's efficiencies will replace conventional Lithium extraction methods, which are slow as they're dependent upon extracting lithium from ponds via a solar evaporation process.' Bottom Line The need for Lithium and Graphite for the EV market, in particular, is pretty much accepted by industry and, by extension, investors. While each company has unique favorable characteristics, the commonality is that each subject Company has exceptional properties and potential, and the price appreciation over the last year has been impressive. Mining methods employed vary, as do the maturity of the properties. What is not in genuine dispute is the need for the graphite and lithium produced by these juniors. Management in each case s well up to the task, and the only decision to make is—with apologies to Lay’s potato chips and its spokesman, the late Bert Lahr: “Bet you can’t buy just one.” |
2021.11.29 20:11 Brice9783 Battery Metal Small-caps to Watch $GEL $EDDY $LIS
The YTD chart for the VanEck Rare Earth Strategic Metals ETF (PSE: REMX) is to your left.While midrange in returns for the sector, it illustrates the solid growth that illuminates the potential of the three Battery Metal stocks examined below.
The 52-week trade range is USD54.83 to USD120.04.
· Performance over 1-Year: 191.0%
· Expense Ratio: 0.59%
· Annual Dividend Yield: 0.47%
· Assets Under Management: $1.0 billion
· Inception Date: Oct. 27, 2010
“The types of mineral resources used vary by technology. Lithium, nickel, cobalt, manganese, and graphite are crucial to battery performance, longevity, and energy density. Rare earth elements are essential for permanent magnets that are vital for wind turbines and EV motors. Electricity networks need a huge amount of copper and aluminum, with copper being a cornerstone for all electricity-related technologies.' (Int'l Energy Agency)
Three Juniors to Watchlist
The global graphite market was valued at USD 14.3 Billion in 2019 and is expected to reach USD 21.6 Billion by 2027, registering a CAGR of 5.3% from 2020 to 2027. Likely a low estimate.
Graphano Energy Ltd. (TSXV: GEL) (FSE: 97G0) (the “Company” or “Graphano Energy“) is a mining company that is focused on evaluating, acquiring, and developing graphite resources with potential—from exploration to production.
The LAB Graphite Property crosses through TIMCAL’s Lac des Iles graphite mine in southern Quebec. That property produces 25,000 tonnes of graphite annually.
Recent results from Graphano’s LAB property show assay results of about 50 (of 190) samples have been received. They are in the range of 0.34% to 23.5% graphitic carbon (Cg) with 19 samples over 10% Cg, 12 samples between 5% and 10% Cg, and the remaining samples with values below 5% Cg. Once all the samples are assessed, the exploration program will be revealed.
The other aspect that should excite investors is that the crossover of the LAB and Timcal deposits bring the ‘Closeology’ benefit to GEL. To review, Closeology benefits a junior mining company by:
· De-risks (or mitigates) smaller plays
· A lot of the exploration already done by large neighbors or predecessors
· Depending on the neighbors, the junior company gets ongoing attention.
· And, of course, the real possibility that the junior will be acquired by a major.
Large flake graphite showings on the property were confirmed with flake size in the range of 0.5 to 5 millimeters, typically present in shear zones at the contact of gneisses and marbles where the graphite content usually ranges from 2% to 20%, based on historical information.
Edison Lithium Metals (TSXV: EDDY) (OTCQB: EDDYF) (FSE: VV0) ('Edison' or the 'Company') is a Canadian-based junior mining exploration company focused on procurement, exploration, and development of cobalt, lithium, and other energy metal properties. The Company’s Lithium properties in Argentina are well placed. The Antofalla Salar is 130 km and five by 20km across. Also 20km from Argentina’s largest producing mine, Livent. It has been publicly stated that Antofalla has the third largest lithium brine reservoir in the world. (Albemarle Corporation).
Eddy acquired Resource Ventures S.A. (ReVe). This Argentinian corporation owns or controls the rights to over 148,000 hectares (365,708 acres) of prospective lithium brine claims in two highly prospective areas in the province of Catamarca, Argentina.
Nathan Rotstein, CEO of Edison, stated;“ReVe’s assets in and around the Antofalla Salar are made up of approximately 107,000 hectares (264,397 acres) of semi-contiguous claims in the northern and southern parts of this salar, offsetting either side of Albermarle's holdings in the center of this salar. This vast block of lithium claims creates what management believes are to be an imposing entry point for EDDY as we enter the burgeoning lithium sector.”
The second area is in the Salar de Pipanaco, a place of early-stage mining. Rotstein further states, 'Our claims in the Pipanaco Salar, while only early-stage exploration, may prove to be strategic for a potential regional lithium processing facility located less than 50 km from Catamarca city.”
The mixture of properties with established potential and expected potential feeds into the growth seen to date and into the future. EDDY has robust lithium property acquisition plans.
Lithium South Development Corporation (the 'Company') (TSX-V: LIS) (OTCQB: LISMF) (Frankfurt: OGPQ) The Hombre Muerto North Lithium Project is surrounded by two leading lithium producers, Korean giant POSCO and Livent at the northern end of the renowned Hombre Muerto Salar. The NRG-43-101 PEA is available on the site for those who like to go deep.
LIS is testing methods for its Direct Lithium Extraction (DLE) method. Once determined, it will form the basis of production.
Benefits include:
· Reduce production time from months to hours
· Increase the recovery from 42% using traditional extraction to over 80%
· Eliminate the need for large evaporation ponds
· Reduce the environmental footprint of any future production facility
The successful deployment of this technology would be necessary to the industry and particularly LIS shareholders.
Two production wells drilled and cased:
Resource Category | Brine Volume (1000 m3) | Li Grade (mg/Liter) | Li (Tonnes) | Li2CO3 Equivalent (Tonnes) | K Grade (mg/liter) | K (Tonnes) | KCI Equivalent (Tonnes) |
---|---|---|---|---|---|---|---|
Measured | 119,862 | 797 | 96,000 | 509,000 | 7,039 | 844,000 | 1,609,000 |
Indicated | 21,936 | 534 | 12,000 | 62,000 | 5,517 | 121,000 | 231,000 |
M+1 | 141,798 | 756 | 107,000 | 571,000 | 6,804 | 965,000 | 1,840,000 |
· Measured and Indicated Mineral Resources of .57M tonnes Lithium
· Carbonate Equivalent (LCE) and a projected mine life of 30 years.
· A recent Preliminary Economic Assessment returns a Present Net Value of US$ 217 million, CAPEX of US$ 93 million, and an Internal Rate of Return of 30%.
· A Feasibility Study on the project is in progress, including upgrading the current resource to reserve status.
CEO Adrian Hobkirk states, 'I personally feel very optimistic that DLE's efficiencies will replace conventional Lithium extraction methods, which are slow as they're dependent upon extracting lithium from ponds via a solar evaporation process.'
Bottom Line
The need for Lithium and Graphite for the EV market, in particular, is pretty much accepted by industry and, by extension, investors. While each company has unique favorable characteristics, the commonality is that each subject Company has exceptional properties and potential, and the price appreciation over the last year has been impressive.
Mining methods employed vary, as do the maturity of the properties. What is not in genuine dispute is the need for the graphite and lithium produced by these juniors. Management in each case s well up to the task, and the only decision to make is—with apologies to Lay’s potato chips and its spokesman, the late Bert Lahr:
“Bet you can’t buy just one.”
submitted byBrice978toCanadianstockpicks [link][comments]
2021.11.29 19:52 Brice9783 Battery Metal Small-caps to Watch $GEL $EDDY $LIS
The YTD chart for the VanEck Rare Earth Strategic Metals ETF (PSE: REMX) is to your left. submitted byBrice978toSmallCap_MiningStocks [link][comments] https://preview.redd.it/cke1wyy9dk281.png?width=437&format=png&auto=webp&s=fdbd0b45816f6f175061b3f33862b75de5339d24 While midrange in returns for the sector, it illustrates the solid growth that illuminates the potential of the three Battery Metal stocks examined below. The 52-week trade range is USD54.83 to USD120.04. · Performance over 1-Year: 191.0% · Expense Ratio: 0.59% · Annual Dividend Yield: 0.47% · Assets Under Management: $1.0 billion · Inception Date: Oct. 27, 2010 “The types of mineral resources used vary by technology. Lithium, nickel, cobalt, manganese, and graphite are crucial to battery performance, longevity, and energy density. Rare earth elements are essential for permanent magnets that are vital for wind turbines and EV motors. Electricity networks need a huge amount of copper and aluminum, with copper being a cornerstone for all electricity-related technologies.' (Int'l Energy Agency) Three Juniors to Watchlist The global graphite market was valued at USD 14.3 Billion in 2019 and is expected to reach USD 21.6 Billion by 2027, registering a CAGR of 5.3% from 2020 to 2027. Likely a low estimate. Graphano Energy Ltd. (TSXV: GEL) (FSE: 97G0) (the “Company” or “Graphano Energy“) is a mining company that is focused on evaluating, acquiring, and developing graphite resources with potential—from exploration to production. https://preview.redd.it/o0ff85kcdk281.png?width=131&format=png&auto=webp&s=530bb05ec73ae5ab025b9591e72a82836b3fc241 https://preview.redd.it/z846x2lgdk281.png?width=358&format=png&auto=webp&s=338a3ef1a42fb2949c8e4a629ce3df17b3e6da4b The LAB Graphite Property crosses through TIMCAL’s Lac des Iles graphite mine in southern Quebec. That property produces 25,000 tonnes of graphite annually. Recent results from Graphano’s LAB property show assay results of about 50 (of 190) samples have been received. They are in the range of 0.34% to 23.5% graphitic carbon (Cg) with 19 samples over 10% Cg, 12 samples between 5% and 10% Cg, and the remaining samples with values below 5% Cg. Once all the samples are assessed, the exploration program will be revealed. The other aspect that should excite investors is that the crossover of the LAB and Timcal deposits bring the ‘Closeology’ benefit to GEL. To review, Closeology benefits a junior mining company by: · De-risks (or mitigates) smaller plays · A lot of the exploration already done by large neighbors or predecessors · Depending on the neighbors, the junior company gets ongoing attention. · And, of course, the real possibility that the junior will be acquired by a major. Large flake graphite showings on the property were confirmed with flake size in the range of 0.5 to 5 millimeters, typically present in shear zones at the contact of gneisses and marbles where the graphite content usually ranges from 2% to 20%, based on historical information. Edison Lithium Metals (TSXV: EDDY) (OTCQB: EDDYF) (FSE: VV0) ('Edison' or the 'Company') is a Canadian-based junior mining exploration company focused on procurement, exploration, and development of cobalt, lithium, and other energy metal properties. https://preview.redd.it/zcrj9vvndk281.png?width=283&format=png&auto=webp&s=ce157be36ce8016bcda6126c5f090c07f023b2a3 https://preview.redd.it/08dt22fpdk281.png?width=458&format=png&auto=webp&s=8da148205376fa2ff463d75fdcd51a6cc4c2adfc The Company’s Lithium properties in Argentina are well placed. The Antofalla Salar is 130 km and five by 20km across. Also 20km from Argentina’s largest producing mine, Livent. https://preview.redd.it/2ze5xitrdk281.png?width=1110&format=png&auto=webp&s=82d47ea9b197bdff52b229eb3b01ee4ac6167f03 It has been publicly stated that Antofalla has the third largest lithium brine reservoir in the world. (Albemarle Corporation). Eddy acquired Resource Ventures S.A. (ReVe). This Argentinian corporation owns or controls the rights to over 148,000 hectares (365,708 acres) of prospective lithium brine claims in two highly prospective areas in the province of Catamarca, Argentina. Nathan Rotstein, CEO of Edison, stated;“ReVe’s assets in and around the Antofalla Salar are made up of approximately 107,000 hectares (264,397 acres) of semi-contiguous claims in the northern and southern parts of this salar, offsetting either side of Albermarle's holdings in the center of this salar. This vast block of lithium claims creates what management believes are to be an imposing entry point for EDDY as we enter the burgeoning lithium sector.” The second area is in the Salar de Pipanaco, a place of early-stage mining. Rotstein further states, 'Our claims in the Pipanaco Salar, while only early-stage exploration, may prove to be strategic for a potential regional lithium processing facility located less than 50 km from Catamarca city.” The mixture of properties with established potential and expected potential feeds into the growth seen to date and into the future. EDDY has robust lithium property acquisition plans. Lithium South Development Corporation (the 'Company') (TSX-V: LIS) (OTCQB: LISMF) (Frankfurt: OGPQ) The Hombre Muerto North Lithium Project is surrounded by two leading lithium producers, Korean giant POSCO and Livent at the northern end of the renowned Hombre Muerto Salar. https://preview.redd.it/nozh66nvdk281.png?width=264&format=png&auto=webp&s=48362810afe6cbd881639b500000f6301ba75dde https://preview.redd.it/txk6cqpwdk281.png?width=449&format=png&auto=webp&s=d801d59bde1810743aef41ad62a62d4976efdda2 The NRG-43-101 PEA is available on the site for those who like to go deep. LIS is testing methods for its Direct Lithium Extraction (DLE) method. Once determined, it will form the basis of production. Benefits include: · Reduce production time from months to hours · Increase the recovery from 42% using traditional extraction to over 80% · Eliminate the need for large evaporation ponds · Reduce the environmental footprint of any future production facility The successful deployment of this technology would be necessary to the industry and particularly LIS shareholders. https://preview.redd.it/crrn4k7zdk281.png?width=977&format=png&auto=webp&s=0db8d878a7616d710f86072e375503aa4aeaa4df Two production wells drilled and cased: https://preview.redd.it/sfct58e3ek281.png?width=2790&format=png&auto=webp&s=97f439a06dffb45978714ebf86c64b197a6552b2 HMN Li Project outlined · Measured and Indicated Mineral Resources of .57M tonnes Lithium · Carbonate Equivalent (LCE) and a projected mine life of 30 years. · A recent Preliminary Economic Assessment returns a Present Net Value of US$ 217 million, CAPEX of US$ 93 million, and an Internal Rate of Return of 30%. · A Feasibility Study on the project is in progress, including upgrading the current resource to reserve status. CEO Adrian Hobkirk states, 'I personally feel very optimistic that DLE's efficiencies will replace conventional Lithium extraction methods, which are slow as they're dependent upon extracting lithium from ponds via a solar evaporation process.' Bottom Line The need for Lithium and Graphite for the EV market, in particular, is pretty much accepted by industry and, by extension, investors. While each company has unique favorable characteristics, the commonality is that each subject Company has exceptional properties and potential, and the price appreciation over the last year has been impressive. Mining methods employed vary, as do the maturity of the properties. What is not in genuine dispute is the need for the graphite and lithium produced by these juniors. Management in each case s well up to the task, and the only decision to make is—with apologies to Lay’s potato chips and its spokesman, the late Bert Lahr: “Bet you can’t buy just one.” |
2021.11.29 02:11 Rdick_LvaginaOak Island Research Archive
This is the temporary location of the Oak Island research archive. This is being transfered over to the wiki and the dead links are being fixed as time permits.Full credit goes to the reddit user mostly known as Oak Island Historian.
Dating Sites For Disabled People
The Legend of Oak Island (incomplete)
- 1857-1867 - Blockhouse (Les MacPhie Archives) - Early Oak Island Documents - Large PDF File
- 1929 - The North American Review - The Oak Island Treasure, by C. B. Driscoll (Blockhouse) - provided by Cydnee99999
- 4/17/19 - 1965 - The Rotarian - The Strange Case of the 'Money Pit' by David MacDonald
- 1965 - Reader's Digest - Oak Island's Mysterious Money Pit- Adapted from 1965 David MacDonald's article in The Rotarian
Timeline (incomplete)
- CHMS: Timeline of Searchers, Ownership of Oak Island 1795-Present
- Blockhouse: Early Portuguese settlement in Nova Scotia
- 1603 - Voyage de Samuel Champlain (Latin) - Translated version below
- 1604-1616 - The voyages and explorations of Samuel de Champlain - (page 181) Large PDF File
1802-1805 The Onslow Company
- 1803 - The First Treasure Company: 1, 2, 3, 4
- 1849 - The Second Attempt at Recovery: 1, 2, 3, 4, 5, 6, 7, 8, 9
- 1850 - Man Made Flood System
1863-1865 Oak Island Association
- 1861 - Meeting Notes on Formation of Oak Island Association: 1, 2
- 1862 - Journals and Proceedings of The House of Assembly of the Province of Nova Scotia
- 1863 - Rambles among the Blue-Noses
- 1865 - The Third Attempt: 1, 2
- 1866 - The Fourth Attempt: 1, 2, 3, 4, 5
- 1867 - Notes from James McNutt: 1, 2, 3
- 1893 - Oak Island Treasure Company Prospectus
- 1893 - Operations of the Oak Island Treasure Company: 1, 2, 3, 4, 5
- 1894 - Notes on the Eastern Chronical article from April 5, 1894
- 1896 - F. Blair's account of the Oak Island Treasure Co.'s operations 1896-1900: 1, 2, 3, 4, 5, 6
- 1897 - The Penny Mazaine - The 100 Years' Search
- 1900 - Letter from Burrows on search attempts: 1, 2
- 1909 - The Old Gold Salvage and Wrecking Company: 1, 2, 3, 4, 5
- 1909 - List of Old Gold Salvage and Wrecking Company Crew
- 1909 - MG1 Vol. 380 activity description: 1, 2, 3
- 1911 - Collin's - Solving the Mystery of Oak Island
- 1912 - The Old Gold Salvage and Wrecking Company Prospectus: 1, 2, 3
- 1912 - Details about the Salvage Co.: 1, 2
- 1920 - The Wide World Magazine - Pirate Gold: The Burried Treasure of Mahone Bay
1934-1938 Gilbert D. Hedden
- 1938 - Agreement between Blair and Hedden: 1, 2
- 1939 - Hamilton's notes on work done in summer of 1939: 1, 2
- 1939 - Letter from Hamilton to Blair about problems with timbering work: 1, 2
- 1940 - Letter from Hamilton to Blair about Hedden possibly selling the island
1955 George Greene
- 1955 - OakIslandTreasure.Co.UK - George Greene - Contains links to 11 documents
1959-1965 Robert Restall & Family
1964-2016 Frederick Nolan
1965-1967 Robert Dunfield
- 1965 - Robert Dunefield Excavations (OakIslandTreasure.co.uk): 1, 2
- 1966 - Robert Dunfield’s Field Sketches
1969-2007 Triton Alliance
- Triton Alliance documentation - multiple documents
- 1969 - Transcript about Oak Island by Norman Creighton for Radio Talk
Maps (incomplete)
- 1612 - Map of New France (Samuel de Champlain) - Need to verify
- Blockhouse: Timeline of 90 Foot Stone, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- CMHS: Inscribed (90 Foot) Stone
- 1957 - John Whitney Lewis Notes on Money Pit
- 2005 - Les MacPhie Review of Geotechnical and Archaeological Conditions at the Money Pit (1967 –2005)
- 1850 - Man Made Flood System
- 1936 - Letter from Hedden to Harris discussing Skidway: 1, 2
- Secret Treasure of Oak Island (D'Arcy O'Connor) - Note about Coconut fibers found in Smith's Cove
- Cononut Fibers Carbon Dating - multiple reports
- Blockhouse (Les MacPhie Archives): Smith's Cove - Large PDF File
Daniel McGinnis (1758-1827)
- 1810 - Land grant on Oak Island to Donald McInnes: 1, 2, 3, 4
- Blockhouse: 1, 2, 3
- Wikitree.com: Daniel Donald McInnis
- Genealogy.com: Forum Discussion on Magennis Family
- OakIslandTreasure.co.uk: Forum on Dan McGinnis
- Reddit: 1, 2, 3
- Blockhouse: 1, 2
- Blockhouse: On the trail of Oak Island's Lieutenant Daniel Vaughan
- 1791-1795 - Nova Scotia Archives - Poll Tax Records
- 1809 - Land grant on Oak Island to Samuel Ball: 1, 2
- Blockhouse: Sam Ball's Hook Island
Sheriff Thomas Harris of Pictou
Captain David Archibald
Simeon Lynds
- 1799 - Journal and votes of the House of Assembly for the province of Nova Scotia - Bottom of page
- 1810-1812 - UPENN - Medical Degree Discrepancy*
- The Nova Scotia Medical Bulletin*: 1, 2
Richard Craig
- Chair of the Oak Island Association
- 1861 - Meeting Notes on Formation of Oak Island Association: 1, 2
- Secretary of the Oak Island Association
- 1861 - Meeting Notes on Formation of Oak Island Association: 1, 2
- 1863 - Letter from Captain W. Thompson to J. B. McCully about 90 foot stone
- Secretary of the Oak Island Eldorado Company (The Halifax Company)
- 1867 - James McNutt's History of Oak Island: 1, 2, 3, 4, 5
- 1867 - Notes from James McNutt: 1, 2, 3
- The Spanish in Nova Scotia in the XVI century: a hint in the Oak Island treasure mystery - PDF
- Les Macphie Carbon Dating Reports (Blockhouse)- multiple reports
- 1865 - Parliamentary Debates of the Province of Nova Scotia
- 1870 - The New Dominion Monthly (July 1870)
Databases (incomplete):Veridian - Projects, Newspaper.com, NewspaperArchive, Early Canadiana Online, Internet Archive, Hathi Trust, EBSCO, ProQuest, Gale, WorldCat, NYS Historic Newspapers, The British Newspaper Archive, Google Newspaper Archive, Nova Scotia Virtual Archives, The National Archives (British), The National Archives (USA), Library and Archives Canada (LAC), Ancestry, NYS Archives
Websites (incomplete):Oak Island Tours (Official), The Oak Island Compendium (Blockhouse), Oak Island Mystery (CMHS), Critical Enquiry, OakIslandTreasure.co.uk
submitted byRdick_LvaginatoOakIslandDiscussion [link][comments]
2021.11.28 23:03 PlannMannJust trying to get feedback for an article I wrote on Hollister Biosciences HSTRF
I wrote up an in-depth article for HSTRF on Seeking Alpha not realizing they don't allow new contributors to write about stocks with less than $100 market cap or $1 per share :(I ended up publishing it as a blog post. I wanted to post the full article here but the character limit is low. Double :(
So below is the link and highlights from the article.
Full article
https://seekingalpha.com/instablog/53078010-plan-man/5667902-hstrf-value-buy-profitable-multi-bagging-marijuana-penny-stock-multiple-catalysts
(Condensed Article below)
Summary
- Hollister Biosciences HSTRF is a dramatically undervalued penny stock with a market cap of around $48 million compared to 2020 revenue $30 million and expected 2021 revenue of ~$70 million.
- HSTRF has no debt, ~$15 million cash on hand, and has been profitable since Q1 2021. I expect profitability to grow through 2022 given both multiple cost-saving and growth catalysts.
- Q2 2021 revenue shrank compared to Q1 only because Q1 2021 had additional one-time sales of extra products that obscured the 100%+ YOY growth experienced during Q2.
- HSTRF has both high-quality and unique products that combine with multiple celebrity and business partnerships for low-cost customer acquisitions and high customer retention.
FINANCIALS
Looking at the numbers HSTRF is dramatically undervalued. Sales in 20202 were $30 million. Sales for 2021 are $40+ Million just with Q1 and Q2 reporting (~5million below market cap; $23.1 Million Q1 revenue and $17.6 Q2 revenue). The reason there was a dip between Q1 and Q2 was due to HSTRF’s wholly-owned subsidiary Venom Extracts selling marijuana to other companies in Arizona when recreational legalization occurred earlier than many growers were ready for. Essentially HSTRF had extra flower on hand which it sold wholesale, at a lower profit margin, in order to help the recreational industry in AZ as a whole. I would argue that in addition to helping AZ get a head start on the recreational industry, which benefits Hollister long-term as well, this also introduced a lot of high-quality marijuana early. This will likely pay metaphorical dividends as other companies struggle or don’t even aim for the same quality but where customers got a taste of high-quality marijuana early on.
Thus Q1 was an aberration that is unlikely to be reproduced. Specifically, HSTRF does not operate in states outside of CA or AZ and thus there should not be any more of these opportunities. I think this is a distraction as the profit from this type of selling is lower than HSTR’s normal sales. However, the high quality of Marijuana and this previous success does allow HSTRF some additional safety margins if their products do face issues. If, say, one of their partner products, such as Clown, suddenly gets dropped for some unforeseen reason and HSTRF is left holding a lot of flower they will be more likely to sell the flower compared to taking a loss like many other companies have done in the past, most notably in Canada where an oversupply of low-quality marijuana lead to mass crop destruction. So, this experience does offer hints at minor long-term safety compared to low-quality flower.
As proof of the profitability of HSTRF’s high margin business between Q1 and Q2 EBITDA increased despite not having the additional one-time revenue. Q1 saw adjusted EBITDA of $2.8 Million, a record for the company at the time. But compared to Q2 adjusted EBITDA of $3.2 Million it would still be a step back. So while revenue between Q1 and Q2 2021 decreased by 23% EBITDA increased by ~14%. Q2 still saw over 100% YOY growth from Q2 2020 where revenue was $8.5 million compared to $17.6 million in Q2 2021. YOY EBITA grew 560%+ Q2 from $0.5 million in 2020 to $2.8 Million in 2021.
Net income in Q2 2021 was $1.6 million compared to $0.3 in Q2 2020. Q1 2021 had a net income of $2 million. So Q1 net income was just under 9% of earnings compared to just over 9% earnings in Q2. While the difference was less than one-half of one percent the higher percentage shows HSTRF’s high margin strength.
(Hollister Biosciences Inc. Reports First Quarter 2021 Financial Results) (Hollister Biosciences Inc. Reports Q2 2021 Financial Results including USD $17.6 million revenue, and USD $3.2 million of Adjusted EBITDA)
Thus, other than one excessively strong quarter with one-time sales bumps throwing off the trend, HSTRF has seen quarter-over-quarter revenue growth, EBITDA growth since mid 2020, and there is more on the way.
MARKETING AND PARTNERSHIPS
Hollister is unique in its marketing, its presence in CA (where about 27% of the world's legal cannabis sales occur) allowed Hollister to market its products with celebrities to create celebrity brands. This is not uncommon in other industries with apparel probably being the most common. However, this is harder for Marijuana given the inability to sell products across state lines. This would normally require one of two models. A capital heavy huge interstate operation where each brand and product has to be specially grown and processed in each state. Or a capital-light model where sales are initially limited to the biggest market(S), in this case, Cali’s 27% of global recreational sales, and Arizona with its Billion dollar industry. This is why HSTRF’s CA presence is huge. It provided the customer base to justify working with celebrities in a low capital model to create custom specialized marijuana/pre-rolls that fit the tastes of each celebrity and their fans. The celebrities themselves add millions of dollars worth of free marketing and HSTRF includes some unique partners.
Tommy Chong partnered with HSTRF for a specialty tincture line Tommy Chong Cannabis. Tommy Chong is one of the first big marijuana celebrities with the infamous Cheech and Chong movies that will be shown to potheads for decades, and he has continued his career as an actor in film and TV. Tommy survived a cancer diagnosis in 2012, and another in 2015. He credited Marijuana with helping him endure the treatments that saved his life in 2015 and with helping him beat back cancer from his 2012 diagnosis. Tommy Chong has half a million Twitter followers and 2.6 million Instagram followers. His successful career as a marijuana advocate and pot comic helps strengthen Hollister’s image as a high-quality marijuana brand and will help draw in additional customers and partners as HSTRF expands and legalization tantalizes the stock market, probably for years to come.
Slipknot co-founder Shawn “Clown” Crahan partnered with HashBone and Heavy Grass (both HSTRF brands) to create Clown Cannabis. HashBone (photo from the presentation below) is a specific pre-roll product that is 75% top-Shelf flower near the tip with 25% cold water bubble hash toward the crutch. This allows for a high-quality product experience with a nice smooth burn. Clown follows this model and upped the THC levels above 40% because who expected a heavy metal band co-founder to go light on THC. Hashbone is not normally that strong focusing on a nice experience and smooth burn with varying formulas. Sales of Clown started in select dispensaries on May 17th, 2021. As they are pre-rolls and Hollister only started manufacturing pre-rolls in AZ in June these will only hit the AZ market significantly in Q3.
Additional customized products include Tactical Relief and Easy Rider.
Tactical Relief is a tincture brand created by a Green Beret with 17 years of active service and is designed for service members suffering from mental and physical wounds. War is hell and service members deserve a lot more respect for the price they paid for our freedom than simple recognition. Millions of Americans have destroyed their bodies and minds for our freedom. Custom products to help with related issues seem responsible and I personally think veterans insurance should cover treatments like this assuming they can be proven to be effective.
Easy Rider is a motorcycle enthusiast brand selling merchandise to the biker community. Products from Easy Rider include pre-rolls, mini-pre-rolls (0.2MG), and a cannabis tattoo balm used after inking oneself. The October presentation by Hollister makes it sound like additional products will be launched by the end of 2021. Hollister was able to partner with Easy Rider because they shared local roots.
“Hollister Biosciences was founded in the California town where an infamous 1947 biker rally birthed the outlaw biker image and inspired the Marlon Brandon film The Wild One, while Easyriders has been the definitive voice of motorcycle culture for more than half a century. Shared roots in a classic Americana culture made the company's natural ride partners from the start.” The First Round of Easyriders Products Hit Shops this Month
These types of specialty products and partnerships are possible because of HSTRF high-quality products and presence in CA/AZ. Easy Rider specifically shares cultural roots with Hollister. I have consistently seen positive reviews of HSTRF products on sites and message boards and the growing list of partners indicates to me that it’s not just investors and customers but celebrities and brands that claim to know their stuff who like HSTRF. I would expect these types of offerings to help HSTRF stand out upon legalization in the US, help keep customer acquisition costs low (free advertising from A-D ranked celebrities, targeting specific demographics such as veterans or bikers getting tattoos), and also reward Hollister with increased customer retention.
Both interestingly and tangentially celebrity partnerships have not just extended to product partnerships. Kevin Harrington of Shark Tank fame joined the board of directors for HSTRF in August. It will be interesting to see how this will help as I am not familiar with Kevin Harrington other than on Shark Tank where he left a positive impression on me. I don’t have a lot of experience evaluating management of companies but there will always be a possibility that Hollister may receive shout-outs on Shark Tank. This additional wildcard could payout, most likely after legalization.
CORPORATE REBRANDING AND GROWTH CATALYSTS
One of the few issues with Hollister Biosciences is that they are in the process of going through a corporate rebrand and are in the process of bringing many aspects of their business in-house. This has made information on the company somewhat scarce at the moment as they are in a transitory period and have taken down some materials including their primary website. It can be scary to not know what changes are being made but this is one of the reasons why I feel HSTRF is rocking it. They are making changes when it makes sense to make changes. They followed through with their 2021 growth strategies and are regearing for 2022, eliminating their weaknesses and capitalizing on strengths, at least theoretically.
Specifically, Hollister has not received a lot of coverage or respect as a company. Hovering between $0.17 and $0.22 per share with a market cap of around $40-50 Million HSTRF genuinely falls outside the coverage of many sites and media outlets. It’s hard to find a small-cap stock when its earnings don’t even make it into screening software. Supposedly many funds are not even allowed to invest in companies valued at less than $1 per share but I was not able to confirm this.
Additionally including Bioscience in the name and having purchased a mushroom and psilocybin company in 2020, Alphamind. This caused many outlets to treat HSTRF as a bioscience or pharmaceutical company, often using the term 'psychedelic' company or something similar. For many, this will push interest away from HSTRF thinking it's a psychedelic-focused company when in reality Hollister only has a toe stuck in. This is actually how I personally found out about HSTRF. My background is in Psychology and I was looking to invest in some psilocybin companies given the promising research showing long-term improvement with 1-3 guided psilocybin mental health sessions. HSTRF popped up and as someone who believes in the industry's growth prospects. I ended up jumping on the strong financials, unique marketing, and low valuation. However, if Hollister is seen as a bioscience company with no Phase I drugs then it makes sense to be discounted by many sites that have other companies to cover.
Their logo, featured below focuses more on mushrooms than the stylized marijuana flower. A new investor would see this and many will see the focus on mushrooms rather than the artistic marijuana flower.
Thus, I expect this corporate rebranding to help solidify the image of Hollister. As the name Hollister doesn't bring a lot to mind for me at least I would imagine a rebrand may consider a potentially more appealing name, possibly relying on the strong recognition of their Venom Brand.
It is unlikely that Hollister will rebrand any of its product lines that involve business partnerships. And their Venom Brand has strong recognition in AZ.
Announcing the corporate rebranding directly after good earnings for Q3 may help, assuming they announce the details then.
Recently The Motley Fool Wealth Management fund bought 10,000 shares, Just under $2K. And in July it was added to the Solactive US Marijuana Companies Index. And in October Ischgl Management Llc, a small mostly unheard of company, increased its shares by ~42% according to Simplywall.st.
There is no reason for the Motley fool Wealth Management fund to buy such a small amount unless they wanted to watch the stock and potentially buy more later or expect growth to be high enough to justify the purchase. There may also be some internal procedures that make it easier to invest in stocks they have already invested in and seen growth. I obviously don’t know as I have only ever been a retail investor.
However, the interest leads me to believe that some institutional buyers are circling HSTRF, and may possibly buy more with continued good performance or passing over the $1 limiter some investment groups apparently have. Seeking Alpha originally declined this article as an article because I would be a new contributor, the stock price is less than $1, and the market cap is less than $100.
So how can HSTRF start to really shine and start generating interest? I would say getting to $0.01 EPS would be the needed standout point. The corporate rebrand and restructure will be part of that. Currently, HSTRF outsources finance, administration, and marketing. Bringing these operations in-house are expected to lower costs and allow for more internal controls and communication. Per the announcement on October 12th the intent is also to help Hollister prepare for its next phase of rowth which indicates to me that Hollister has a plan moving forward. Hollister Biosciences Inc. Announces strategic initiatives including a planned rebrand, executive and board updates
Considering that HSTRF is already profitable and is showing QOQ increasing revenue with high margins, Reaching $0.01 EPS should not be too far off. I would estimate that would occur either in Q3 or Q4 of 2021 especially as the high margin pre-rolls in AZ hit 30,000 per day. There will be additional costs discussed below for bringing a new facility online. This may push back EPS achieving $0.01 per share to Q1 or Q2 next year. A quarterly EPS of $0.01 would immediately drop the PE to less than 10 as Q1 and Q2 combined would equal $0.01. And if that can be maintained, much less grown, the run rate PE (PE across the next 4 quarters) would be 5 if HSTRF maintains in the price range of $0.2 per share. It likely won't. A high growth penny stock with a PE of 20, that will help people stand up and take note if they had not already, much less a PE of 5.
For comparison, MMMB, a small-cap meatball company I have invested in, has had a price range of $2-$3 per share for the past 8 months and ended Friday, November 26th with a market cap of ~$77 million (~1.5x HSTRF's Cap) with a price per share of $2.17. Their revenue is about $12 million per quarter (Less than Hollister) with $0.01 to $0.02 EPS and no debt. Though there were 2 standout months of $0.03 and 0.05 EPS over the past 6 quarters. While MMMB is not a marijuana stock I think HSTRF reaching EPS of $0.01 per share in a higher growth space with higher growth revenue will warrant a price in the $1.5-$3 range depending on growth, 7x-15X current valuations. There is also the possibility of a run-up to $5 once people start finding out about Hollister, a 30x growth.
HSTRF’s high quality and unique products will help customer retention and its unique marketing in the Marijuana space will help them grow and acquire customers affordably. Manufacturing custom products for high-quality partners like Tommy Chong and the co-founder of Slipknot should help Hollister acquire more such partners in the future. Being able to lower costs due to the restructure is just lubricant for increasing EPS.
LONG TERM EPS CATALYSTS
I am including growth catalysts and cost reduction together as the ultimate goal is EPS, not just growth. Any company in the Marijuana sector can grow sales by buying struggling competitors. While this is a great way to generate interest and growth it doesn’t necessarily lead to a strong company.
Hollister has several long-term growth catalysts. The biggest one is the acquisition of a 30-acre campus in AZ with 700,000 square feet of cultivation area and 28,500-square feet of processing space. The current agreement is for Hollister to lease the space for 5 years. There are 3 options to renew the lease as well as purchase it outright which Hollister has announced it intends to do.
I will say it is nice how Hollister layed out the financial impact the corporate presentation lays out exactly what this campus will do for Hollister and the cost. This is especially nice as HSTRF is a small-cap company. Phase 1 is expected to be completed Q2 2022. The total cost is expected to be $3 million and production output is expected to be 2 million grams annually (almost half 2020 total sales). That investment comes out to a cost of approximately $1 million per quarter. I am assuming the rental costs are accounted for in that estimate. However, for conservative measures let’s say it won't. Yearly rent is $420,000 per year with additional costs of $150,000 to $250,000 depending on land use as HSTRF has to develop the land before use. Phase one will be complete in Q2 leading to 3 quarters of rent, $315,000. On top of $3 million for phase 1. HSTRF clearly has the profit to do this and stay profitable. They are consistently profitable at more than $1 Million per quarter so $1.1 Million is well within Hollister's range to remain profitable. HSTRF can cover this growth with cash flow, not even cash on hand. However, it may prevent Hollister from having a quarterly EPS of $0.01 for several quarters.
If work began in Q4 then Q4 may have $1.5 or even $2 million in additional costs. The advantage to this is that Q3 may be able to reach $0.01 EPS given growth especially high margin pre-rolls and settling initial inefficiencies in the recreational industry in AZ. However, if construction costs began in Q3 then I expect Q3 and Q4 will likely miss the EPS goal of 0.01. Until Q1 or more likely Q2 next year. At the latest, I would expect EPS of $0.01 in Q3 given the cost savings that phase 1 of the new facility would provide. The only thing stopping HSTRF from achieving the goal of $0.01 EPS is investing a lot in growth which won’t necessarily be a bad thing.
In phase 1 this facility will reduce input costs by an estimated 30%.
Phase 2 is expected to be complete in Q1 2023, cost $4.5 million, allow for 8 million grams of production (almost twice 2020 sales), and reduce input costs by 50%, 20% more than phase 1. Phase 3 is expected to be complete in Q3 2023, reduce input costs by 60% and result in 12 million grams of production.
So going forward Hollister can expect to drastically reduce costs in AZ while increasing supply and therefore revenue. Hollister’s reliance on high quality demands they maintain that quality and HSTRF seems to have that goal in mind. This new facility will rely largely on solar power, which is one of the reasons for cost lowering. Solar power is expected to generate ~50% of the historical power used for the facility. None of these numbers seem to put Hollister at risk of going into the Red as all expansion costs are easily maintained by existing cash flow.
The push for this facility and bringing resources in-house for the restructure will both help lower costs long term. Facilitating EPS growth before including actual revenue growth.
Additional long-term growth catalysts may come from Hollister's modest investment in mushrooms.
In April 2020 Hollister Purchased 100% of the company Alphamind in a mixed cash and stock offering. Alphamind is a medical mushroom company that plans on releasing capsules and powdered products. While this initially includes products that are legal, with a focus on a special blend of 5 different legal mushroom varieties, Alphamind does intend to expand into psilocybin. Alphamind does in-house testing and research. Hollister Biosciences Inc. Subsidiary AlphaMind Brands Inc. Plans to Launch Initial Medicinal Mushroom Based Product Line
Initial plans were for first product releases in July 2020. Not much news has come out since Hollister announced the initial intended product release date. This is a new product and is a high risk to me. If Hollister was not already profitable I would question such pursuits. Indeed Hollister was profitable in Q2 2020 with net revenue of $0.5 million. The company did not reach profitability again until Q1 2021. This indicates to me costs associated with Alphamind have not significantly impacted profitability long term. However, with Hollister profitable and the initial product development costs seemingly behind them at this point costs should remain manageable. With the potential for psilocybin for medical use Hollister may be able to pick up some nice revenue 3-10 years down the line with some possible additional revenue from their non-psilocybin offerings. However, Psilocybin for medical use will likely follow more closely to FDA standards than medical marijuana in my opinion and research has focused on 1-3 doses under the supervision of a professional therapist. This would necessitate large investments that would worry me especially as multiple other companies have already invested tens if not hundreds of millions overall. However, if Hollister simply supplied the mushrooms and collaborated/assisted with product releases the investment costs would remain low at the expense of modest profits.
That said if psilocybin is ever legalized for recreational use I would imagine Hollister to be a leader. Their dedication to high-quality products would mean that they would have the lead over low-quality products or companies scrambling to enter the space where Hollister has planned for years. Alternatively, Alphamind may be sold off to another company in the future after development and with the presence of any patents. Overall I consider this a possible long-term growth asset that may not pay out and maybe a minor drain on earnings. So a high chance of losing little going forward with multiple paths for a moderate or high-yield payout.
We may find out more with the corporate rebrand.
Additional traditional long-term growth includes regular industry growth for Cannabis in CA and AZ. CA is expected to grow with a CAGR of 17.3%. California has struggled with illegal marijuana sales competing with legal sales similar to situations in Canada. Historically one of the issues with illegal weed has been the higher quality product from long-time growers compared to mass-produced low-quality marijuana. HSTRF is a direct counter to this with high-quality Marijuana and between that fact and HSTRF’s partners/specialized products, I would not be surprised if HSTRF continues to outperform the industry average growth. However, I lack the specific data to show this going forward and given the expected rebrand I would not want to speculate on specifics.
Arizona is a little harder to quantify as they have been going through a lot of changes given their newness to recreational cannabis. Some reports even have medical marijuana sales dropping in favor of recreational where there was previously significant growth. Because of this, I won’t speculate but we have consistently seen growth in states that legalize recreational cannabis. AZ does have the second most marijuana sales for US states as of September. AZ Marijuana Sales Have Surpassed $1.6 Billion in 2021
That article also shows that pre-rolls are growing from about 5% of sales in January 2020 to about 10% of sales in September, as mentioned before.
The last long-term catalyst is the ever-present legalization/decriminalization/easing of banking restrictions. While this is the type of opportunity that many companies laud as a growth catalyst we know from Canada’s legalization that things may not go smoothly. My wife referred to this as Cannagedon which is apt.
VFF owns the one large publicly traded profitable Canadian pot growers and their claim to fame was high-quality products just like HSTRF. I remember the CEO talked about how hyper-aggressive growth tanked the price of lower-grade marijuana in Canada simply because of oversupplying. Many companies had to destroy weed they couldn’t sell and could not recoup costs resulting in billions of dollars in losses. This is a risk that has been mentioned in various articles across the internet, often by Canadian growers trying to warn American growers and investors to not make the same mistake.
HSTRF seems to be following VFF in terms of some of its business decisions. A focus on high quality vs mass-produced products. Not going into debt or buying growth, though Hollister has made some acquisitions such as Venom Extracts and Aplhamind. The difference between HSTRF and other such acquisitions is that they are generally smaller purchases and they are limited to 1-2 different companies that add different things. But HSTRF has specialty partner products which VFF does not have to my knowledge and additional marketing via celebrity partnerships will help keep customer acquisition costs low. With high-quality products, their customer retention should be high. So, long term there is some risk to legalization, and people should not forget. Just because the industry would be growing does not mean every business endeavor will succeed. HSTRF is one of the few companies positioned in the one way we know businesses were able to actually succeed in the harsh Canadian legalization effort, plus HSTRF has additional catalysts and safeguards via their partnerships.
SHORT TERM CATALYSTS
HSTRF has had great growth in 2020 and 2021 so far. While it is always easier for smaller companies to grow I would expect HSTRF to continue growing considering some of the moves it has made, general growth trends, and the free capital HSTRF has on hand. Arizona is a new and growing market where HSTRF has stood out and CA leaves a lot of market share to grab especially with growing sales YOY and more people moving from illegal sales to legal sales. The introduction of pre-rolls in AZ should help reflect noticeable growth in Q3 relative to Q2 revenue as should the general growth in the CA and AZ markets. Partially this is because HSTRF’s partner products are largely pre-rolls and HSTRF is just starting to increase pre-roll production.
While we don’t know exactly how the numbers will land, we can make some assumptions. In 2020 HSTRF sold 4.5 million grams of the product. If their pre-roll production in AZ starts at 10,000 units a day and we assume each unit is 0.5G (which may be lowballing it but considering easyrider includes 'micro-dosing pre-rolls that are 0.2G compared to the normal 0.5, 0.75, and 1G prerolls I am being conservative). That ends up being 5,000G per day. Q3 included around 64 working days (https://www.calendar-12.com/working_days/2021). While HSTRF may not sell all their pre-rolls made in the quarter they were also ramping up to 30,000 units in Q4 and started in Q2 so I feel it's safe to conservatively assume all 10,000 grams per day were sold.
5,000 grams X 64 days is 320,000 grams of product. That is roughly 7% of 2020 sales by gram. If we assume the price point is the same as 2020 average you end up with 7% of $30.6 million or ~$2.14 million dollars. As pre-rolls are high margin this will lead to higher than normal earnings per gram of sale. Compared to Q2 revenue of $17.6 million that's a 12% increase. With this being, high margin product EPS in Q3 should surpass Q1 unless the costs for the new facility overshadow that gain.
That growth is one product type in one of two markets.
I should note here, Hollister seems to be introducing new products every quarter. In addition to AZ pre-rolls for Q3 some Easy Rider partnership products were expected to see initial release toward the end of 2021 so possibly some Q3 growth but more likely Q4 (I don't have specifics). As one of the products is an oil meant to be applied after tattoos this is a more unique product than many company offerings.
This kind of quarterly product release in different markets helps HSTRF achieve QOQ growth. While it's possible this may start falling off in 2022 given HSTRF’s dominance as a company for celebrities and other businesses to partner with, I expect more partnership announcements and possibly more unique offerings letting HSTRF achieve early dominance with new Marijuana offerings.
The last short-term catalyst is holiday sales. I know I personally like to get nicer products for special events and with HSTRF including several top-shelf brands like Hashbone and Clown as well as a wide variety of high-end concentrates I would expect Q4 to peak for Hollister more than for bargain brands.
CONCLUSION / TLDR
Hollister1 is an interesting marijuana stock. Its small-cap size hides a strong and relatively safe growth model that uses its capital wisely. While 100% YOY growth probably won’t continue Hollister is poised for noticeable growth and should lead industry averages. Low customer acquisition costs/high retention will be key factors as will the high margin for many of their products. Specialty products show HSTRF is leading growth into new areas, not just following trends. Arizona is seeing massive pre-roll growth, HSTRF’s strength and they are just now focusing on pre-rolls in AZ. New cost-reducing expansions that are covered by cash flow, not just cash on hand but cash flow, will help increase margins without risking the companies stability.
Hollister has made a lot of similar decisions that lead to the profitability of VFF in the cutthroat Canadian legalization / cannagedon, but Hollister has additional strengths.
Hollister’s market cap is less than expected total 2021 revenue, which is rare for a pot company being a high-growth space. Depending on when you look marijuana stocks tend to have a market cap of several times revenue. Considering that HSTRF is small-cap and most investors are unaware of the company due to poor coverage it makes this a great time to buy as the value of the purchase can only increase so far before the stock starts running up.
Some unusual business moves may prove to be long-term catalysts like Psilocybin or turn out to be duds that at least don't put HSTRF into debt. Short-term catalysts include expanded releases of proven products and new products manufactured in partnership with celebrities and existing brands as well as traditional growth and peak positioning for holiday sales.
No company is without risk but the primary risk for Hollister is its low investor awareness and scant coverage. I couldn't even post the full article on Seeking Alpha as anything other than a blog. Aspects of the businesses that may struggle or even fail should not affect HSTRF so much as to prove unprofitable. Some expenses may keep the price suppressed for 1-2 more quarters by obscuring earnings, but I expect HSTRF to stand out and start moving once it hits $0.01 EPS and there should be more movement once the Price per share passes $1. $1 for me is a fair evaluation price for Hollister's current positioning and at the current price, it would not be hard to see Hollister being a 5-10 bagger by the end of 2022. Hollister is profitable, growing, innovative, and dramatically undervalued. Q3 earnings should show growth and future cost savings from their new facility combined with cost savings from bringing outsourced services in-house will maximize EPS as growth continues.
Hollister is actively rebranding and restructuring to some unknown degree. This can be scary when a company has proved itself to this point, however, this appears to be Hollister staying ahead in the market and addressing the thing that has been holding the stock back including coverage.
Thank you for your time. There may be some awkwardness due to having to cut sections out to meet limits on Reddit. I apologize if this occurs. I am not used to reddit as every time I try posting different places the groups delete my posts because I never have enough Karma so I never end up with the Karma to engage with the community. This is the 5th place I am trying to post this article so really, any feedback is ppreciated.
submitted byPlannManntoCannabisInvestors [link][comments]
2021.11.27 01:00 theyellingcat2021 Black Friday Etc. Sales and Releases Masterpost (2.0)
(doc will be updated less frequently than spreadsheet/post)Note: the previous version of this post was removed by reddit's spam filter but I think I have it figured out now!
We're back again for 2021! Sales are coming out earlier this year due to supply chain and shipping disruptions, so here's this year's masterpost. I'm grateful to have the assistance of u/causticFish this year, who you may know from the Asian Indies Resource and Latino/Hispanic Indies directories.
- If you have something new to share, please check to see if it's already on the list, then submit it using the survey and it'll go in the spreadsheet for everyone to see. Brand owners are welcome to submit their own info!
- If you have an update or correction for something already on the list, please comment below and tag the lovely u/causticFish and they'll update it on the spreadsheet.
- There are once again filters for the sheet! Browse just makeup, perfume, nail polish or 'and more'! You can switch between filters on Google Sheets under Data>Filter Views, or find them linked below for your convenience.
- Text list is included below for easy skimming. I plan to update that at least once per day through 11/20, and then more frequently 11/21-11/27 (week of US Thanksgiving). The spreadsheet is directly populated by the survey and will always be most up-to-date, so check there first for new stuff!
- Last year's post can be found here, and 2019's post is here if you'd like to get an idea of past sales/releases.
- Important note: this is a community-produced list, the shops here have not been vetted for legitimacy/good business practices/etc. other than by the fact that a community member thought they were worthy of inclusion. Please use your own discretion when choosing to patronize any of these indies. Consider doing a reddit search for reviews on any shop you're curious/unsure about!
- Finally, as much as this is an exciting time for indies I realize this can be a financially (and generally) stressful time of year. My hope is that this list will help people make informed, planned purchasing decisions, but if you'd prefer not to see this post at all, you can hide it using the option in menu below the post on desktop or in the menu to the right on mobile.
- Makeup only
- Perfume only
- Nail polish only
- 'And More' only (includes bath & body, apparel, etc.)
- MUAonthecheap's list - mostly mainstream but also several indie brands.
Brands added today: Rosmarino candles, L'Aventura Perfumes, Nadine Cosmetics, Obscura Hortus, House Pozen
Brands updated today: Kheimistrii
20% off everything on the site with code: cyber2021Aewen Jewellery now - 11/30
15% off + free shipping on orders over £20 until 30th of November. Discount will show once items are added to your cart.Alchemy 7 Creations unknown end, assume 11/26
40% off sitewide (etsy)Alpha Musk 11/24-11/25 (unconfirmed)
Details TBA; will update once confirmed.Andra Marie Studio now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 10% Off Stickers, 20% Off PrintsAndromeda's Curse 11/26-11/29
30% off11/22-29
No code required; 25-50% off various products, plus special products and bundles are available only during this sale (while supplies last)! AND every order will receive a free eyeshadow gift with purchase! Details in sheet.Aromi Cosmetics (standalone site) now - unknown end, assume 11/26 or 11/29
Website: use code 2021 for 20% off all lipsticks. Etsy Cyber Sale: 15% Off StorewideAstrid Perfume 11/15-11/29
New Winter + Brioche collections release. Free Black Friday/Cyber Monday perfume for each $75 spent. Limit 2 of each BFCM scent, total limit 4 per customer--details on sheet.Ate Ethel's ~ Fond ~ Memories 11/22-11/29
20% OffAthame + Alchemy 7pm EST 11/12-12/31
15% off with code WINTER2021, free US shipping over $50 with code FREESHIPPING, only one code can be used at a time but shipping can be refunded after checkout, details on sheet.Avery K Draws now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 10% OffBaby Bat Beauty 11/25 4pm EST- unknown end
TBA, will update with more infoBeam Paints 10/22 - unknown end (assume Black Friday 11/26).
25% off sitewide with code ULTRAGREYFRIDAYBeautometry 11/18-11/30, unknown time zone
25% off with code BFCM21, excludes some brands--details on sheet.Beige/Dusk/Greys unknown end (assume through 11/26 or 11/29)
30-40% off all productsBlack Hearted Tart Now - 11/30 CT
15% off with code BHTLovesYouBlackTree Jewelry unknown dates
25% OFF SILVER and 15% OFF GOLD. Free World Wide Delivery all orders over $100BLAX Studio now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 10% OffBones Coffee 11/17-11/30
20% site-wide by using code BFCM21. Up to 50% on select items! Plus, every order gets a free, never-before-released mystery flavor AND a chance to receive one of 180 hand-numbered mugs, snazzy brewing equipment, and much more!Bonita Fierce Candles 11/21 - 11/29
Up to 25% Off No Code Needed. New Releases.ByDarkTales
Everything listed off up to 25%. See shipping note on sheet.Carved Wooden Spoons (standalone site) 11/22-unknown end date
20% Off. Discount already applied on etsy, use code CYBER2021 on standalone site.Cellar Door Bath Supply Co now - 11/29 11:59pm
Save 15% on $25+, 20% on $75+, 25% on $125+, 30% on $200+, discount codes on sheet.Chagrin Valley Soap and Salve 11/26 9AM EST - 11/29 11:59PM EST
10% off everything, 15% off gift setsChicOmine now - unknown end, assume 11/26 or 11/29
50% offChiommani 11/24-12/4
20% off (automatic on Etsy, use code HOLIDAYPARTY2021 on standalone site). 10% of sales will be redistributed to QPOC in need in the community. Free 'Sunny & Proud' sticker with all orders of $25 or more.Chris Rusak Perfume 11/26-11/28 (?)
Discovery Sets & All Perfumes on Sale Up to 35% off. Free US shipping over $33Chuan Skincare 11/26 12AM MT-11/29 11:59PM MT
Free scrunchie with all orders - no code needed. Free all natural lotion bar ($18 value) with all orders over $50 - use code SMALLBIZSATChydiki (standalone site) now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 20% OffCirque Colors 11/22-11/29 11:59 PM EST
20% off with code BIGGESTSALE, free US shipping @ $35Cleanse Your Soul 11/20-unknown end date, assume Black Friday
25% off entire site with code 'hollydays'Clionadh Cosmetics11/19 3PM EST - 12/3 5PM EST
15% of Stained Glass singles and bundles, 30$ off circle shadows and bundles, 40% off accessories. Restocking Stained Glass collection. 0.50 CAD off each when purchasing 6-9 multichrome single shadows with code 'CROSS FORMULA 6', $1 off each when purchasing 10 or more with code 'CROSS FORMULA'Color 4 Nails 11/14-11/30
25% Off Using Coupon Code BF2021, excludes KBShimmer which is 15% off. See sheet for details.Colores de Carol 11/26 12:01 AM EST - 11/29 11:59 PM EST
30% off with code CDCBF2021, free mystery polish for first 30 orders over $50, excludes Merry & Bright collection.Concrete Minerals Unknown end date, assume 11/26
40% Off All ProductsCopacetic Cosmetics 11/26 10am CST - 11/30
Everything 15-60% off, see details on sheet. Two grab bag options both with exclusive items (eyeshadow only and nail polish only, details on sheet)Crafty Days Studio 11/24 2PM PST-unknown end
30% off Everything. Free macaron Charms and shipping with purchases over $35.Crystal Knockout 12:00am EST 11/26-11:59pm EST 11/29
Use code BFR2021 for 30% off all orders. Free US shipping on purchases $25+.Cupcake Polish now -11/29 11:59 PM CST
30% off with code THANKFUL21Cyan Owl 11/25-11/30
15% of everything including the art printsDamask Haus 11/19-11/29
Freebies at $25, $50, $75, $100, free shipping with code FREESHIP at $100Dandy Lions Cosmetics 11/24 12pm EST - 11/30 11:55pm EST
UPDATE: All single eyeshadows will be 30% off, various discount levels from 20-40% off on other categories, see sheet for details!Darling Doll Cosmetics 11/25 12PM PST - 11/28 11:59PST
25% off for orders over $35 with the code “BLACKFRIDAY”Death and Floral Midnight 11/26-11:59pm 11/27 (Assuming CST)
20% off, no minimum, Black Friday exclusive scent as GWPDeconstructing Eden 11/24-11/29
New Winter Korean Folktale collection. Black Friday/Cyber Monday weekend exclusives + GWP, details on sheet.Devinah Cosmetics 11/25 12PM PST, unknown end date
35% off with code BLACKFRIDAY21, some exclusions listed on sheet. New Releases: Carnival Sweets 50% off, Moonscapes 25% off, Laveau 25% offDifferent Dimension 11/24 at 12AM EST - 12/01 at 11:59PM EST
35% off entire store using code BF2021. Gift with purchase for the first 100 orders, $6 Mystery Doorbusters, new releases and rereleases. Flash sales on various social media channels, see sheet for info.DiTo Cosmetics unknown dates, assume through 11/26
50% Off SitewideDown to Earth Beauty 11/26 12PM PST - 11/28 10AM PST
11/26: 20% off entire site, plus chose either B1G2 Free on Body Frosting/Souffles or spend $x get $y off (details on sheet). 11/27: 20% off and B1G1 on Merch & Accessories, 11/28 (or 11/29?): 30% offDSH Perfumes 11/19-1/10/22
20% off sitewide with code light20Emme Cosmetics 11/26/2021 @10am EST - 11/27/2021 @12pm EST
All shimmers: 30% OFF, All mattes: 30% OFF, Empty Palettes, Compacts & Accessories: 40% OFF. No code needed, other coupons won't be available.Euphoric Sun 11/25 10PM PST - 11/29 10PM PST
15% Off Everything, No Code Needed. Buy Two Palettes Get One Free. First 20 People Who Order Get $20 OffFace Glaze Beauty now-11/28
Discount 25%-40% everything in the shop will be on sale. New multichromes, holographic, duochrome, and palettesFanchromatic Nails/Galatea Cosmetics 6am PST 11/26 - 11:59pm PST 11/29
Various daily deals (GWP, free months in Nail Polish OTM club), see sheet for detailsFanesha Fabre Art (Etsy Shop)
20% Sitewide (Etsy and standalone)Fantôme N/A
Black Friday sale has been postponed due to dramatic increase in order volume; expecting it to be in January/February instead.Farfalla World 11/26 3pm PST - 11/30
Details TBA, will update.Flame And Fable Candle Co now -11/27
Preordecoinciding with Black Friday 15% off of regular priceFélin Lune Apothecary 11/26-11/29, early access 12pm PST 11/25 for subscribers
20% off on all purchases with code BLACKFRIDAY20. Discount cannot be combined with other codes and is not valid on holiday sampler sets.Fennec Design now -11/29
20% off everythingFictional Boutique now - unknown end, assume 11/26 or 11/29
10-40% off various categories, details on sheetFriday Tea midnight 11/26-midnight 11/29
November 26th: 20% off all black teas using code BlackTeaDay, November 27th: 20% off any tea that comes from one specific region or farm using code SmallFarms, November 29th: 20% off all our fandom and nerdy tea blends using code CyberTeaParty.Frostbeard Studio 11/12-11/15
20% off Early Bird sale; may be additional Black Friday Sale, will update if more info comes out.Gato Glitter 11/15-11/30
15% offGavissi Beauty now-11/30
Bundle deal and various discounts, see sheetGeoffrey Siu unknown dates
Restocks + Sales TBA, will update if more infoGive Me Glow Cosmetics 11/25 8pm CST (unknown end, assume through 11/26)
Various discounts 20-40% off, see sheet for details.Glam Shop PL 0:00 (CET) 11/25-11/30
General sale. Will update if there are more details.Glaminatrix Cosmetics 11/26 12am AEST-11/28 12am AEST
20% off of everything except the new Silent Night Palette with code BLACKFRIDAYGlisten Cosmetics now - 12/1 at 11.59pm GMT
35% off Sitewide with Code:BFCM2021Haus of Gloi 6AM PST 11/26-11/29
Black Friday: Yule Collection Release. Saturday: Surprise restocks on previous seasonal items. Sunday: 4 new soaps release. Monday: 25% off GC pumpkin butters, bubbling scrubs, 50% off Hair oils. Various new releases/gift sets, details on sheetHappy Turtle Tea 11/25-11/26
TBA, will update with more infoHearts and Promises 8pm EST 11/25-unknown end
30% off the ENTIRE store with a doorbuster polish, free gift with purchase and 12 brand new polishes!Honey Vanilla Designs now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 25% off StickersHouse Pozen 11/27-?
15% off with code RAISETHEBLACKSALEILNP 11/26-11/29
25% off entire site and double reward points with code BF2021JD Glow Cosmetics Two sales: 12am CST 11/25-11:59pm CST 11/26, 12am CST 11/27-11:59pm CST 11/29
40% off Pink Friday Sale, excluding Special Edition category (includes their multichromes) and HD Flakes with code PINK2021. 30% off Cyber Weekend Sale Saturday-Monday with code CYBER 2021Jessica Mcrory now - 12/2
Etsy Cyber Sale: 10% Off SitewideKailav Beauty (Musée Beauty) 11/18-unknown end
Holiday Sale: 20% offKaleidos now - 11/30 at 12pm PST
20% off sitewide, excluding bundles. Special Offers for 3 Collection Sets. Free 'Off the Chain' socks for all orders over $100Kawaii Amai now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 15-20% OffKawaii Goods now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 10% OffKBShimmer 9am CST 11/19-11/29
15% off with code BLACKFRIDAY15Kheimistrii 11/25 11:59pm CST-11/29 11:59pm CST
UPDATE: 35% off 11/26 - 11/29 11:59pm CST. Visit https://kheimistrii.com/discount/BLACKFRIDAY2021 for discount. Free gifts with orders $35 and over, and free shipping for orders $100 and over.Kinsey Kakes 11/26-?
Up to 50% off, new releasesKirakira Karakasa11/22 4pm (unknown time zone/end date, assume 11/26)
Wallets: $13, Pins: $7, Masks: $12, Stickers: $3, B Grade Mystery bags: 3 for $10Klarity Kosmetics 11/25 Midnight CST - 11/25 11:59 CST
25% Off All Lip Products, 30% of All Palettes, 40% Off All Highlighters, Setting Sprays, and Loose Pigments, 40% off All Multichromes & Duochromes, $5 For All Matter and Regular Foil ShadowsKyse Perfumes 11/27-12/25, possibly starts earlier
Until Christmas (25th December) everything has a 25% discount. The discount is added once you add things to the basket.Land of Aahs (standalone site)
Etsy Cyber Sale: 10%. Sale on Website: TBA (https://landofaahs.com/) Will update if more info.Last Looks Grooming 11/26-11/29, IMAM early access 11/22 with code
30% off everything through BFCM weekend. IMAM community exclusive: shop the sale right now with code IMAMBF2021L'Aventura Perfumes 11/26-11/28
20% off everything in the shop with the exception of single samples (2ml & 4ml) and gift cards with code SHOPSMALL21LBCC Historical Apothecary (LitttleBits) 12am-11:59pm 11/26, 11/27, 11/29 (CST?)
11/26: 25% off all in stock items, 11/27: 15% off all in stock items, 11/29: 15% off all in stock items. Free priority shipping on US orders over $35Lethal Cosmetics 11/26 Midnight CET
Sale up to 45% off, new makeup launches. UPDATE: new releases include 9 multichrome shadows, lip care set, mixing liquid, mystery bags valued at 75€ for 25€Lively Ghosts 11/26 (dates unknown)
35% Off All Products with Code: FRIDAY35Lollies by Leah 11/26
New Holiday collection and new permanent collections releasing 11/26Long Winter Farm 11/26 12:01am EST - 11/29 11:59pm EST
Free 'Polar Bear Farts' lip balm with orders of $35+ (before shipping). Free US shipping over $100Love Potion Magickal Perfumerie (standalone site) 11/17-12/18
25% off Going, Going, Gone section (both Etsy shop and standalone site)Lucky Rainbow Boutique now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 15% OffLucky 13 LacqueLotion of Immortality 11/26 noon PST-11/30 11:59pm PST
30% off with code TOFURKEY. Shop is closing for the Winter at the end of this sale. New release + OOAK items, details on sheet. Free US shipping @$50Lumichee Shop (Etsy Shop) 11/26-11/28
Black Friday/Cyber Monday Sale 25%Off EverythingLuna Alchemist unknown end, assume 11/26
10% off sitewide (etsy)Lunar Celestial Essence 11/20-11/30
30% Off Preorder Black Friday Nov 20th to Nov 30th, Use Codes: FRIDAY30Lunar Glow Skin Co 11/27, unknown time zone
Whipped soaps, body scrubs, body butters, and shower gels will be BOGO free. Up to 70% off for other products.Lurker and Strange Perfumery 11/2-unknown end, assume 11/26
Spend $30 or more and receive 20% off entire order. New releases 11/5.LVNEA (US/Int'l site) now - 11/15 11:59pm EST
20% off all LVNEA productsLyn B Designs 11/24 - 12/1
50% off storewide with code BFRIDAYMad City Soap now - 11/26 11/:59pm CST
20% off all productsMad Lab Studios 11/22-28
Use code BLACKFRIDAY20 at checkout to receive 20% off your whole purchase!Maison De L'Alchimie 11/24-unknown end (11/26?)
SALE -Choose 3 for $32.95, Special Black Friday Bundle- 7 Fullsize Perfumes from the Fall/Winter CollectionMarshmallow Darling 11/25 Midnight PST -11/26 Midnight PST
30% Off Entire Store, Excluding Mystery Boxes & Sticker packs.Free Stickers for First 50 Orders. New Mystery boxes & Mystery Sticker Packs (10$ CAD - 23$ CAD)MBA Cosmetics 11/25-11/26
15-75% off, details on sheet. Special Christmas shop section.Meow Meow Tweet 11/16-?
20% off sitewide with code EARLYCATS20Metamorphosis 11/22-11/26 Midnight
Up to 75% Off.Meyoco Apparels 11/23-unknown end
Use code FRIDAY for 25% off apparel store ordersMint and Apple 11/23-12/1
Black Friday Clearance Section, 10% SidewideMiss Durianne 11/19-11/29
20% off storewideMoon and Serpent Jewelry unknown dates
15% off select jewelryMPZ Cosmetics N/A
No Black Friday Sale; may list some sewing supplies this weekendMysteries of Mayhem 11/26 - 11/29
Black Friday Sale! 20% off 11/26 - 11/29Nadine Cosmetics 11/27- 'until Christmas'
30% offNight Owl Lacquer 6pm MST 11/16 - midnight MST 11/30
20% off with code HOLIDAY21, excludes cremes, collection bundles, and already discounted items. Orders >$60 get free domestic or discounted int'l shipping. New releases; details on sheetNotyce Beauty now - unknown end, assume 11/26 or 11/29
40% OFF Holiday Sale EventNomad Cosmetics New release 11am EST 11/16, various sales 11/23-29, free/reduced shipping 12/1-12/24
New holiday palette release 11am EST 11/16. Pre-Black-Friday Sale 11/23-26: get 30% off $50 or more, 40% off $100 or more, 50% off $150 or more. 11/26: 50% off Iceland palette. 11/27: Free Stockholm highlighter with purchase. 11/29: sitewide % off, TBA. 12/1-12/24: free US shipping, reduced international shippingNotoriously Morbid 11/26 12am - 11/30 8am EST
25% off entire storeNui Cobalt Designs Now - 11/29. New release 11/26.
New collection releases Friday November 26th at 11:11 am Pacific. Coupon codes: BlackFriday10 - 10% off any order, BlackFriday15 - 15% off orders of $75+, BlackFriday20 - 20% off orders of $125+, BlackFriday25 - 25% off any order $200+Obscura Hortusnow - unknown end, assume 11/29
15%Ocean Vixen Art now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 20% Off PrintsOden's Eye 11/26-11/28
40% off all products, free international shipping over 50 Euros (excludes some countries)OfGraveConcern 11/26 only
Free Shipping on all artworkOM Organics 11/22-11/29
25% off sitewideOnichu Art 11/26 17:00 GMT/12:00 EST
Pink Friday Sale: Up to 50% Off SitewideOrquidias Creations unknown end, assume 11/26
20% Off Sitewide (etsy)Pacific Northwest Perfume 12am PST 11/26 -11:59pm PST 11/28
10% Off Sitewide with coupon code GOBIGBUYSMALLPahlish 11/26 12:01 am CST-11/29 11:59 pm CST
All new shades on sale, some older shades as well. Free US shipping @$50, Canada @$80, everywhere else @ $120. GWP shades at $50 and $100, details on sheet.Pariah Cosmetics 11/23-11/28
30% Off with Code: pariahfridayPeach Milk Co 11/26 12:00 AM EST - 11/27 8:00 PM EST
20% off entire site, plus choose code for either Buy 2 Get 1 Free or spend $x get $y off (details on sheet).Peachy Dreams Designs now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 10% Off Prints & PinsPersephone's Bijoux now - unknown end, assume 11/26 or 11/29
Up to 25% offPetals Bath Boutique 11/26-11/29
50% off all products with code 'WINTER21Poesie 11/24 12EST - 11/28 Midnight EST
GWP tiers @ $25, $50, $75, $100, $150, $200, $250Posh Goth Apothecary (standalone site) 11/22-11/29
25% off Posh Poisons Perfume, free US shipping over $35, no coupon required on either Etsy or standalone site.Possets 11/26-11/27
30% off with code thanks30Precious Bbyz 11/23-11/28
30% off sitewidePretties For Your Face 11/25 6PM EST-11/29 12:00AM
All shadow and highlighter singles will be 50% OFF. The ENTIRE rest of the site will be 30% OFFPylies 11/26 - midnight 12/01
20% off everything & GWP for orders $20 and up. Details on sheet.Rachel Sullivan Illustration now -11/30
50% off Clearance, 20% off everything else except custom portraits!Red Panda Lacquer 11/26 midnight EST - 11/29 11:59pm EST
25% off, new WinteChristmas release 11/26, exclusive mystery GWP polish on purchases over $30Redwood Alchemy 11/13-11/20
Daily flash sales between 11/13-11/20.Rituel de Fille 11/26-11/29
20% off all full size products with code NYMPH20. Stacking GWP @ $50, $100, $150. Free US shipping @ $75, Canadian shipping $150. Flat rate shipping $24 other int'l.Rococo Chocolates unknown end, assume 11/26
Buy 5 nibble bags this Black Friday for £50 with code Nibbles5. 20% off all hampers with code hampers20. 10% off all orders with code BLACKFRIDAY10. Select discount/bundles as well, details on sheet. Codes do not stackRogue Lacquer 1pm MST 11/25-11pm MST 11/28
10-40% off sitewide, no code needed. Mystery Grab bags $14 for 2 polishes. First 24 hrs: $6 doorbuster polish, 10% off all new winteholiday polishes, free mystery polish for all orders >$40Rose Garden Apothecary now-12/2
ETSY Cyber sale: 20% OffRosewood Cosmetics 11/25-28, 12/1-4
45% Off All Products. BOGO Free: All Spring & Summer Gloss, Rose Dust Highlighters & EyeshadowRosmarino Candles now -11/28 midnight
$10 off orders over $100 with code BlackFriyaySaints Angels Sinners Cosmetics unknown end, assume through 11/26
40% offSamael's Tuesday 11/16-unknown end date
10% OFF 2 or more items - use coupon code HAPPYHOLIDAYS21Sarah Alden Mermaid & Fairy Art now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 15% Off SitewideScents of Friendship now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 10% OffShine By D Cosmetics 11/25 11am AST - unknown end time
Up to 40% off site wide excluding new items.Shroud Cosmetics 12/3
Belated Black Friday Sale: Details TBA. New Product Launch.Sihaya and Company 11/26-11/29
15% off for all candles, bath and body, and jewelry. Winter Box and Advent Box excluded. Free 'Fireside Glow' lip color with orders over $35.Smell Bent 11/22-11/28
40% off the Entire Inventory of Full Sized SpraysSmelly Yeti Perfumery 11/25-11/29
20% offSol Luna Alchemy 11/4-unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 30% Off SitewideSpirit & Venom Olfactory Arts 11/26 @ Midnight EST- 11/28
15% off any order with code SVBF15, 20% off $75+: SVBF20, 25% off $100+: SVBF25. Winter collection release. GWP for orders before 11/27 11:59pm, various flash freebies on socials. More details on sheet.Stereoplasm
New release preorder sale is 11/19 to avoid Black Friday; will ship by 11/27. See brand owner notes in sheet for some details on this decision! UPDATE 11/19 50% off 1.8ml samples, 30% off 4.5ml bottles, 20% off 7.5ml bottles, plus GWP at 50/100/150/200 USD, see sheet for details.Stratia 11/15-11/29 (assuming ends Cyber Monday)
20% off with code BIGSALESucreabeille 11/18-11/21
Black Friday Tiered Gift sale. UPDATE: details on sheet, all tiers stack.Sugar Milk Co 11/26-12/7
12 Days of Christmas Sale: Each day will have a surprise discount, offer, or free gift!Sugar Works Bath and Body unknown dates
$30 off $150 or more, no code.Sweets for Your Skin 11/26-11/29
BOGO 50% including Discounted Items, Free shipping with purchases over $40Sydney Grace Co 11/26 9am PST - 11/29 12am PST
25% off all in stock products. Sale on the out-of-stock items in January.Sylvan Dream Designs unknown dates
15% off most itemsTabby Divine 11/26 only until midnight MST
20% off all ready-to-ship items with code stripedfriday20Tasty Taiga now - unknown end, assume 11/26 or 11/29
20% off storewide, free shipping on all orders.Tea Ray Art now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 15% OffTerra Moons Cosmetics 11/24 3PM EST - 12/4 11:59 EST
BOGO on all regular mattes and shimmers and highlighters, Specialty shadows will be discounted separately 20%, Lipglosses will be discounted 25%, Empty magnetic palettes will be discounted 20%, Flakes will be discounted 20%, New ReleasesThe Cupcake Bathery 11/23-12/11 PST
20% off storewide, no code necessaryThe Little Book Eater 11/7-11/27
10% offThe Parlor Company 11/25-11/29
20% off with code Blackfriday21The Pickety Witch 11/22-11/29, unknown time zone
20% off store wideThe Strange South 11/25 - 11/29
50% off until midnight CST 11/26. 30% off 11/27-11/29. Free shipping over $100 USD. Custom fragrances available at full price through the weekend.The Witching Hour Art (standalone site) Unknown dates, assume through 11/26
10% off select items on Etsy site. 10-50% off select items on standalone site.Tiffany Chen Art 11/22-11/28
20% Off SaleTiny Hands now - unknown end, assume 11/26
Etsy Cyber Sale: 20% OffTouch of Glam Beauty 11/23 12PM PST/ 3PM EST - 12/5 4PM PST/7PM EST
25% Off Everything with Code BF25OFFTracy's Powder Room 11/19-unknown end date, assume 11/26
UPDATE: up to 50% off, some exclusions on sheet. Free US shipping over $65 with code FREESHIPPING, free international shipping over $125 with code FREEINTERSHIPPINGUkiyoe Heroes 11/9-unknown end, assume 11/26
Buy 2 get 1 free! Works on all giclee prints, pins and shirts.Unearthly Cosmetics (Alien Cosmetics) 11/24 12am - 11:59pm EST
30% Off Products, No Codes neededUnique History Shop now - unknown end, assume 11/26 or 11/29
10% off most itemsUniversal Zone now - unknown end, assume 11/26 or 11/29
15% to 20% marked off all of the catalogue (except the silk scarves)Valas Enchanted now - unknown end, assume 11/26 or 11/29
Cyber Sale: 10% OffVani Cosmetics 11/19 11:59 EST - 11/29
Up to 50% off, new shades releasing. Details on sheet.Vintner's Reserve 11/25-12/1
Tiered discounts, stacking GWP, new winter collection + return of seasonals, various deals through social mediaVIXII Shop now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 20% OffWearable Masterpieces now - unknown end, assume 11/26 or 11/29
Large selection marked down 10%Werther & Gray 11/26-11/29
15% Off All Candles with CODE BF2021Wild Veil Perfume (Etsy shop) now - unknown end, assume 11/26 or 11/29
20% off, use code 20WILDVEIL on standalone site, no code needed for Etsy shop.Willow Waxcraft 12:01 AM EST 11/26 - 11:59 PM EST 11/28
15% off all orders with code: FESTIVE15, 25% off orders over $60.00 with code: TWINKLING25. Free US shipping over $35. Mystery shot samples for $9, exclusive scent shot GWP @$25 and $50.Wise Child Botanticals now - unknown end, assume 11/26 or 11/29
Etsy Cyber Sale: 20% OffWise Mountain Botanicals now -11/30
Up to 25% off through the month of November, free US shipping over $55Witch Baby Soap 11/26
Details TBA, will update when more informationWitchen Herbals now - unknown end, assume 11/26 or 11/29
All jars and skin care potions listed at 25% offWonderland Apothecary 11/26 8pm EST - unknown end
Up to 50% off Select ItemsWood Berry Art 11/22-12/1 (no time zone listed)
10% discount almost on every item, and 15% discount when buying 3 or more itemsYummi Butta Skin Care Co. 11/24-unknown end
TBA, will update if more info
2021.11.24 21:21 WatsonLewRodDD on $RWBYF (OTC), or $RWB:APH, might be worth the buy
So, right, check this stock out $RWBYF, Red White & Bloom, pretty much in a perfect situation right now - for both short term and long term investors. As recreational legalization is happening sooner or later, RWBYF is benefiting from the SAFE Banking Act and the Republican Legalization Bill hype alone. submitted byWatsonLewRodtopennystocks [link][comments] https://preview.redd.it/riv0rp8c5l181.jpg?width=1200&format=pjpg&auto=webp&s=91e0b5f33ddcfafa42c56aa86a98cac3e906b56d Current news & progress Besides the SAFE Banking Act and Republican Legalization Bill, Nancy Mace (US Rep) will be announcing further legalization and/or information regarding the legalization bill at 2PM est. Surprisingly this stock doesn't move as much as the more well known marijuana stocks and ETF's, so this is still a nice opportunity to join a delayed rocket. More recently news relating to Red White & Bloom has been their expansion phase in Florida, which will help generate an additional $30mm in nearly 20,000sq space. They will now be operational in California, Arizona, Oklahoma, Florida, Massachusetts, Illinois and Michigan, they're fast tracking expansion and acquisitions to establish a strong presence in all of these markets, and with the help of their High Times Licensing Agreement to sell their product under the High Times trademark in Florida, Michigan and Illinois. Their partnership alone with the High Times can bring in hundreds of millions in revenue and in attraction on social media platforms - ask yo mom or grandma about it and of course they've heard of The high Times. https://hightimes.com/ Fundamentals Besides all their current progress, there's still a ton of fundamentals to go over. Since this stock is OTC and in the Canadian exchange it's been hard for institutions and large investors to check this stock out, however it's still at a $100mill market cap. Red White & Blooms CEO Brad Rodgers is focusing on brand recognition and cultivation to expand the company - RWB has multiple subsidiaries like the brand Platinum Vapes (which produces $100m current revenue through vape cartridges), Mid-American Growers (which produces and distributes CBD gummies from their own 3.6 Million square feet of automated indoor growing space), as well owning all assets in the Florida operations from Acreage holdings (around 11,000 sqft cultivation facility, and 4,000 sqft administrative office building). https://ir.redwhitebloom.com/news-events Technicals The first part of the technicals I want to talk about is the all time lows we've seen on the stock, it's dropped under $0.50 just a few times and isn't able to break pass the support line that's been established as time goes on, $0.48 has been hit 4 times with support bouncing it back immediately after since October last year, as well as $0.50 being a key phycological movement for investors to average down back into, and that's been been tested around 8 times since the same time in October (Chart link below as a reference point). RWBYF has been accumulating shares and has been consolidating over the past 2 weeks, testing ATL's a few times, seeing the same accumulation before the pump on Jan 4th 2021. And since October 29th to now, we've seen more volume accumulating compared to the 30 day average (Friday, 11/12/21, RWBYF had 389K volume compared to the 251k avg 30 day volume, and RWB 359k compared to 261k avg 30 day volume. The Volume Profiling indicator is also showing that it can skip past $0.60 with more than average volume and then can consolidating around $0.75 for a while. For those who also already understand volume profiling would agree that $0.6 needs to be filled eventually for more accumulation space, however personally I would believe it jumps to $0.75 before dropping back down after a while. https://share.trendspider.com/chart/RWBYF/6710l570x4 for better resolution (Thank you @BlueMoonTrades, follow him on twitter, same tag!) Analysis Basically I'd go balls deep in this. Key statistics though - - EPS at the moment is $-0.294 - Earnings date between Nov 29 & Dec 3 - Volume growing more than 40% over the last 30 days - CEO Brad Rogers receiving $1.5mill compensation through stock and $300k salary - $0.68 Price / Book value - Key buying price at $0.5, any massive drop below would leave to it continuing to fall - Consolidation is not shown on the chart above as it is a week old, newer data shows that the chart has consolidation from $0.48 to $0.55 - 63% of Americans, 83% of Democrat's and 50% of Republicans support this movement - Estimated to have 300 storefronts in Michigan by 2023 - THC House of Brands, Platinum Vape & High Times brand gives RWB well known products to sell in over 450 dispensaries across 3 states (Michigan, Illinois, Florida) Legalization Just like any other marijuana stock you have the risk that marijuana potentially might not be legalized or will continually to be delayed for years. However as you probably know, approx. 83% of U.S Democrats and 50% of Republicans support the legalization of Marijuana. As well as 68% of Americans also support legalizing marijuana. This would come at the cost of taxing marijuana at the same rate as Alcohol, which you know, would actually be a good thing that it supports areas where marijuana is already a massive market that isn't being taxed for local community growth. Subsidiaries Platinum Vapes - Again, back to source 3., they run a huge slice of the pie in Michigan with around 30% of sales from vape cartridges going to them. They are partnered with TILT ($TLLTF, I'm bullish on too) to sell 'Industry leading inhalation technology', top quality cartridges and TILT has the capacity to produce and distribute hundreds of thousands of cartridges on demand, and Platinum Vapes now has the capacity and store front to distribute over 450,000 carts monthly. PV also sell Gummies, CBD, Chocolates, Disposables and some merch. Last year in September PV was making a gross margin around 81%, with adjusted EBITDA (bullshit) of $6.5mill in PV and in PharmaCo (PV subsidiary). Mid-American Growers - Probably the largest automated harvesting facility in America with 3.6million square feet of CBD producing plants, they offer 12 different CBD products.. not much too it honestly - however a great physical asset for RWB to carry during the next few years. Positions Probably worth disclosing that I've been following this stock a month prior to COVID19, I have around 25% of my stock portfolio in Red White & Bloom I'm very optimistic about the future of $RWBYF, obviously not endorsed but hell if they gave me free merch I'd be a kiss ass for life. I think it's time sooner or later that this stock and company outperforms the market, it's all in due time. Please do your own proper DD, this is a great starting point to help newer traders / investors finding an opportunity. Most of my family has a position in this, and I'll continue to add more shares as time goes on. Sources -
(First Florida Location banner) (Competition and their Enterprise Value) https://www.sec.gov/.../00010529182100.../rwb20fsep15-21.htm (Brad Rogers compensation is $350k salary, and $200k option awards based off encouraging the stock price to grow) https://www.facebook.com/.../RedWhiteandBloomInvestorsSource (Investors group on FB) https://www.tradingview.com/.../financials-income-statement/ (Financial & Income statement for RWBYF) Thanks for reading, relight that joint and have a good night. |
2021.11.24 20:09 BigCyanDinosaurCubicFarms Announces $2.7 Million HydroGreen Sales Commitments in British Columbia
The new dealer, HydroGreen CanWest, is a 50/50 joint venture between Bill Vanderkooi, MSc., founder of Nutriva and owner of Nutritech Solutions, a livestock technology company, and Ryan de Lange, owner of J&D Farmers Dairy Service, a leading supplier of dairy automation technology. HydroGreen CanWest signed a letter of intent (“LOI”) to become a member of the HydroGreen Certified Dealer Network. In aggregate, HydroGreen CanWest has committed to an initial 18 HydroGreen Grow System modules under contract by the end of 2022.
An experienced dairy owner and operator, Bill Vanderkooi installed the first HydroGreen Grow System in Canada in 2018 and has since expanded to four systems at the EcoDairy in Abbotsford, British Columbia. “Installation and integration with HydroGreen were easy,” said Vanderkooi. “The EcoDairy feed supply is consistent and reliable, every day. Beef cattle finish better and earlier, and dairy cows perform better when fed HydroGreen feed.”
Vanderkooi’s Nutriva Group consists of grassroots companies dedicated to promoting health and wellbeing by commercializing innovations through partnerships in the dairy, egg, and beef industries. They are driven by their commitment to a healthy planet, with key partnerships and strong customer relationships.
The EcoDairy is known for showcasing industry-leading technologies contributing toward a net-zero emissions future for farms. Underscored by the recommendations of forward-thinking early adopters, the EcoDairy is a working dairy farm featuring automated robot milking devices, a green energy solution digester, and the HydroGreen indoor fresh livestock feed growing solution.
“Ongoing research trials are underway on the nutrition, health, and wellbeing of grass-fed beef and dairy cows,” said Vanderkooi. “We’re looking at replacing grain and/or forage in the dairy herd, analyzing milk yield, and overall animal health and performance. Things like reproductive performance on the dairy side has a lot of promise and ongoing trials are showing the difference between cows fed HydroGreen or not.”
“I’ve established trusted relationships with dairies by consistently identifying and delivering innovative new technologies that maximize benefits to the farmers and their herds,” said Ryan de Lange, a third-generation dairy farmer with 20 years of experience as a DeLaval milking robot dealer. “We’re excited to bring the HydroGreen indoor growing technology to dairy farms to experience not just how much the cows love to eat it but also better nutritional, health, and animal performance. For many dairies, sourcing enough high-quality feed is an ongoing challenge. The HydroGreen Grow System provides farmers with land savings and dairies with improvements for close up cows and peak milk production.”
“As pioneers in the dairy and beef cattle industry, we’re thrilled to officially welcome our long-time supporters Bill Vanderkooi and Ryan de Lange as HydroGreen CanWest to our HydroGreen Certified Dealer Network,” said Dan Schmidt, President, HydroGreen. “They have been our leading demonstration location in Canada. Expanding the operations and research data collection has been instrumental in measuring the benefits of using HydroGreen livestock superfeed. Their ability to provide the firsthand experience of both a demonstration site with four modules and having seen the animal benefits over the past several years makes them truly unique in our dealer network and well-positioned to showcase HydroGreen in the province of British Columbia.”
“Canadian farmers were using robots to milk cows before most people had desktop computers,” said Dave Dinesen, Chief Executive Officer, CubicFarms. “Farmers need the latest innovations in technology to continue growing profitably and sustainably. With the powerful combination of Bill’s direct experience growing with HydroGreen and Ryan’s leadership in implementing innovative on farm solutions, we’re confident HydroGreen CanWest will successfully bring this indoor growing technology solution to new customers in the beef and dairy industries in this part of the world where it is so needed.”
About CubicFarms
CubicFarms is the leading local chain agricultural technology company developing and deploying technology to feed a changing world. Its proprietary ag-tech solutions enable growers to produce high quality, predictable produce and fresh livestock feed with HydroGreen Nutrition Technology, a division of CubicFarm Systems Corp. The CubicFarms™ system contains patented technology for growing leafy greens and other crops onsite, indoors, all year round. CubicFarms provides an efficient, localized food supply solution that benefits our people, planet, and economy.
For more information, please visit www.cubicfarms.com.
On behalf of the Board of Directors
“Dave Dinesen”
Dave Dinesen, Chief Executive Officer
2021.11.23 02:53 500scnds[Table] r/PersonalFinanceCanada — Ask us anything! We are the co-founders of Epilogue, Canada's only online estate planning platform created by lawyers
SourceNote: There is no guarantee that the coupon code mentioned in this AMA hasn't expired yet.
Rows: ~180 (+comments)
Questions | Answers |
---|---|
In Alberta can I just write out my will and it works? I thought this was related to stories of farmers getting crushed my farm machinery and writing out a will before they died stuck under a tractor. If so how do these services improve the DIY route I can choose to do? What are the biggest oversights you see people miss when they come to make a will? | In most jurisdictions a Will that is written entirely in someone’s handwriting and signed by the person is completely valid - it’s called a holographic Will. The story you’re referring to is a part of Canadian estate planning lore, but it’s totally true (it happened in Saskatchewan in 1948). |
| If someone ever finds themselves in a pinch (like the fellow in this story), then it can be an effective solution. But for people who have a bit more time on their side, a more traditional Will helps ensure that all of the bases are covered. |
| When someone DIYs a Will without any support, they’re likely to miss some key provisions that may be needed to cover all eventualities or ensure that the trustees have the powers they need to administer the estate. |
| Unlike a holographic Will, a Will that is not written in the testator’s own handwriting needs to be signed in the presence of witnesses. |
| To answer your last question: What are the biggest oversights you see people miss when they come to make a will? |
| When people think about making Wills completely on their own, they often don’t think about all the things that could happen in the future and how those things would affect their Will. |
| For example, someone who has adult children might think, “I just want to divide everything equally between my kids”, and so they would be happy to have their Will say just that. |
| But unless they are asked the question, “What happens if one of your kids dies before you?”, it’s not a situation that they would necessarily even think about. When someone tries to create a Will on their own, this is the type of thing that can be easily missed, which is why having a lawyer or online provider, like Epilogue, to prompt these things is important. |
| Thanks so much for this question! It’s an important one. |
For many young people, we skip getting a will until it feels truly needed. At what life stage should we really, really be getting a will done up? What kind of 'events' might trigger going from 'optional' to really should? | Younger people are definitely less likely to have Wills and it's because they think they don’t need one. We often hear people say they are “too young” or “don’t have enough assets”. |
| No matter what age you are, if you pass away without a Will there are some negative consequences. Here are a few: |
| - No executor. If you don’t have a Will, you won’t have named someone you trust to manage your property after you’re gone. That means there is nobody that can go to a bank, or start the process of collecting your assets. Money will be frozen in bank accounts until someone with authority can present themselves to the bank. |
| - No guardians. Without a Will, you won’t have named any guardians for minor children or pets. |
| - Distribution. Without a Will, the distribution of your assets will be based on the laws of your province. This might mean that people (or organizations) you would want to share in the distribution of your assets get left out entirely (common-law partners, friends, charities, etc.) |
| All of that being said, some of the life events that generally motivate people to make a Will are marriage, divorce, birth of a child, getting a pet, and buying property (condo, house, etc.). |
the below is a reply to the above | |
I think what makes me think I didn't need one is the assumption that my assets would go to my parents. That they would find it easy enough to get the right to those assets, and the distribution to them would be straight forward. In the scenario where I am married, it would go to my wife entirely. The situations I can think of as problematic would be breakdown of your relationship with your parents, an unmarried partner, birth of a child, buying property. These are obvious-ish to me. Getting a pet is a great example I did not expect. Is there any other non-obvious ones maybe that some of us can look out for? | Thanks for the follow-up question, CrasyMike! Even if there aren't any problematic situations, you'll still need an executor to be able to carry out your wishes. Without a Will that names an executor, it can be a very time-consuming and costly process to have one appointed. Only an approved executor can get access to things like your bank account. This adds stress to an already stressful time and delays the entire process of having your estate wrapped up. |
| Plus, a lot of people make assumptions in terms of what would happen but that's not always the case. For example, if you have a spouse AND kids and die without a Will in Ontario, not everything will go to your spouse. |
| At the end of the day, writing a Will is a safety net for the fact that the status of your relationships today won't necessarily be the same as the status of your relationships at the time of your death. An updated Will protects both your wishes and your loved ones in any eventuality. |
the below is a reply to the above | |
This is great, and it's helpful. I think this leads me into probably the last thing I wonder about wills. For many of us, we are told that a will is an expensive thing but you need it - you need to hire someone competent, to consider your whole situation with due care, and this can cost quite a bit. For me, it's hard to think of getting some of the key basics out of the way like having an executor, and assignment of my assets, needs to cost so darn much. The explanation is usually that you don't know if a 'boiler plate' will can work for you until you hire someone competent to evaluate the situation in detail. And at that point, you're now stuck with paying a reasonable sum so really it just has to be expensive. If you offer a lower cost option, or an automated / low involvement option, how do you identify the situations that truly deserve more attention and therefore a higher cost, to ensure that someone like me who decides to get a low-cost-low-involvement will out of the way does not end up underserved? | Within the Epilogue platform, we ask specific questions that help people understand when their situation might be more complicated and when Epilogue wouldn't be a good fit. In those situations, we don't let those people continue the process and we let them know they should speak to a lawyer (we also refer them to lawyers in their area.) Those situations include the following: |
| * If someone wants to exclude a spouse or child from their Will |
| * If someone is in a second marriage and has children from a prior relationship |
| * If someone has an immediate family member with a disability who is receiving government benefits |
| For some people, there may also be tax planning opportunities that they can take advantage of when making their Will with a lawyer. For those people, an Epilogue Will is not necessarily a 'bad' Will, but it may not offer the same results that could be achieved when planning is done with a lawyer. |
| With all that said, if you're still unsure, it's best to speak to a lawyer to understand how best to meet your needs. |
I had never heard of a social media will before checking out your website. Is this just a gimmick to appeal to a digital/younger audience? Your website does not make it clear, what does a social media will do? What happens without one? | Thanks for your question! The reason you’ve never heard of a Social Media Will is because it didn’t exist before we created it. In this digital age, it is important to think about the digital legacies we will leave behind after we pass away. The Social Media Will is a way for people to let family members and personal representatives know what to do with social media accounts after someone passes away. It is important to note that a Social Media Will is by no means required. It is a document that can be helpful for your loved ones because it gives direction about what to do with your accounts after you pass away. If you don’t have one, your family members will likely not know what decisions you’ve already made with respect to social media accounts and what decisions you would want to be made. |
| Some companies (like Google and Facebook) offer pre-planning tools so that people can make decisions today about what to do with certain accounts. Our service helps point people to those tools to make those decisions, and then the Social Media Will acts as a place where you can record those wishes. |
| You can read more about why we created the Social Media Will here: https://epiloguewills.com/blog/epilogue-social-media-will/ |
| And if you’re interested in reading more about why thinking about your digital legacy is important check this out: https://epiloguewills.com/blog/digital-assets-estate-planning/ |
the below is a reply to the above | |
Thanks for the response. Couldn't these directions be rolled into a conventional will? | You could definitely include provisions in a conventional Will; however, since your wishes for your social media accounts may change more often, you'd have to go through the witnessing and signing procedures any time you made a change, which could be very tedious. |
| Wishes for your social media accounts aren't legally binding and can live in a document like the Social Media Will for your loved ones to refer to. |
| Lastly, a Will primarily deals with your physical, tangible assets and the Social Media Will is more about your online identity and how you want it managed once you're no longer alive. |
| Hope that clarifies! |
What kind of information usually goes with a will? A list of bank accounts/investment accounts? Property titles? What are the things that should be in this package? | Good question! Generally speaking, someone would not include a list of assets (bank accounts, investment accounts, personal property) in their Will. Wills typically deal with assets more generally (like dividing everything someone owns like a pie). |
| A few reasons why including lists of accounts is generally avoided: |
| - The value of accounts will fluctuate over time |
| - Accounts may be moved between institutions |
| - Some accounts may be closed |
| - New accounts may be opened |
| Having to change a Will based on fluctuating account values or which accounts are in existence at a particular point in time would be overly arduous and quite honestly impractical. |
| To help their executor find all the assets, some people like to leave a list of their assets with the Will. This would not be a legal document, but rather just something to help the executor do their job. It’s the type of thing someone would want to review every so often to make sure it’s up to date. |
| We created this Will Preparation Checklist to help people feel more prepared and confident when making their Will. There’s a PDF version you can download as well. Hope this helps! https://epiloguewills.com/blog/will-preparation-checklist/ |
the below is a reply to the above | |
So if an executor doesn't have a list of accounts, how do they go about finding them after death? | It can definitely be challenging to track down accounts if an executor doesn’t have any idea where to look. Some people will create a document that can be kept with the Will to let family members know where their accounts are held. This document can be updated on a regular basis to make sure that it has the most up to date information. |
| The reality is that not enough people take the time to do this exercise, but it is really helpful for the executor when this is done. |
Are you giving us a good promo code? | Sure! No problem. Feel free to use PFC25 for $25 off any Epilogue package. |
| It expires June 30th at midnight. |
Hi Arin and Daniel, One problem I've found with other online platforms that allow you to create a Will is that they didn't make much attempt to screen for situations where their platform wasn't appropriate and let the user know that. That is, when the facts required something beyond what their platform could create. I understand you're in business to make money but I'm curious whether you have questions as part of your process that will screen out situations that are too complex and advise potential clients of this rather than let them go through the process and end up with something that may not be suitable for them. For clarity, I think online providers of Wills and POA documents is a great development that I hope encourages more people to pay the more reasonable price to have one created but I worry that users are not being told when the solution isn't appropriate for them. | Hi eagle_am - thanks for the question. You’ve identified a VERY important point. It’s one of the biggest issues we noticed in the online planning space, and one of the main reasons why we took a different approach when we built Epilogue. Our platform asks a number of questions up front (before someone has even created their account) to help identify people who should probably speak to a lawyer for their planning needs. This includes people with blended families or people who have family members that receive government disability benefits. We have relationships with lawyers in each jurisdiction that we support, and our platform helps connect people with those lawyers directly if Epilogue isn’t a good fit. |
| As experienced lawyers, we understand that even something as simple as wanting to divide assets unequally between children (e.g. a 60/40 split) is a situation that is better handled by a lawyer than an online platform. We’ve built in a bunch of guardrails to help ensure that Epilogue is only helping people with the most basic planning needs. |
How much should a will cost? For example... My wife and I own a house, and a car, and have some investments ... But not much else too extravagant. | We get this question a lot! It is hard to answer the question of what a Will “should” cost because there are a lot of factors. When it comes to lawyer-drafted Wills, the costs probably start around $500 on the very low end. More sophisticated planning can cost thousands of dollars. With online options, the costs generally sit in the low hundreds. |
| If you have a simple situation, an online option could be a good fit for you. With Epilogue, a couple can get Wills and Incapacity Documents for $289 + tax. That comes with unlimited updates for life. |
the below is a reply to the above | |
How do the 'unlimited updates for life' work if your startup goes out of business (no offence, but it happens all the time). Would we be responsible for finding another lawyer to update, or is the doc in some sort of editable format? Any extra info here would be appreciated :) | No offence taken. I should say that our goal is to stay in business, but it is a fair question. If we go out of business, it’s important to note that it would have no effect on the validity of the documents you have already created - so long as they have been printed and signed in accordance with the rules of your province. That’s the good news. |
| If we happen to go out of business, you might lose the ability to make free unlimited updates to your documents in the future. |
the below is another reply to the original answer | |
I have a follow up question related to this. If I snuff it unexpectedly won't my husband just get everything by default since we have no kids? Or does the government get involved in every case where there is no will? | Thanks for the question, ragecuddles. If you 'snuff it unexpectedly', and you don't have a Will, the rules of your province will determine what happens to your assets. Usually, when a person has a (legally married) spouse but no kids, their spouse gets everything. |
| But even if that's what someone wants, not having a Will complicates things. If there is no Will that names someone as executor, there is nobody with the legal authority to make decisions for the estate until an application can be made to court. |
Where is the best place to keep a will stored? I feel like only having a copy in a filing cabinet isn't ideal in the event of a fatal house fire. Are they filed with the government somewhere? What's the best way to setup a trust for a minor child? Were not rich by any means, however between home and pension etc, there's definitely some assets to consider and we want to make sure our daughter will be looked after properly. | You are quite right that it can feel “risky” having just one copy of a Will in the event of a house fire. Right now, because Wills need to have physical signatures (that’s right, no e-signatures allowed), there will only be one true original. If it is possible to store the Will somewhere that is fireproof and waterproof that is ideal. |
| While a safety deposit box might seem like a good option, it’s usually not. It can be very difficult for family members/executors to access the Will in a timely fashion if it is stored in a safety deposit box. |
| In Ontario, it is possible to deposit a Will with the Superior Court for safekeeping. If this is something you’re interested in doing, you may wish to contact your local estates court. |
| In most provinces, there is no official registry where you can register the location of your Will for your loved ones. That said, there are some services available, like Canada Will Registry, that can help with this. |
| Trusts for minor children are included in most Wills. These are often very simple trusts which provide that funds are held in trust and are not paid out until the child reaches a certain age. Trustees are often given the authority to distribute funds earlier if the child needs money for things like education. |
Lawyer in BC here. Really productive conversations in this thread. Thanks for hosting the AMA. Also, great idea on the website. A great way to provide access and ease of use for those who can't afford or simply don't consider going to see a lawyer. Well done. | Thank you so much, Hallgire! A compliment like this coming from a lawyer means so much. |
[deleted] | We’re sorry but we can’t provide any advice on your particular situation. We would suggest speaking to a lawyer in your province that specializes in estate planning and administration. |
Are wills province-dependent? For example, if someone lives in one province then moves to another the next year (e.g. Ontario to Quebec, or vice versa), does the person need to have two wills? | When someone moves to a new province and they have an existing Will, it’s a good idea to check with a lawyer to ensure that the old Will is still going to cover them in the new province. It is possible to have multiple Wills for assets in multiple jurisdictions. But this is more often seen in cases where there is real estate in a different country that needs to be dealt with under the laws of that country. |
| More often, a lawyer might advise the person to just make a new Will in the new province that would replace the prior Will. |
Not so much a question as it is a comment. Your website lacks appropriate focus states and a skip navigation button, critical to making your site accessible and navigable by keyboard. The FAQ doesn't seem to be accessible to the keyboard at all. Also, the header menu breaks on narrow viewports. Hope that helps! | Thanks for the feedback. We are always looking for ways to improve the accessibility of the site! |
the below is a reply to the above | |
This could be a good start: https://wave.webaim.org/report#/https://epiloguewills.com | Thank you! |
What happens to an RESP if the sole or joint subscribers die and the will doesn't name a successor subscriber? Would the estate administrator be able to name a subscriber anyway? It is always shut down or only if the assets are needed to pay creditors and named beneficiaries? | Until a payment is made for the benefit of an RESP beneficiary, the funds in an RESP actually belong to the subscriber(s). If the last living subscriber dies, the RESP forms part of the estate. Without any specific instructions to the contrary, the RESP would likely be liquidated and the funds would be distributed among the estate beneficiaries (who may not be the RESP beneficiaries) - even if there are no creditors. Any accrued benefits (e.g. tax-free growth and CESG grants) could be lost as well. |
| An RESP subscriber’s rights can be acquired by someone else after death. This is why someone would want to include a specific provision about this in their Will. |
| Interestingly, this is something that even a lot of lawyers miss when drafting Wills. As far as we know, Epilogue is the only online planning platform that lets people include an RESP provision in their Will. |
the below is a reply to the above | |
Sincere thanks for your response. Whenever I've read about this the wording has always been more like 'If the last living subscriber dies the RESP may form part of the estate' which made me wonder if there were any circumstances (other than a specific provision in the will) where the RESP could remain intact for the benefit of the beneficiary. | Here is a brief article from the Canadian Tax Foundation about what happens on the death of an RESP subscriber, which should provide you with a bit more information. According to the Income Tax Act (section 146.1), a “subscriber” of an RESP includes a person (including the deceased’s estate) who acquires a deceased individual’s rights as a subscriber under the plan or a person who makes contributions into the deceased’s plan in respect of a beneficiary |
For immigrants or their descendants, who have assets in another country (or may inherit in the future), what special considerations should be included if they make a will in Canada ? Would that require a more complex will, and therefore expensive ? | Unfortunately, there is too much complexity here to offer a simple answer. For example, in some cases the inheritance of real estate located in other countries would not be subject to a Canadian Will, and a separate Will in the other country may be required. |
| Whenever there are cross-border considerations like this it’s a good idea to reach out to a lawyer in Canada as well as lawyers in each country where you have assets to see if any special planning is required. |
Why can’t I just write my Will on a napkin at McDonalds? | Hey Kiirk, depending on the province where you live, you probably can. Holographic Wills (written entirely in someone’s handwriting and signed at the bottom) are legal in most provinces. |
| That said, they aren't often used because most people don’t know what needs to go into a Will. |
the below has been split into three | |
1) If I had a will written already at a lawyer's office, and want it updated, can I just write a new one (like with your service), or is there something special that needs to be updated? | Yes, you can use a service like Epilogue to create a new Will. When you make a Will it has the effect of revoking any earlier Will that you would have made. In addition, there will likely be a specific provision in the new Will (which exists in all Epilogue Wills), that specifically revokes any earlier Will you would have made. |
| It’s a good idea to also let your family/executor know that you created a new Will. |
2) How does a will fit in with the concept of a 'death binder' that I've heard about but never really gotten around to. I assume they address completely separate concerns but would one involve/reference the other? | A Will is likely one of the documents (and arguably the most important) that could go in a “death binder”. A death binder would include any documents that would help your executor deal with the administration of your estate. That could include insurance policies, pre-paid burial plots, statement of funeral and burial wishes, inventory of assets, among other things. |
(Bonus question: The similarity of your partners' names to that of the comedy music group _Starbomb_ is giving me chills. Have you ever heard of them? :P) | I have never heard of them but will definitely check them out. The next company hire should probably be someone named Brian. Thanks for all your questions! |
When the time comes for a will to be executed, what sort of fees/taxes/expenses are taken from the deceased’s estate before it’s passed onto the beneficiary/beneficiaries? | Here are a few: |
| Expenses: Most Wills direct the executor to pay funeral, burial and other expenses out of the estate. |
| Income Taxes: The executor is responsible for filing the deceased’s final tax return to report income earned from the start of the year up to the date of the individual’s death. |
| If the person owned a RRSP or RRIF at the time of death, this may have to be reported as income (if it is not rolled over to a spouse, for example). If the person happens to own assets that have increased in value from the time they were purchased (e.g. stocks) the gain may also be subject to income tax at the time of death. |
| Probate Fees: Depending on the province, when a Will gets submitted to court for probate, there may be “probate fees” payable to the court. In some provinces it’s a flat fee, while in others it is based on the value of the deceased’s assets. In Ontario, probate fees can be up to approximately 1.5% of the value of the deceased’s assets dealt with under the Will. |
| Debts: If the deceased had any debts outstanding at the time of death, these will need to be paid. Remaining assets are available to be distributed to beneficiaries. |
If you do t have a will, who will then get all your stuff? First of kin, brother, sisters? Or will the courts just do your everything up amongst all living relatives? | Each province has its own set of “intestacy” rules that determine how assets are distributed when someone dies without a Will. These rules differ from province-to-province. For example, in Alberta and BC common-law partners may inherit part or all of the estate. In Ontario, common-law partners have no entitlement under the intestacy rules. |
| When someone makes a Will, they get to make the decisions that they believe are best for their loved ones. When someone chooses not to make a Will, their assets just get dealt with in accordance with the default rules of the province. |
Would you ever be interested in hiring an Articling student, or 1st year associate? -Asking for a friend | We recently hired a law student for a summer internship. It is entirely possible that in the future we will look to hire for other legal-related roles. Tell your 'friend' to reach out to careers[at]epiloguewills.com And if they know any full-stack developers, we’re looking to hire a few of those as well. |
Given the number of 'Surprise, you're American!' dual-citizens, are there any plans to provide or assist in cross-border estate planning? | For dual-citizens, a Will may be an opportunity to address potential tax issues like US estate tax. At the moment, we have no plans to provide planning that is specific for dual-citizens. It may be a good idea to speak with an estate lawyer that specializes in cross-border planning. |
this might sound really stupid, but how do you know if somebody has a will? like if I made a will on Epilogue and didn't tell anyone in my family, and died tomorrow, what happens? | This is not a stupid question at all. It’s actually a very good question. In most provinces a Will does not have to be registered, which means it is entirely possible that someone could have a Will that their family members don’t know about. |
| When someone dies and the family doesn’t know whether that person had a Will they usually start looking for one (checking the house, or where important documents are kept). If they can’t find one, some options include contacting the estates court, posting a notice, or using a service like Canada Will Registry to see whether a Will was registered with them. |
| If the Will is found, the family/executor can start the process of administering the estate. If no Will is found, the family will need to proceed on the basis that the person never made a Will. |
| After someone makes a Will (using Epilogue or otherwise), it’s a good idea to speak to family members to let them know about the existence of the Will and where it is being stored. |
the below has been split into three | |
Stupid question here, I am 31yo and recently had baby, and my older brother recently had a mild heart attack and wrote a will, my father recently passed without a will and it was a big hassle. So writing a will is something that has crossed my mind many times in the past year but I still have not done my due diligence on it. Hence I dont know much about it. * what makes your platform better compared going to a lawyer like others do? | No stupid questions _dennykhoe! This AMA is a safe space :) We do not say that our platform is “better” than going to a lawyer. But, we do think there are some features that make our online planning platform easier and more accessible. |
| Our platform is considerably less expensive than going to see a lawyer, and it takes less time. Making a Will with Epilogue can be completed from the comfort of home. |
| However, we understand that we are not right for everyone. When a situation is more complex, it is a good idea to speak to a lawyer. Some examples of these situations include: |
| * When someone wants to exclude children from their Will or leave things to them unequally |
| * If there is a family member that is receiving government benefits in connection with a disability (like ODSP in Ontario) |
| * When someone is in a relationship (like a second marriage) and has a child from a previous relationship. |
im always worried that since my family is still growing, making the will now would require many adjustments in the future and it will become expensive? | One of the things estate planning lawyers try to do is draft Wills in a way that is “future-proof” as much as possible. For example, when someone has a young family, a Will most likely won’t refer to that child only, but will contain more generic language (e.g. an equal distribution between all children). If a Will is drafted in this manner, it doesn’t necessarily need to be updated as a family grows. |
| Some other online Will platforms create “point-in-time” Wills, which specifically name children and may need to be updated each time there is a new child in the family. |
| In addition, Epilogue offers free updates for life. So if life’s circumstances change our customers can come back anytime and update their documents. It’s just important to remember that an updated Will needs to be printed and signed according to the rules of the province in order to be valid and replace the old one. |
| When someone works with a lawyer, updates will usually come at an additional cost. But if your situation is complicated, you should still speak to a lawyer. |
and could you ELI5 about the whole process? | Of course, here it is: |
| * Go to the website at https://epiloguewills.com |
| * Click “Get Started” |
| * Choose “Start My Will” |
| * Answer all of the questions in the questionnaire |
| * Pay for your documents |
| * Get immediate access to your documents |
| * Follow the signing instructions to make sure your documents are legally binding |
the below is another reply to the original question | |
when i had a child, and had a will made, it doesn't name the actual child, it speaks to passing the estate (or whatever) to my children, so if you want equal distribution, you can put that in without naming the children and if you have 1 they get 100%, if you have 2 they get 50% etc. - here i cut and paste it out of my doc. I direct my Trustee to divide the residue of my estate equally among those children of mine living at the date of my death upon each of them attaining the age of twenty-eight(28) years; | Hi Heartolion! It is perfectly fine for a Will not to list a person’s children by name. In fact, it is preferable to do it this way because if the person has any more children, they will not necessarily need to update the Will as long as they still want everything divided equally among their children. |
Can I write a Will in secret and then give it to some government office that deals with estates, so that my family can visit that office after I die? Because otherwise your relatives would have to randomly stumble upon your Will while rummaging through your old things, and that doesn’t seem like the ideal process. | It is usually a good idea to let family members know that a Will has been created and where it is stored. If keeping the Will a secret is important, there are a few options to consider. Most estate planning lawyers will offer to store their clients’ Wills at their office. Someone can let their family members know which lawyer to contact if something happens, but the lawyer should not be releasing the Will to anyone other than the named executor, and certainly not before the person has died. |
| Some provinces will also allow people to store their Wills with a local court office. If a family member is searching for the Will of a deceased relative, this would be an important place to look. |
| Hope this answers your question! |
How do I will my Canadian property and estate to my American son? Is that a thing I can do? Any way to do it where he doesn't have to pay basically all of it in taxes to both countries? | There is nothing stopping someone from leaving assets to beneficiaries outside of Canada. However, there may be Canadian and/or foreign tax consequences that arise, which someone might be able to mitigate with professional estate planning advice. |
| If you have beneficiaries in a different country, you may wish to speak with a lawyer. |
[deleted] | We get it, but we do plan on launching in Quebec down the road. We only launched Epilogue about a year ago and have been working hard to expand across the country. We are currently available in 6 provinces (ON, BC, AB, SK, NS, MN). We won't stop working hard until we can democratize estate planning for all Canadians! |
| Merci! |
I just did it, it was super simple, thank you! | Wow! Thank you, tyomax! Really appreciate the positive feedback. |
Hello there, I am immigrant settled permanently in Canada. I want to get a will made but I have few doubts: I do not trust anybody in Canada to act as an executor. I only trust my parents who are not Canadian citizens. Should I make them the will executor it has to be a lawyer who drafted the will? How can I trust the lawyer? | Someone who is not a citizen or resident of Canada may be named as the executor of a Will. However, this decision can have some implications that can make administering the estate more costly and time consuming. For example, the court may require a non-resident executor to post a bond as security. Also, there are likely going to be tax implications for the estate if the executor is not a resident of Canada. |
What happens if the executor of my will dies shortly after I die ? | A Will should name both an original executor as well as an “alternate” executor. That way, if the executor dies, there is someone to take over the responsibility. |
| If there is no alternate executor, or the alternate executor also dies, then it depends on the rules of the province where the deceased lived. In Ontario, if the last surviving executor had a Will when they died, then the executor named in the original executor’s Will has the right to administer the first estate as well (subject to some conditions). |
| If the last surviving executor did not have a Will, or some of the conditions are not met, someone else would need to apply to court to be appointed as executor. |
| Hope this helps! |
I have no heirs. I would like to list a parent in the US (dual citizen) as beneficiary. Can I also make her executor or would she face tax issues while performing that role? | There is no rule that prevents someone from naming a US executor or beneficiary. However, there are issues, including with respect to estate administration and income tax (both from the Canadian side and the US side), that can arise in these cases. |
| You should speak to a lawyer in each jurisdiction to understand the consequences of this decision. |
I don't have a question, just passing to say that I love the name of your company. It has something poetic to it. | Thank you so much! A lot went into the naming of the company. We went with the whole 'book of life' theme. We appreciate that you took the time to leave this compliment! |
| Your name is pretty cool too, VenetianBauta! |
I'm not sure if I understand you well but as I'm a foreigner Can I own real estate in Canada Knowing that I am not a resident of the country, does it make me pay more taxes, or are there more restrictions? | This is an excellent question, but not directly related to estate planning, so we can only offer limited help here. There are different tax rules that apply to non-residents in Canada. So before buying any Canadian real estate, you would want to speak to a Canadian real estate lawyer (and likely also a tax lawyer) to understand all the implications. |
We've been procrastinating about making a will for years... I guess this will make it easy :) | You are DEFINITELY not alone on this one. There are a ton of reasons why people put off making a Will (time, cost, feel like they’re too young, etc.) |
| We built Epilogue with the goal of removing as many barriers as possible for people who only need basic documents. Definitely check us out to see if it could be a good solution for you! |
2021.11.18 18:17 RozyRed23TRU Precious Metals Moves Drilling to King George IV Area of Golden Rose Project After Discovering More Visible Gold Grains at Surface
TRU Precious Metals Corp. (TSXV: TRU) (OTCQB: TRUIF) (FSE: 706) ('TRU' or the 'Company') is pleased to announce that the Company has commenced drilling in the King George IV lake area ('KG4') at its flagship Golden Rose Project ('Golden Rose'), in the Central Newfoundland Gold Belt, building off a recently-completed IP geophysical survey. This is part of the Company's approximately 5,000 metre (m) diamond drill program underway at Golden Rose, as previously announced on October 19, 2021. submitted byRozyRed23toNewfoundlandGoldStock [link][comments]Highlights
Current Exploration TRU is pleased to report that several geologically well-situated IP targets have been identified and initial drill targets have been selected. The initial drilling is focusing on a 500m x 400m N-S trending IP anomaly (Figure 1) located a few hundred meters upslope of the KG4 shoreline, where 97 gold grains were returned from the previously-announced panned sample containing numerous pristine gold grains. The IP anomaly is directly upslope of the cemented hardpan gossan identified near those gold grains. A similar layer of hardpan gossan can also be traced for approximately 500m south, coincident with the trace of the IP anomaly. https://preview.redd.it/akz7lqv9fd081.png?width=550&format=png&auto=webp&s=0a3b7c0a192fbb239557925bac571c67aa0e9c29 Figure 1: IP Chargeability Anomalies at KG4 With Gold Grain Counts in Till To view an enhanced version of Figure 1, please visit: https://orders.newsfilecorp.com/files/5993/104130_b081faf4341eabaf_001full.jpg Furthermore, an expanded till sampling program has also been completed in the surrounding area for gold grain analysis and for geochemical analysis. Results from these samples has revealed multiple sites containing high gold grain counts (Figure 1), including pristine gold grains suggestive of a locally derived source. Gold grain counts include a sample containing 50 gold grains also coincident with the IP anomaly. In addition, geochemical results have returned highly anomalous gold values coincident with the same IP anomaly, including multiple tills over 500 ppb Au and one till sample grading 1,699 ppb Au (Figure 2). https://preview.redd.it/xc0shf2cfd081.png?width=518&format=png&auto=webp&s=8bc4eeaaba93cf8e23eb83da46fd79fb7ad2da0a Figure 2: Till Sampling Results at KG4 To view an enhanced version of Figure 2, please visit: https://orders.newsfilecorp.com/files/5993/104130_b081faf4341eabaf_002full.jpg Further drilling at KG4 will focus on a large horseshoe-shaped IP anomaly measuring approximately 1.5km x 1.1 km. This anomaly coincides with and expands upon a cluster of large angular blocks of mineralized rocks with a quartz stockwork containing chalcopyrite, sphalerite, pyrite and pyrrhotite found on the shoreline of KG4. TRU Co-Founder and CEO Joel Freudman added: 'We are increasingly excited about our ongoing drilling program at Golden Rose. The strong presence of even more visible gold grains at KG4 than previously discovered further justifies the prospectivity of Golden Rose. I am extremely pleased with Barry's leadership of our field team, and their excellent execution to date of TRU's 5,000-metre diamond drill program, which continues on schedule under the close supervision of our Exploration Manager Pearce Bradley and our other teammates. With more than half of our planned drill metreage remaining, we look forward to a continued flow of good news to report.' Geological Background The KG4 area within Golden Rose is geologically located along the structural contact between the younger Windsor Point Group and the older King George IV ophiolite. Fieldwork by TRU's geologists in the 2021 field season has led to the interpretation that this contact is an inferred thrust fault and can be regionally correlated with the Cape Ray Shear Zone. Notably, the cluster of mineralized quartz stockwork blocks and panned pristine gold grains are located along the magnetic low which defines this structural contact. To the southwest, on Matador Mining Ltd.'s ('Matador') Cape Ray project, gold deposits are associated with a similar structural contact. Golden Rose overall is a regional-scale land package covering approximately 236 square kilometres, including approximately 45 km of strike length along the deposit-bearing Cape Ray -Valentine Lake structural corridor between Marathon Gold Corp.'s Valentine Gold Project immediately to the northeast and Matador's Cape Ray Gold Project immediately to the southwest. Note that till samples and other exploration results are select samples and are not necessarily representative of mineralization on KG4. Readers are cautioned that these grades are conceptual in nature; there has been insufficient exploration by the Company or its qualified person at KG4 to define a mineral resource or mineral reserve; and it is uncertain whether further exploration will result in these targets being delineated as a mineral resource or mineral reserve. Qualified Person Barry Greene, P.Geo. (NL) is a qualified person as defined by National Instrument 43-101 and has reviewed and approved the contents and technical disclosures in this press release. Mr. Greene is a director and officer of the Company and owns securities of the Company. About TRU Precious Metals Corp. TRU is drilling for gold in the highly prospective Central Newfoundland Gold Belt and has an option with a subsidiary of TSX-listed Altius Minerals Corporation to purchase 100% of the Golden Rose Project, located along the deposit-bearing Cape Ray - Valentine Lake Shear Zone. TRU also owns 100% of the Twilite Gold Project, located along the same Shear Zone, and earlier-stage properties in the region. TRU's common shares trade on the TSX Venture Exchange under the symbol 'TRU', on the OTCQB Venture Market under the symbol 'TRUIF', and on the Frankfurt exchange under the symbol '706'. TRU is a portfolio company of Resurgent Capital Corp. ('Resurgent'), a merchant bank providing venture capital markets advisory services and proprietary financing. Resurgent works with promising public and pre-public micro-capitalization companies listing on Canadian stock exchanges. For more information on Resurgent and its portfolio companies, please visit Resurgent's website at https://www.resurgentcapital.ca/ For further information about TRU, please contact: Joel Freudman Co-Founder, President & CEO TRU Precious Metals Corp. Phone: 1-855-760-2TRU (2878) Email: [ir@trupreciousmetals.com](mailto:ir@trupreciousmetals.com) Website: www.trupreciousmetals.com To connect with TRU via social media, below are links: Twitter https://twitter.com/corp_tru LinkedIn https://www.linkedin.com/company/tru-precious-metals-corp YouTube https://www.youtube.com/channel/UCHghHMDQaYgS1rDHiZIeLUg/ Facebook https://www.facebook.com/TRU-Precious-Metals-Corp-100919195193616 Acknowledgement TRU would like to thank the Government of Newfoundland and Labrador for financial support of the Twilite Gold Project through the Junior Exploration Assistance Program. TRU has been approved for funding for a portion of its 2021 exploration activities at the Twilite Gold Project. Cautionary Statements Regarding Forward-Looking Information Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release contains certain forward-looking statements relating to the drill program and other exploration activities at Golden Rose. These statements are based on numerous assumptions regarding Golden Rose, and the Company's exploration and drilling plans, that are believed by management to be reasonable in the circumstances, and are subject to a number of risks and uncertainties, including without limitation: mineralization hosted on adjacent and/or nearby properties is not necessarily indicative of mineralization hosted on Golden Rose; the exploration potential of Golden Rose and the nature and style of mineralization; risks inherent in mineral exploration activities, and operational problems relating to drilling; volatility in precious metals prices; and those other risks described in the Company's continuous disclosure documents. Actual results may differ materially from results contemplated by the forward-looking statements herein. Investors and others should carefully consider the foregoing factors and should not place undue reliance on such forward-looking statements. The Company does not undertake to update any forward-looking statements herein except as required by applicable securities laws. To view the source version of this press release, please visit https://www.newsfilecorp.com/release/104130 |
2021.11.18 01:50 MillennialBetsNews for Steel and Construction Industry related Stocks Nov-17-2021
AADate | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Alcoa Purchases Group Annuity Contracts for Certain U.S. Pension Plans | PITTSBURGH--(BUSINESS WIRE)--Alcoa Corporation (NYSE: AA) today announced the purchase of group annuity contracts that will facilitate the transfer of approximately $1 billion of pension obligations and assets associated with defined benefit pension plans for certain United States retirees and beneficiaries. The transfer, which will be complete later this month, will further enhance Alcoa's strong balance sheet, reduce the risk from volatility in pension plan obligations, and continue to meet c | 48.2 | Business Wire |
Nov-17-2021 | Alcoa to transfer $1 billion in pension obligations to Athene Holding | Alcoa Corp. AA, -4.80% said Wednesday that it has bought group annuity contracts that will help transfer $1 billion in pension obligations for defined benefit pension plans for certain retirees and beneficiaries in the U.S. The aluminum company's stock rose 1.6% in premarket trading. The transfer will be completed later in November. | 48.2 | Market Watch |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Global need for copper, nickel will multiply over next 30 years -BHP | The global markets will need four times the nickel and double the copper in the next 30 years to facilitate a decarbonised world, a BHP Group executive said on Wednesday. | 52.74 | Reuters |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Jesse Gary, Century's President and CEO, to participate in conference hosted by Goldman Sachs | CHICAGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Century Aluminum Company (NASDAQ: CENX) announced today that Jesse Gary, Century's President and Chief Executive Officer, will participate in a question and answer session at the virtual Goldman Sachs Global Metals & Mining Conference, beginning at 10:00 a.m. EST on Thursday, November 18, 2021. | 14.2 | GlobeNewsWire |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-16-2021 | Enviva and J-Power Join Efforts to Decarbonize Power Generation in Japan | BETHESDA, Md. & TOKYO--(BUSINESS WIRE)-- #Biomass--Enviva will work with J-Power to develop a global supply chain of sustainable woody biomass to replace coal in J-Power's power plants. | 68 | Business Wire |
Nov-17-2021 | EY Announces John Keppler as an Entrepreneur of The Year® 2021 National Award Winner | BETHESDA, Md.--(BUSINESS WIRE)-- #BioEnergy--EY Announces John Keppler as an Entrepreneur of The Year® 2021 National Award Winner. | 67.945 | Business Wire |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Israel Chemicals (ICL) Hits 52-Week High, Can the Run Continue? | Israel Chemicals (ICL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. | 9.55 | Zacks Investment Research |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Lithium Americas Enters into Definitive Agreement to Acquire Millennial Lithium | Vancouver, British Columbia--(Newsfile Corp. - November 17, 2021) - Millennial Lithium Corp. (TSXV: ML) (FSE: A3N2) (OTCQX: MLNLF) ('Millennial') and Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) ('Lithium Americas') are pleased to announce that they have entered into a definitive arrangement agreement dated November 17, 2021 (the 'LAC Arrangement Agreement') pursuant to which Lithium Americas has agreed to acquire all of the outstanding shares of Millennial (each, an 'ML Share') by way of a plan of arrangement (the 'LAC Transaction') for... | 33.44 | Newsfile Corp |
Nov-17-2021 | Lithium Americas Enters into Definitive Agreement to Acquire Millennial Lithium | VANCOUVER, British Columbia, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Lithium Americas Corp. (TSX: LAC) (NYSE: LAC) (“Lithium Americas”) and Millennial Lithium Corp. (TSXV: ML) (A3N2:GR: Frankfurt) (MLNLF: OTCQB) (“Millennial”) are pleased to announce that they have entered into a definitive arrangement agreement dated November 17, 2021 (the “LAC Arrangement Agreement”) pursuant to which Lithium Americas has agreed to acquire all of the outstanding shares of Millennial (each, an “ML Share”) by way of a plan of arrangement (the “LAC Transaction”) for C$4.70 per ML Share, payable in common shares of Lithium Americas (the “LAC Shares”) and C$0.001 in cash per ML Share (collectively, the “Purchase Price”), representing total consideration of approximately US$400 million. Based on Lithium Americas' closing price on November 16, 2021, this consideration would result in Millennial Shareholders owning approximately 9.1% of Lithium Americas. | 32.92 | GlobeNewsWire |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Mercer International Inc. to Present at Upcoming 2021 RBC Capital Markets Forest Products Virtual Conference | NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Mercer International Inc. (Nasdaq: MERC) today announced that David K. Ure, Senior Vice President Finance, Chief Financial Officer and Secretary, will be presenting at the following upcoming conference: | 11.19 | GlobeNewsWire |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | ArcelorMittal announces closing of its fourth share buyback program and the launch of a fifth US$1 billion share buyback program | 1 7 November 2021, 14 : 15 CET | 30.44 | GlobeNewsWire |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Royal Gold (RGLD) Announces Highest Dividend Hike Since 2013 | Royal Gold (RGLD) announces a 17% hike in its quarterly dividend on record revenues in first-quarter fiscal 2022 and the prospects of revenue growth from its assets. | 108.2 | Zacks Investment Research |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Rio Tinto invests to increase low-carbon AP60 aluminium production in Canada | MONTREAL--(BUSINESS WIRE)--Rio Tinto invests to increase low-carbon AP60 aluminium production in Canada | 60.67 | Business Wire |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Sandstorm Gold Royalties Announces Hod Maden Project EIA Approval | DESIGNATED NEWS RELEASE VANCOUVER, BC, Nov. 17, 2021 /PRNewswire/ - Sandstorm Gold Ltd. ('Sandstorm Gold Royalties' or the 'Company') (NYSE: SAND) (TSX: SSL) is pleased to announce that Lidya Madencilik Sanayi ve Ticaret A.S. | 6.92 | PRNewsWire |
Nov-17-2021 | Sandstorm reports major permitting milestone for Hod Maden gold project in Turkey | (Kitco News) - The granting of the EIA represents a major milestone for the Hod Maden project. | 6.92 | Kitco |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Steel Dynamics (STLD) Up 2.9% Since Last Earnings Report: Can It Continue? | Steel Dynamics (STLD) reported earnings 30 days ago. What's next for the stock? | 64.02 | Zacks Investment Research |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Teck (TECK) Diverts Shipments as Heavy Rain Hits Rail Line | Teck (TECK) reroutes some shipments to Ridley Terminals in Prince Rupert to mitigate the impacts of disruption. | 27.11 | Zacks Investment Research |
Nov-17-2021 | Teck Announces Dividend | VANCOUVER, British Columbia, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) announced today that it will pay an eligible dividend of $0.05 per share on its outstanding Class A common shares and Class B subordinate voting shares on December 31, 2021, to shareholders of record at the close of business on December 15, 2021. | 27.195 | GlobeNewsWire |
Nov-17-2021 | Teck Donates $250,000 to Support British Columbia Flood Relief Efforts | VANCOUVER, British Columbia, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced a donation of $150,000 to the Canadian Red Cross and $50,000 to the British Columbia Society for the Prevention of Cruelty to Animals (BC SPCA) in support of flood relief efforts in British Columbia. A further $50,000 will go to match donations to emergency relief efforts made by Teck employees. | 27.12 | GlobeNewsWire |
Date | Title | Summary | Price | Source |
---|---|---|---|---|
Nov-17-2021 | Wheaton Precious Metals Reports Record Numbers – How's The Stock Reacting? | Wheaton Precious Metals stock has rallied 9% in just the last one week, completely outperforming the S&P 500 which was down 0.3% in a week. If you look at the change in stock price over the last ten days and one month, WPM stock has increased (13% and 10%, respectively) and outperformed the broader. | 45.06 | Forbes |
2021.11.17 13:33 iChinguChingNatural carbon sequestration
I wrote this back in 2014 so apologies if it a bit dated. submitted byiChinguChingtopreppingForExile [link][comments]Natural carbon sequestration to offset the thawing permafrostIf your not familiar with why climate change is the most pressing issue humanity as ever faced then please read this first. There are 2 related issues in the Arctic. One is the release of carbon from the sub-sea of the Arctic ocean that is dealt with in this article. The other is the release of carbon from the permafrost which is what this article deals with. What is the problem;World-wide, permafrost contains 1700 billion tons of organic material equalling almost half of all organic material in all soils.[5] This pool was built up over thousands of years and is only slowly degraded under the cold conditions in the Arctic. The amount of carbon sequestered in permafrost is four times the carbon that has been released to the atmosphere due to human activities in modern time.[28] (link)The majority of permafrost carbon is deep. If we were to decrease emissions, use the tools nature has given us, large amounts of carbon would be sequestered and the current rate of warming would slow. That would mean the releases from the permafrost would slow. Currently we have a situation where during summer the top layer is heated dramatically, Arctic winters are increasing at a rate of 0.34C per decade. So with the current annual average temperature of -5C we have precious little time. It will be some time before the deeper permafrost can thaw, but every decade that more carbon is released into the atmosphere the warming rate will increase. When, not if, the permafrost melts the organic matter will be converted into CO2 and methane. The challenge is to convert this organic matter into a form that can be sequestered. There are a number of natural mechanisms that can be used to achieve this. Nature gives us the tools, why we don't we use them? First how much carbon is there? From this CSIRO article; Involving collaboration between scientists from Australia, Russia, the US, the UK, Canada and Europe the three-year study concluded that accounting for carbon stored deep in the permafrost more than doubles – to more than 1500 billion tonnes – previous estimates of the world’s high-latitude carbon inventory.It is not possible for all of that carbon to be released, from here; The amount of carbon that will be released from warming conditions depends on depth of thaw, carbon content within the thawed soil, and physical changes to the environment.[7] The likelihood of the entire carbon pool mobilizing and entering the atmosphere is low despite the large volumes stored in the soil. Although temperatures are projected to rise, it does not imply complete loss of permafrost and mobilization of the entire carbon pool. Much of the ground underlain by permafrost will remain frozen even if warming temperatures increase the thaw depth or increase thermokarsting and permafrost degradation.[4]How much will be released per year, is at best a guess but current estimates are; This corresponds to an average annual emission rate of 4-8 billion tons of CO2 equivalents in the period 2011-2040Best case 4, worst case, 8 billion tons of CO2e. Billions tonnes is written as Gt. Assuming the carbon is released as methane (CH4), and methane has a ratio of 1 to 25 CO2e. So this represents 8 /25 = 0.3 Gt CH4. 75% of the weight of methane is carbon so the final emission estimate is for 0.24 Gt of carbon emitted per year. In this article I will attempt to describe the various ways in which carbon can be sequestered (stored) naturally and rapidly. This is not a purely scientific exercise with little practical value. There are simple changes we can make in our day to day lives that can dramatically affect the atmospheric carbon. These are dealt with at the end of the article. Soil carbonFrom the excellent booklet.If the bulk density of the soil is known, it is a simple matter to relate % soil carbon to tonnes of carbon per hectare. Most Australian soils have a bulk density of between 1.0 and 1.8 grams/cm3, or expressed in another way between 1.0 and 1.8 tonnes per cubic metre. In the following example we will assume that the bulk density is 1.4 grams/cm3 or 1.4 tonnes/per cubic metre. (Note: bulk density can vary with depth, so we will assume this is an average for the 0 to 30 cm range). This example demonstrates just how much carbon is stored in the soil at even a relatively low percentage of soil organic carbon. It also demonstrates that if soil carbon levels were improved, a significant amount of carbon dioxide could be taken from the atmosphere and stored in the soil, for a small increase in soil carbon. In the previous example, suppose the soil carbon was increased from 2.0% to 3.0% (an increase of 1%). The extra carbon stored in this soil to a depth of 30 cm would be 42 tonnes per hectare.So the world has 12 billion hectares of arable land, improving that soil by 1% would result in a sequestration of 504 billion tonnes of carbon. To put that in perspective, in a simplistic world, that would neutralize the entire permafrost problem in 3 decades if we achieved a 1% improvement in all soil every decade. Keep in mind that that estimate was only for the first 30cm of soil depth. Carbon has been found at significant levels down to 1.1m. However, the rate of sequestering would fall off quickly as more carbon was accumulated in the soil due to saturation. The greatest gains would be in the most impoverished soil. Of the 41 samples analysed, Strzelecki (1845) found …On a practical level. The best way to improve soil locally is to take vermicast liquid (worm pee), aerate it for 3 days, or until it foams. Then spray it onto the soil preferably late in the day. That rebuilds the soil ecosystem. If that was done with bamboo biochar dug into the soil and inoculated plants the gains are large. An article on how to inoculate your plants is here. Another permaculture one here. The gains in improving degraded soil would be higher than that of high performing soil. Therefore, it would follow that the place with the greatest need, and creating the best gains, would be Australia. HempFrom this article;... one tonne of harvested stem contains: Its usesLet's start by saying that if you choose to smoke it you are at risk of harming yourself. With that out of the way, the industrial uses of hemp are so many that I would defer to the wikipedia article rather than repeating it all here.In modern times hemp is used for industrial purposes including paper, textiles, clothing, biodegradable plastics, construction (as with Hempcrete and insulation), body products, health food and bio-fuel. The benefitsHemp can be grown on existing agricultural land (unlike most forestry projects), and can be included as part of a farm’s crop rotation with positive effects on overall yields of follow on crops. This, along with super versatility in diverse soil conditions and climates, makes hemp cultivation a viable and genuine potential large scale contributor to GHG mitigation. Human excretiaOn average every day you produce 227 grams of faeces. Of that 40 - 50% is carbon. That is approximately 91 grams of carbon. It adds to 33kg per year per person. There are 7 billion of us, that means 231 million tonnes of carbon in our waste every year. Remembering the thawing permafrost will emit 0.24 Gt which is 240 million tonnes. So we would virtually be at a balance. It is time that we got serious about using the sludge from waste treatment plants to treat our soil. Composting toilets are a form of carbon sequestration.AzollaAzolla is a symbiotic plant that some 50 million years ago caused 2850ppm CO2 to be removed from the atmosphere. Azolla's carbon fixing rate is 1.86 tonnes CO2 in 1 ha per year (link).A study of ArcticPaleoclimatology reported that Azolla may have had a significant role in reversing an increase in greenhouse effect that occurred 55 million years ago that caused the region around the north pole to turn into a hot, tropical environment. This research conducted by the Institute of Environmental Biology at Utrecht University claims that massive patches of Azolla growing on the (then) freshwater surface of the Arctic Ocean consumed enough carbon dioxide from the atmosphere for the global greenhouse effect to decline, eventually causing the formation of Ice sheets in Antarctica and the current 'Icehouse period' which we are still in. This theory has been termed the Azolla event.(link)The reason it is so effective at removing CO2 is that it reproduces at such a fast rate. First let's do the math;
Animal feedIt is palatable to: molluscs, ducks, chickens, pigs, cows, goats, sheep and rabbits (and probably lots of others too)...azolla is finding increasing use for sustainable production of livestock feed.[17] Azolla is rich in proteins, essential amino acids, vitamins and minerals. describe feeding azolla to , chickens and egg production of layers, as compared to conventional feed. OneFAO study describes how azolla integrates into a tropical biomass agricultural system, reducing the need for inputs.[18]Azolla has also been suggested as a food stuff for human consumption. However, no long term studies of the healthiness of eating Azolla have been made on humans.[19]The pressing question is why can it not be used for human consumption? If it could, it would change the agricultural landscape. The use of azolla in recipes appears to be limited to a small number of researchers. From this site; Azolla is rich in essential amino acids, proteins, vitamins and minerals and can therefore be advantageously used for animal fodder. Humans can also eat the plant; it tastes a bit like lettuce and is very healthy and nutritious. Azolla is sold in some health food stores in dried and powdered form and can easily be eaten every day as part of the salad.Some people are certainly getting on-board; There is a 42-page article in the journal of Economic Botany #34 (2) 1980 pgs 111-153. There it is mentioned as a green manure, fish food and animal food including pigs. It also helps to purify water, is used in soap production and chewed to ease a sore throat. However, on page 144 it says: 'Bui (1966) implied that with suitable processing Azolla could become a good source of human food. Dr. P. K. Singh** (personal communicatioin) wrote from Cuttack, India, that he has eaten Azolla regularly in several fried preparations; he reports that these preparations are tasty and do not cause digestive difficulties. He was taking steps to popularize the cultivation of Azolla in small trays for human consumption.'* *Bui Huy Dap. 1966. Planting and cultivation of spring rice. Khoa Hoc Ky Thuat Nong Nghiop(Agricultural Science and Technology) 59: 645-653.1967. Some characteristic features of rice growing in Vietnam. Vietnamese Studies 13,Agricultural Problems 9 Rice. 2: 67-73 9 9 1971. Agronomic research. Vietnamese Studies 27, Agricultural Problems, Some TechnicalAspects 3: 73-88. 9 1976. The xuan (spring) rice as revolutionary factor in the rice production in North Vietnam 9Sel'Skokhoziastvennia Biologiia (Moscow) I l: 299-303., and Tan Nhu Nguyen. 1976. Practice of Azolla fertilization in Vietnam. Unpublished IRRIMemo based on visit to IRRI between April 15-24. **Singh, P. K. 1977a. Multiplication and utilization of fern 'Azolla' containing nitrogen-fixing algalsymbiont a green manure in rice cultivation. !1 Rizo 26:125-137.1977b. Azolla plants as fertilizer and feed. Indian Farming. 27: 19-22.1977c. The use of Azolla pinnata as a green manure for rice. Int. Rice Res. Newslett. 2/77.p. 7.1977d. Azolla fern plant-rice fertilizer & chicken feed. Kerala Karshakan 26: 5-6. FertilizerThe nitrogen-fixing capability of Azolla has led to Azolla being widely used as a biofertiliser, especially in parts of southeast Asia. Indeed, the plant has been used to bolster agricultural productivity in China for over a thousand years. When ricepaddies are flooded in the spring, they can be inoculated with Azolla, which then quickly multiplies to cover the water, suppressing weeds. The rotting plant material releases nitrogen to the rice plants, providing up to nine tonnes of protein per hectare per year.[8] (link)This makes it a great input to worm farms and compost piles. Prevents algal blooms in damsAzolla is a nutrient feeder and prevents Algal blooms in farm dams as a result, keeping water more usable for stock. This is a much more important point than it would first appear. The implication is that using azolla to clean water catchment areas could prevent Algal blooms like the one in Ohio.Grey waterThe main limiting factors on Azolla growth are salt, temperature and phosphorus. Phosphorus is plentiful in grey water. Making Azolla a perfect companion for cleaning grey water prior to its use in other areas. This site has a lot of useful information on practical applications. It removes BPA a toxic organic pollutant.It is concluded that Azolla able remove BPA by Phytodegradation from the aqueous solutions. Since conventional methods of BPA removal need to high cost and energy, phytoremediation by Azolla as a natural treatment system can decrease those issues and it can be a useful and beneficial method to removal of BPA.(link)It can remediate diesel polluted soil In laboratory experiments, a consortium composed of A. pinnata-derived bacteria displayed dense growth in a 4% diesel-containing mineral salts medium and was found to lower the fluorescence from aromatic compounds by approximately 50% after 19 d. (BIODEGRADATION OF DIESEL FUEL BY AN AZOLLA-DERIVED BACTERIAL CONSORTIUM Michael F. Cohen,1 Jolene Williams,2 and Hideo Yamasaki1,3,*) BiocharIt seems little research has been performed on converting azolla to biochar.Reclamation of Saline SoilsFrom this research;Although, Azolla is relatively sensitive to salt, cultivation in saline environment for a period of two consecutive years decreased salt content from 0.35-0.15 and desalinate rate (71.4%) was 1.8 times faster than through water leaching and 2.1 times faster than Sesbania and also reduced the electrical conductivity, pH of acidic soil and increased calcium content of soil70 Waseem Raja et al./ International Journal of Research in Biological Sciences 2012; 2(2): 68-72 conductivity, pH of acidic soil and increased calcium content of soil Biodegradable plasticCould it also be used to make bioplastic (link)? There is an existing patent for exactly that process (Macrophyte-based bioplasticWO 2013029018 A1)BambooBamboo is the world's fastest growing plant. (Azolla is a symbiotic organism so doesn't count here). The implications are enormous. A lot of the information from this site is so appropriate that I will reproduce it verbatim;https://preview.redd.it/vinre04it4081.jpg?width=1024&format=pjpg&auto=webp&s=044be38fd23e352a205d42adebf8f49e54bf3df9 One species of bamboo, the guadua angustifolia, found in Venezuela, Ecuador, and Colombia, has been shown to grow up to 25 meters in height and 22 centimeters in diameter, with each plant weighing up to 100 kilograms (Rojas de Sánchez, 2004). This doesn’t match the stature of many trees, but it is still big enough to be significant. It is not all about size, however. How fast a plant grows has a part in determining how much CO2 it can absorb in a given time. In this respect, bamboo wins hands-down: it grows faster than many trees,growing up to 1.2 meters per day. In fact, bamboo holds the Guinness World Record for the world’s fastest growing plant.The INBAR 2010 article actually states the carbon sequestration abilities at 150 t/ha over a 10 year period in a managed bamboo plantation. It is important distinction that natural bamboo forests do not work this way. It is only when the bamboo is harvested at 5 year intervals (species and location dependent) that the levels of sequestering can be achieved. When bamboo is harvested and not dried typically that carbon is sequestered for 80 years under normal use, however artifacts have been dug up that date back to 2,200BC, which incidentally was the world's first timetables written on bamboo. There is an incredible diversity in the uses of bamboo. Bamboo can be used for products from building, to food, utensils to medicine, clothing to musical instruments, even biochar and charcoal fuels. This is exactly what we need right now. A fast growing plant, that demands to be pruned and it's uses vary from carbon neutral to a natural sequestration. Usually a bamboo plantation can be harvested within 3 years of planting, as against decades for traditional trees. https://preview.redd.it/kyrm2vxmt4081.jpg?width=500&format=pjpg&auto=webp&s=eff4b6f158128c0dbb9a8113d17e5fb118b10f78 How could this be applied to the permafrost problem. There are a large number of bamboo species (more here) that are cold climate hardy. Most of the cold growing varieties are running types, normally considered invasive. The invasiveness can be managed by digging trenches around plantations. Shoots extending into the trenches are pruned. That means it is a viable plantation crop for higher latitudes. It would be a matter of balancing cold hardiness with size to find a suitable species for a financial return. In addition to that is the matter of stabilizing the soil structure to minimize erosion in the thawing permafrost, for that purpose, any species that could handle the temperatures would be appropriate. Siberian bamboo (Miscanthus sacchariflorus), while not strictly a bamboo, could be encouraged. Of course standard bamboo is not likely to grow in the Arctic circle anytime soon, but if things continue the way they are that might not be out of the question. Lets do the math with Moso bamboo; there is a worst case 0.24 Gt of emissions of carbon. A hectare of bamboo can sequester 150 tonnes of carbon over a 10 year period. So we are averaging 1.5 tonnes per year. So that would mean 0.24Gt / 1.5t per ha/yr = 0.16 billion ha/yrs. That figure is now our constant. Using that constant we can now determine how quickly (inverse to space) we want to sequester carbon in Bamboo. There are 14m ha currently in production between China and India. So we have; (0.16 * 10^9 ha/yrs) / 14 * 10^6 ha = 11.4 years to reclaim the annual emissions. So 11 years is too long, anything over 1 year will mean an accumulation of atmospheric carbon. For a carbon neutral balance we need 0.16 billion ha of bamboo plantations. In 2008 there was approximately 12 billion hectares of productive land. That is, 1.3% of all farmland on the face of the Earth would have to be used. Given the uses of bamboo, that is actually not that bad. So we need to fund Bamboo plantations both in cold climate areas and in other parts of the world. The way to do this is simple, and it is something everyone can participate in. Buy bamboo products. Every product you buy, from nappies to kitchen counter tops, see if there is a bamboo derived product available. There is a caveat. Carbon may be released from permafrost as CO2, or CH4. Limited studies have demonstrated that particular species of trees (pine, spruce and birch) do actually absorb CH4 which is fortunate as those trees are found in Boreal forests. However, little is known about the absorption of CH4 into bamboo leaves. Without further studies, Bamboo would then seem only to deal with the CO2 problem. Once converted to biochar however, it can directly sequester methane into the soil (see Biochar). BiocharAdding Bamboo Biochar to soils increases the soils ability to sequester CH4 from the atmosphere. Could you apply biochar to the soil to trap the CH4 methane emitting from the permafrost? When you have water logged soils that are generating methane they have methanogenic communities of bacteria. It's the bacteria that generate the methane. This study demonstrated that Bamboo Biochar could cut CH4 emissions from water logged soils by 50%, but the conclusion was that straw biochar was actually better for the job at 90%;... when soils were amended with biochar, CH4 emissions were reduced. CH4 emissions from the paddy soil amended with BC and SC at high rate were reduced by 51.1% and 91.2%, respectively, compared with those without biochar. Methanogenic activity in the paddy soil decreased with increasing rates of biochar, whereas no differences in denaturing gradient gel electrophoresis patterns were observed. CO2 emission from the waterlogged paddy soil was also reduced in the biochar treatments.It also reduces entric fermentation methane from this study. https://preview.redd.it/s0r9hpstt4081.jpg?width=300&format=pjpg&auto=webp&s=1df4c785ec279aa68d33c850ebc73a5d845c35a2 Twelve local “Yellow” cattle with initial live weight ranging from 80 to 100 kg were assigned in a completely randomized block design to a 2*2 factorial arrangement of four treatments with three replications.How would this work for permafrost areas? Trapping the CH4 at the point of emission would be ideal, however, digging in biochar throughout massive areas of Siberia would be a great challenge. It would seem better then to convert bamboo into biochar where it is grown and then distribute the biochar as a soil conditioner to farms. The soil would then act as a sink for the methane generated from the permafrost. MushroomsDon't underestimate the humble mushroom, they were here first. 1.3 billion years ago they were the first land organism.https://preview.redd.it/fpceq84wt4081.jpg?width=220&format=pjpg&auto=webp&s=907ad724d7e93714393dcad6bea60aeeef47678c mycorrhizal fungi, can sequester carbon in the soil. This is important because carbon stored in soil over long periods can help to offset the release of greenhouse gases to the atmosphere. Most fungal species act as decomposers that elicit a net release of CO2 to the atmosphere, but mycorrhizal fungi could be a notable exception. (link)Fungi are simply amazing. Mycorrhizal fungi will form highways in the soil. Those highways can transfer nutrients and carbon to trees. The scale of fungi activity can be significant representing 50-70% of stored carbon in a forest. Boreal forest soils function as a terrestrial net sink in the global carbon cycle. The prevailing dogma has focused on aboveground plant litter as a principal source of soil organic matter. Using 14C bomb-carbon modeling, we show that 50 to 70% of stored carbon in a chronosequence of boreal forested islands derives from roots and root-associated microorganisms. Fungal biomarkers indicate impaired degradation and preservation of fungal residues in late successional forests. Furthermore, 454 pyrosequencing of molecular barcodes, in conjunction with stable isotope analyses, highlights root-associated fungi as important regulators of ecosystem carbon dynamics. Our results suggest an alternative mechanism for the accumulation of organic matter in boreal forests during succession in the long-term absence of disturbance. (link)Not only were fungi the first land based organism, they are also the biggest. That's right you are looking at it. It's right there, beneath the soil. https://preview.redd.it/osjpt5c0u4081.jpg?width=448&format=pjpg&auto=webp&s=d5433f695e68601250559ed8470b11b764ee6fd9 A mushroom of this type in the Malheur National Forest in the Blue Mountains) of eastern Oregon, U.S. was found to be the largest fungal colony in the world, spanning 8.9 km² (2,200 acres) of area.[203][204] This organism is estimated to be 2400 years old. The fungus was written about in the April 2003 issue of the Canadian Journal of Forest Research. While an accurate estimate has not been made, the total weight of the colony may be as much as 605 tons. If this colony is considered a single organism, then it is the largest known organism in the world by area, and rivals the aspen grove 'Pando)' as the known organism with the highest living biomass). (link)There is simply no other practical natural solution that could compare with this. The question then is, could this be used with bamboo? The conclusion from this study was Yes; Thus, the results showed that utilization of effective AM fungi can enhance the productivity of bamboo.You cannot miss this video. TED video by Paul Stamets What is required is tree planting and soil inoculation with spores. The species of tree required? Those that already exist in Boreal forests. ConclusionWe need to expand the use of Bamboo, extend and sustainably manage the Boreal forests. Both these actions should be done with the use of AB fungi. But most of all, we need to improve the soil. There is a symbiotic relationship that can be enhanced between bamboo and fungi. The sequestration of carbon through either process would be significant. By using them together we could get the problem under control. There is an advantage as well when biochar is inoculated with fungi. Obviously inoculating permafrost soil with AM fungi is a bit of a stretch for the average person, but making a difference at a personal level, is still something everyone can do. We need to;
|